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ABSTRACT 
Lea M. Beaulieu: Role of the Protein C System in Breast Cancer Cell Invasion and 
Endothelial Cell Angiogenesis 
(Under the Direction of Frank C. Church) 
 
 Cell migration is involved in multiple processes including development, 
angiogenesis, and cancer invasion. Various receptors, signaling pathways, and extracellular 
proteases all work in concert to promote cell motility. Stimuli cause cells to move, including 
soluble chemoattractant and extracellular matrix-bound molecules. Two examples of cell 
migration, cancer cell invasion and endothelial cell angiogenesis, are explored further in this 
Dissertation. 
 Serine proteases have key roles in coagulation. Some proteases have non-hemostatic 
functions related to regulation of inflammation, apoptosis, and cell migration. Activated 
protein C (APC), anticoagulant serine protease, is also involved in regulating such cellular 
functions. However, it is unclear which receptors, signaling pathways, and/or extracellular 
proteases are involved in the mechanism utilized by APC to regulate cell motility. I tested a 
hypothesis that APC increased cell migration of breast cancer and endothelial cells through 
similar interdependent extracellular and intracellular processes. I studied the mechanism of 
how APC promoted cell motility using MDA-MB-231 breast cancer cells in chemotaxis and 
invasion assays and using human umbilical vein endothelial cells in angiogenesis assays. 
 APC increased breast cancer and endothelial cell migration. For breast cancer cells, 
increase in migration was concentration dependent. Endothelial cells responded to an optimal 
APC concentration, closer to physiological protein C levels. Only active APC increased 
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cancer cell migration and endothelial cell tube formation. APC-increased cell motility was 
also dependent on binding endothelial protein C receptor, and activating protease activated 
receptor-1 and epidermal growth factor receptor (EGFR). Through these receptors, APC 
activates phosphatidylinositol 3 kinase (PI3K) and mitogen activated protein kinase pathways 
to increase cell migration. Extracellularly, APC does not interact with urokinase and 
plasminogen activator inhibitor-1. Instead, APC-promoted invasion involves degradation of 
the extracellular matrix (ECM) by matrix metalloprotease-2 (MMP-2) and -9. Inhibition of 
any component of this mechanism completely abrogates the effects of APC. In ex vivo aortic 
ring assays, active APC increased the formation of endothelial sprouts around the aortic 
section periphery. Similar to cancer cells, APC increased sprout formation through activation 
of EGFR and PI3K, along with degradation of the ECM through MMPs. Collectively, APC 
increases breast cancer and endothelial cell migration through similar interdependent 
extracellular and intracellular pathways. 
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 Chapter 1 
Literature Review 
 
A. Introduction 
 Cell migration is a complex series of coordinated events that allow a cell to move in 
response to external stimuli, such as chemokines, and internal processes, such as signaling 
pathways and actin polymerization. Cell migration is divided into 4 types: chemotaxis, 
chemokinesis, haptotaxis, and invasion. Chemotaxis is the directed movement of cells in 
response to a soluble gradient of chemoattractants [1-3]. Chemokinesis is the random 
movement of cells in the absence of any chemoattractant gradient [1]. Haptotaxis is the 
movement of cells towards an insoluble factor [2, 3]. Invasion is the movement of cells 
through an extracellular matrix towards a soluble chemoattractant or insoluble factor [4, 5]. 
Cell migration is involved in multiple processes including development, inflammation, 
repair, and pathological processes, such as cancer and atherosclerosis. Many factors that 
contribute to cell migration during repair, including mediators of inflammation and 
angiogenesis, can also contribute to uncontrolled cell migration involved in cancer invasion 
and metastasis. One such factor is thrombin (IIa), a serine protease involved in blood 
coagulation. IIa promotes inflammation by activating protease activated receptor-1 (PAR-1) 
on endothelial cells [6]. IIa also promotes the migration of the endothelial cells to form new 
blood vessels, a process called angiogenesis, to repair a wound [7]. However, through PAR-
1, IIa can also promote breast cancer cell invasion through Matrigel [8].  
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The following sections further examine two processes, cancer metastasis and 
angiogenesis, where cell migration plays a central role and which will be further studied in 
this thesis.  
 
B. Cellular Migration and Cancer Metastasis 
 Cancer is the second leading cause of death in the U.S. according to the Centers for 
Disease Control. There will be an estimated 1,444,920 new cases of cancer in 2007; of those, 
678,060 will be diagnosed in women, with an estimated 178,480 new cases affecting the 
breast [9]. The 5 year survival rate for localized breast cancer, in which the cancer has not 
spread to the lymph nodes or regions outside of the breast, is 98% [9]. If the cancer has 
spread regionally, the survival rate decreases to 83% [9]. If the tumor has spread and formed 
distant metastases, the survival rate decreases even more to 26% [9]. Breast cancer is second 
in cancer deaths among women, predicted to account for an estimated 40,460 deaths in 2007 
[9].  
Cancer metastasis involves the spread of malignant tumor cells from one site to a 
distant location in the body. It is a multi-step process that begins with tumor angiogenesis, 
the vascularization of a tumor mass. A tumor can grow to be 1-2 mm in thickness and still 
rely on diffusion of oxygen and nutrients from nearby blood vessels [10, 11]. Any growth 
beyond this diameter is limited by hypoxia-induced apoptosis. Vascularization of the tumor 
allows for growth and the spread of the tumor cells to distant organ sites. Angiogenesis is 
induced by the tumor cells releasing angiogenic factors, specifically vascular endothelial 
growth factor (VEGF) and basic fibroblast growth factor (bFGF) [10-12]. Endothelial cells 
that are activated by growth factors release enzymes that degrade the surrounding 
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extracellular matrix (ECM), such as matrix metalloproteases (MMPs). MMPs are a family of 
zinc-dependent proteases, each with a specific substrate, important for extracellular matrix 
degradation and tissue remodeling. The combined activity of VEGF and bFGF derived from 
the tumor cells and MMPs derived from the endothelial cells allows for capillary sprouting 
from existing blood vessels. Ultimately, endothelial cells migrate towards the angiogenic 
growth factors, proliferate, and form tumor vessels, to allow for gas exchange and nutrient 
transfer to the surrounding tumor. Growth factors released by endothelial cells to promote 
proliferation, such as platelet-derived growth factor (PDGF) [10-12] and insulin-like growth 
factor [10], also promote tumor cell proliferation. Proliferating tumor cells at a primary site 
have the potential to migrate and invade the surrounding tissue. Tumor cells will likely 
invade capillaries, venules, and lymph nodes because of (a) the lack of surrounding dense 
connective tissue and smooth muscle cells and (b) the “relaxed” intercellular junctions [10]. 
For some tumors, the overall crowding caused by the growth of the tumor forces cells 
through the intercellular spaces of the vessels [10]. Tumor cells continue to synthesize 
hydrolytic enzymes (including heparanases) and other proteases that degrade the surrounding 
extracellular matrix, such as MMPs and plasminogen activators – urokinase plasminogen 
activator (uPA) and tissue-type plasminogen activator (tPA), which facilitate the ability of 
the tumor cells to invade surrounding tissue [10] [11, 12]. Normal cells express numerous 
protease inhibitors that oppose the degradation initiated by these proteolytic enzymes. Tumor 
cells over express ECM proteolytic enzymes and do not respond to negative feedback 
pathways set up to control ECM degradation [10]. Following this formation of tumor vessels, 
tumor cells invade through the ECM and enter into circulation. In the circulation, emboli can 
potentially form when platelets aggregate with tumor cells, which result in the initiation of 
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the coagulation pathway and fibrin deposition around the tumors cells. The presence of fibrin 
promotes the release of plasminogen activators to degrade the ECM as well as the fibrin 
network itself [10]. The proteolytic activity allows individual tumor cells or clumps of tumor 
cells to be shed. These shed tumor cells can circulate throughout the body and adhere to 
endothelial cells in distant organs, where they can form metastic tumors. Of the millions of 
tumor cells that go into circulation, less than 0.1% survive to form metastases [10].  
A generally excepted theory of how tumor cells form metastases involves (1) the 
nonspecific interactions of the tumors cells with coagulation factors or (2) tumor cells 
becoming stuck in the capillary beds of organs [13]. Alternatively, it is also hypothesized that 
the glycosylation and integrin profile of the endothelium will change in response to the tumor 
cells in circulation and promote the formation of metastases [13]. From clinical observations, 
it has been believed that specific tumor cells will only form metastatic tumors in certain 
tissues. Endothelial cells from capillaries in different organs have a distinct surface protein 
expression profile [13]. The tumor cell surface has an altered carbohydrate composition with 
an elevated proportion of higher molecular weight glycans. These changes in surface 
carbohydrates serve as a signal for deposition of tumor cells in specific organs [10, 13]. 
When the metastatic tumor cells become lodged in the capillary bed of another organ, the 
tumor cells will adhere to the endothelium, diapadese between endothelial cells and into the 
surrounding ECM, invade into the tissue, proliferate, and form another tumor.  
   
C. Cellular Migration and Angiogenesis 
During the process of tissue repair, many of the same events mentioned in tumor 
angiogenesis and invasion occur but with a higher degree of regulation. The purpose of tissue 
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repair is to remove the damaged tissue, regenerate this tissue or form scar tissue, and restore 
blood flow. This process is particularly important for recovery after a myocardial infarction 
or a stroke, the number one and three cause of death in the U.S., respectively, according to 
the Centers for Disease Control. Of the 79,400,000 Americans, who suffer from 1 or more 
cardiovascular diseases, 7,900,000 will be affected with a myocardial infarction while 
5,600,000 will be affected by a stroke [14].  
During myocardial infarction and stroke, blood flow is restricted and/or completely 
blocked, limiting gas exchange and nutrients from the surrounding tissue. Cell death occurs 
over time as a result along with reversible and irreversible damages to the heart, as is the case 
during a myocardial infarction, or to the brain, which occurs during a stroke. The time until 
repair of this affected area is crucial to the recovery of the patient. Because of the 
accumulation of blood in the vessels, coagulation and inflammation can be initiated. During 
inflammation, macrophages will clear the damaged tissue, fibroblasts and vascular 
endothelial cells proliferate to form granulation tissue, consisting of connective tissue and 
leaky blood vessels. Angiogenesis occurs in the damaged area, in which preexisting blood 
vessels produce capillary sprouts that develop into new vessels. Migration of endothelial 
cells during angiogenesis is regulated by integrins, cell surface receptors that mediate 
attachment, by proteins that destabilize cell-extracellular matrix interactions, such as SPARC 
and thrombospondin 1, and by extracellular matrix proteases. The matrix proteases that 
facilitate migration are controlled by inhibitors, plasminogen activator inhibitor-1 (PAI-1) 
and tissue inhibitors of metalloproteases, and by negative feedback pathways, such as matrix 
cleavage products that can signal for the termination of proliferation and migration. There is 
a proliferating zone of endothelial cells behind the migrating front of cells. VEGF binds to 
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receptors on the endothelial cells and promotes proliferation, tube formation, and migration. 
Its expression is stimulated by cytokines and growth factors, such as transforming growth 
factor-β (TGF-β) and PDGF, and hypoxia. Cells then undergo maturation, where they stop 
proliferating and start forming capillary tubes. Pericytes and smooth muscle cells are 
recruited to the developing vessel to form a support system around the endothelial cells. 
Nutrients and oxygen are now able to diffuse further into the tissue and support growth and 
proliferation [11, 15].   
 My thesis will be focused on two types of cell migration, chemotaxis and invasion, 
which occur during cancer and angiogenesis. I hypothesize that a factor, such as APC, could 
increase chemotaxis and invasion of cancer cells and endothelial cells through similar 
pathways. The following sections go into detail of these pathways involved in cell migration. 
 
D. Cell Signaling Pathways Involved in Cell Migration 
 The Mitogen-Activated Protein Kinase (MAPK) and Phosphatidylinositol 3 Kinase 
(PI3K) pathways are known to be key regulators of cell migration. These pathways can be 
activated by receptor tyrosine-kinases and their associated co-receptors, serine/threonine-
kinase receptors, and G-protein coupled receptors (GPCR). For the receptors with kinase 
activity, activation involves dimerization and autophosphorylation of specific tyrosine, 
threonine, and serine residues on the cytoplasmic tail of the receptor [16]. Proteins that 
contain SH2 or PTB domains bind to these specific phosphorylated residues. Both 
phospholipase C γ (PLCγ) and Grb2 contain SH2 domains. PLCγ is phosphorylated by the 
receptor and is able to interact with phosphatidylinositol-3,4,5-triphosphate (PIP3) on the 
membrane. Cleavage of this membrane lipid associated protein results in the generation of 
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inositol-1,4,5-triphosphate and diacylglycerol [16, 17], which activates Ca2+ release and 
protein kinase C (PKC), respectively.  PKC can activate the MAPK pathway. Another way 
the MAPK pathway can be activated is through Grb2. Adaptor proteins bound by the 
receptors induce the coupling of Grb2 with the guanine nucleotide exchange factor, Sos. Sos 
becomes localized to the inner leaflet of the plasma membrane by receptor-associated Grb2, 
allowing it to activate the GTP-ase Ras [16, 17]. Ras will go on to activate the ERK pathway.  
To activate the PI3K pathway, adaptor proteins, such as IRS-1, bind to 
phosphorylated residues on the cytoplasmic tail of activated receptor and subsequently 
recruit PI3K to the membrane. PI3K will phosphorylate phosphatidylinositol-4,5-biphosphate 
(PIP2) in the plasma membrane to PIP3. This modified membrane lipid binds proteins that 
contain a plextrin homology (PH) domain. Two important PH domain containing proteins are 
PDK1 and its downstream target, Akt. PDK1 bound to PIP3 in the membrane can 
phosphorylate Akt. There are 3 isoforms of Akt – Akt1, Akt2, and Akt3. Akt activation leads 
to the regulation of various other pathways involved in cell survival, cell growth, and cell 
migration [18].  
 PI3K activity itself facilitates leading edge formation through its introduction of PIP3 
into the cell membrane which recruits PH domain containing proteins involved in actin 
polymerization [19]. Akt will phosphorylate and inactivate Bad, a pro-apoptotic factors, and 
and the Forkhead family of transcription factors, which upregulates pro-apoptotic factors. 
Akt inactivation of GSK3 prevents the phophorylation of β-catenin and results in the increase 
in cell cycle progression. Additionally, Akt phosphorylates mTOR, which increases mRNA 
translation and cell cycle progression [18]. Although a minor role, Akt can also regulate the 
ERK pathway [16, 20]. Akt regulates cell migration through two transcriptional factors, 
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NFAT and AP-1. NFAT is associated with increased cellular invasion. Akt activation leads 
to the downregulation of this transcriptional factor through ubiquitination by HDM2, 
resulting in the loss of cell invasion. Akt1 down regulation results in MAPK activation and 
subsequent upregulation of the transcriptional factor, AP-1, of the expression of ECM 
degradation proteases [20]. PI3K can directly lead to the activation of the MAPK pathway 
through p21-activated kinase (PAK). PDK1 will phosphorylate PAK, which can activate the 
MAPK pathway [21].  Even though the activation of the ERK pathway by PI3K pathway is 
not a major function of this pathway, I believe that it is a key interaction in the mechanism 
utilized by APC to increase cell migration.  Additionally, APC has been implicated to reduce 
apoptosis in endothelial and nerve cells, which could be potentially mediated through the 
PI3K pathway. Finally, APC has been shown to utilize the PI3K pathway to induce 
proliferation of endothelial cells. Therefore, APC could be activating the PI3K pathway to 
increase cell migration. 
There are three MAPK pathways: the extracellular signal-regulated kinase 1/2 
(ERK1/2) pathway, c-Jun NH2-terminal kinase pathway, also known as the stress-activated 
protein kinase (JNK/SAPK) pathway, and the p38 pathway. MAPKs (i.e. ERK1/2) are 
phosphorylated at conserved tyrosine and threonine residues by MAPKKs (i.e. MEK1/2), 
which results in the nuclear translocation and phosphorylation of various transcription 
factors. MAPKKs are activated by the phosphorylation of 2 serine residues by MAPKKKs 
(i.e. Raf) [22]. ERK1/2 is mainly activated through Ras-Raf-MEK1/2 or PKC-Raf-MEK1/2 
pathways. C-Jun of the JNK pathway is activated through MEKK1/3-MKK4/7-JNK1/2/3. 
p38α,β,γ,δ are activated by MAPKKK-MKK3/6 [22]. The p38 and JNK pathways have been 
typically associated with cellular stress [22]. However, both of these pathways have been 
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shown to affect migration as well. The JNK pathway has been shown to have a role in cell 
survival and cell migration [23-25], and is activated by EGFR [26] and GPCRs [27]. The 
JNK pathway has also been implicated in regulating cytoskeleton formation and focal 
adhesion (FAs) in certain cell types [28, 29]. The p38 pathway is also involved in 
cytoskeleton reorganization and regulation of FAs [28]. The ERK1/2 pathway has been the 
most extensively studied of the MAPK pathways, with regard to cell migration. Activation of 
this pathway leads to FA and focal adhesion kinase turnover, the formation of membrane 
protrusions at the leading edge of the cell, and cytoskeleton reorganization [22, 28]. ERK1/2 
is also involved in promoting the expression of proteases that will degrade the ECM, such as 
MMPs, including MMP-9, and uPA, through activation of transcriptional factor, AP-1 [20, 
22].  Because the JNK and p38 pathways are typically associated with cell stress, I believe 
that the ERK pathway is the important pathway in the mechanism utilized by APC to induce 
cell migration. In addition, this pathway has been implicated in other studies focused on the 
proliferative effects of APC. 
  For GPCRs, activation of the receptor typically involves the binding to extracellular 
ligands. One type of GPCR, PARs, will be cleaved at specific residues on the NH2-terminal 
region with the ligand remaining tethered to the receptor. Activation leads to a conformation 
change in the GPCR, which allows for the removal of GDP and binding of GTP to G-protein 
α subunit (Gα). The Gα bound to GTP will disassociate from the receptor and the β/γ 
subunits (Gβ/γ). Both the GTP bound Gα and the Gβ/γ can modulate various signaling 
pathways [30, 31]. Gαi can activate Ras, which will activate the MAPK pathway. Gαq can 
also activate PLC, which will also activate the MAPK pathway. Gβ/γ subunits can activate 
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PI3K isozyme γ, which will phosphorylate MEK1/2, a MAPKK in the MAPK pathway [32]. 
PI3K isozyme γ can also activate Akt [33]. 
 It has been experimentally shown that GPCRs can transactivate epidermal growth 
factor receptor (EGFR) and tumor necrosis factor-α (TNF-α)-converting enzyme (TACE). 
Activation of EGFR occurs when the Gα or β/γ activate Src [34, 35]. Src phosphorylates the 
cytoplasmic end of EGFR at Tyr 845 [36], which leads to the activation of the MAPK 
pathway and amplification of the PI3K pathway. TACE, a member of a disintegrin and 
metalloprotease (ADAM; known as ADAM17) family, is activated also by the Gα and/or 
β/γ. TACE will cleave transmembrane bound ligands, such as of heparin bound-EGF [37-39]. 
EGF will bind to EGFR and result in the activation of signaling pathways [40-42].  
 Both GPCR, specifically PAR-1, and EGFR are important for APC-induced cell 
migration. I believe that APC utilizes both receptors to amplify the signal to increase cell 
migration in both cancer cells and endothelial cells through the PI3K and MAPK, specifically 
ERK, pathways. Both receptors have been implicated in the other non-hemostatic effects of 
APC, including its anti-inflammatory and anti-apoptic roles. It is possible that APC could 
also use these receptors to activate pathways and amplify the signal in the cell to increase cell 
migration. 
 
E. Hemostatic Function of the Protein C Pathway 
As mentioned before, components of the coagulation pathway interact with tumor 
cells both in circulation and in the organs. The blood vessels that form during tumor 
angiogenesis and tissue repair are leaky, allowing for interaction of cell surface components 
with coagulation proteins. Leaky vessels result in activation of the extrinsic pathway of 
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coagulation. This pathway brings about IIa generation and fibrin deposition. Degradation of 
the fibrin clot is mediated through uPA, tPA, and plasmin, which can also activate MMPs. IIa 
will bind to thrombomodulin (TM) and activate PC. APC can now interact with endothelial 
cells and tumor cells. The goal of this project was to characterize the mechanism of the APC-
mediated effects on invasion and chemotaxis of breast cancer cells and endothelial cells. The 
final sections describe in detail the biological roles of the Protein C Pathway. 
When the blood vessel wall is injured, endothelial cells are torn away from the vessel 
surface and the underlying tissue factor (TF) bearing cells, such as smooth muscle cells, are 
exposed to the blood plasma. Factor VII circulating in plasma binds to TF and becomes 
activated by proteases at the site of injury. Factor VIIa-TF complex will activate factors X 
and IX. Factor Xa and factor Va still on the cell surface will produce enough IIa to activate 
platelets through PAR-1 and -4 and activate factor VIII. During platelet activation, platelets 
localize to the site of injury and adhere to each other and the damaged vessel wall. They 
release α-granules containing factor V, which is activated by IIa and any previously activated 
factor Va. IIa will also cleave von Willebrand factor/factor VIII bound to the platelet surface 
to release factor VIII and activate it. Factors IXa when bound to factor VIIIa on the platelet 
surface will activate factor X. Factor Xa will then complex with factor Va and the zymogen 
prothrombinase to produce enough IIa to form a fibrin clot. IIa will cleave fibrinogen to 
fibrin. Fibrin polymerizes and forms the clot [43-45]. Actions are taken to control the size of 
the fibrin clot to guarantee proper blood flow through the area. The protein C pathway works 
to control IIa formation in the area surrounding the clot. Zymogen protein C circulating in the 
plasma is localized to the endothelium surface by endothelial cell protein C receptor (EPCR). 
Protein C is brought to a nearby receptor complex of IIa bound to thrombomodulin (TM) and 
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is activated. In the presence of protein S, APC inactivates factors Va and VIIIa that are 
beyond the area of the clot, preventing any unnecessary activation of IIa [44, 46].  
Because of this anti-coagulant function of APC, it was believed that it would prevent 
the formation of thrombi in the micro-circulation of organs during sepsis. However, it was 
shown in human clinical trials that APC could do much more. 
 
F. Non-Hemostatic Function of Activated Protein C 
 Investigation into the non-hemostatic functions of APC has shown that it not only has 
an anticoagulant role but also has anti-inflammatory, anti-apoptotic, pro-migratory, and pro-
angiogenic roles. In a clinical trial, the Recombinant Human Activated Protein C Worldwide 
Evaluation in Severe Sepsis (PROWESS), patients diagnosed with sepsis with acute organ 
dysfunction were treated with recombinant human APC for 96 hours and monitored for 28 
days. Treatment with APC reduced the death rate by 19.4%. Because of the anticoagulant 
role of APC, it was initially thought APC was reducing the formation of thrombi in the 
microcirculation of organs, which would lead to organ failure. However, it was also shown 
APC inhibition of IIa formation prevented IIa from activating inflammatory pathways. APC 
also inhibited production of inflammatory cytokines by monocytes and the binding of 
immune cells to selectins on endothelial cells [47, 48]. It was previously shown that young 
patients with purpura fulminans-associated meningococcemia treated with APC had a 
decreased death rate and reduced number of amputations [49]. From these studies, it is 
concluded that APC is not only anti-coagulant but can affect inflammation and other cellular 
processes.  
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Animal studies have further examined the anti-inflammatory effects of APC. In 
asthma studies, mice treated with an inhalation of APC exhibited a reduction in T helper 2 
cytokines expression, IgE, and eosinophils. APC also reduced the binding of co-factors to 
STAT6 and NFκB in the lung, further reducing the inflammatory response [50]. Using APC 
as a treatment in an endotoxin-induced hypotension model resulted in a reduction in iNOS 
mRNA and production of NO2-/NO3-. This reduction leads to a decrease in TNF-α expression 
in the lung [51]. In vivo wound healing models have also shown a reduction in the 
inflammation in the affected area with APC treatment [52]. Knockout animal models along 
with the use of blocking antibodies have been used to further define the role of APC in 
modulating inflammation. Baboons were infected with a sublethal level of E. coli were also 
given antibodies that blocked the binding of APC/PC to EPCR. Blocking this receptor led to 
an increase in thrombus formation and hemorrhage particularly in adrenal and renal cortex as 
well as a reduction in neutrophil infiltration. It was concluded that APC/PC binding to EPCR 
was responsible for its ability to regulate coagulation and inflammation [53]. EPCR-deficient 
mice and mice injected with blocking antibodies to PAR-1 cleavage site were used in a 
murine ischemic stroke model. APC treatment reduced neutrophil infiltration into the 
affected area, which did not occur in the EPCR-/- mice and mice were treated with blocking 
antibodies to PAR-1 [54]. It was concluded that APC bound to EPCR was able to cleave 
PAR-1 at the amino terminal extracellular domain, RSFLLRN, the same site as IIa [6, 54-
57]. Yet, IIa cleavage of PAR-1 has pro-inflammatory, pro-coagulant, and pro-adhesive 
effects [6, 55, 56]. These studies identify how important it is for APC to interact with EPCR 
and PAR-1 in order to affect inflammation. APC does not have any effect while in solution. 
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Work has also been done to identify how APC reduces inflammation. In vitro, 
eosinophils and lymphocytes migration towards chemoattractants was inhibited in the 
presence of APC through its binding to EPCR [58] and EGFR [58, 59]. Gene array studies 
done on endothelial cells showed an alteration in gene expression patterns with APC 
treatment [60]. With regards to inflammation, APC treatment reduced the expression of 
NFκB2 in endothelial cells pretreated with or without TNF-α [60]. However, in another gene 
array study using endothelial cells, APC was shown to induce MCP-1 through PAR-1 
activation [61]. MCP-1, known to be a pro-inflammatory cytokine, has also been shown to be 
protective during sepsis by reducing the expression of inflammatory cytokines [62]. APC 
was shown to not be signaling through EPCR, as mutations in the palmitoylation sites on the 
cytoplasmic tail had no effect on activation of the Egr-1 promoter shown using a luciferase 
activity assay [61]. 
In vitro and in vivo studies have also studied the role of APC as a modulator of 
apoptosis. In vitro work looked to identify how APC affects cells undergoing apoptosis and 
the receptors APC binds to alter apoptosis. Using various cell lines, APC treatment reduced 
the number of cells undergoing hypoxia-, staurosporine-, and N-methyl-D-aspartate 
(NMDA)-induced apoptosis by altering the expression and activation of various pro- and 
anti-apoptotic proteases, including p53, caspases, and Bcl-2. Blocking antibodies to the 
APC/PC binding site of EPCR [54, 63], the N-terminal cleavage site of PAR-1[54, 63, 64], 
and the N-terminus of PAR-3 in mice [64] independently reversed the effects of APC on 
apoptosis. It was further shown that the active form of APC was required to reduce apoptosis 
[54, 63, 64]. APC treatment reduced the expression and protein levels of p53 [54, 64], the 
protein levels of Bax [54, 64], a pro-apoptotic factor, active caspase 3 levels [54, 63-65], and 
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active caspase 8 [64, 65]. APC also increased the expression [60] and protein level [54, 64] 
of Bcl-2, an inhibitor of caspase directed apoptosis.  Gene array analysis of endothelial cells 
treated with APC showed an increase in the expression of anti-apoptotic associated genes, 
including Bcl-2 A1, IAP, and cell cycle related gene, Gu helicase [60]. When these cells 
were pretreated with TNF-α, APC further enhanced the expression of anti-apoptotic genes 
Bcl-2 A1, IAP B, TNF-α-induced A20, IκB, and the cell cycle related gene Gu helicase [60]. 
Finally, APC increased the expression of the cell survival associated gene, PCNA, in 
endothelial cells pretreated with TNF-α [60]. These studies have identified the receptors that 
APC is interacting with to affect inflammation along with the genes/proteins that APC is 
regulating. However, there has been no work done to identify the signaling pathways 
activated by APC to affect these genes/proteins. Identifying these pathways would help us 
understand how APC signaling, resulting in anti-inflammatory effects, varies from IIa 
signaling, resulting in pro-inflammatory effects. From all of this work, I can focus on three 
potential receptors, EPCR, PAR-1, and EGFR, which APC could be interacting with to 
increase cell migration.  
In vivo work has confirmed in vitro findings that APC has anti-apoptotic effects. In a 
murine ischemic stroke model and tPA induced cerebral ischemia, APC has been shown to 
reduce the motor neurological score and the volume of brain injury in a dose dependent 
manner [54, 65, 66]. Treatment with higher doses of APC also decreased fibrin deposition 
[65] and neutrophil infiltration [54, 66], while increasing the post-ishemic cerebral blood 
flow in the murine brains affected by focal ischemic stroke [54, 65, 66]. Additionally, APC 
reduced the expression of ICAM-1 of endothelial cells in the area affected, thereby reducing 
the adhesion of neutrophils to the endothelium [66]. Apoptosis was shown to be reduced with 
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APC treatment through a reduction of both caspase 3 and 8 activities [65]. The anti-
inflammatory, anti-apoptotic, neuroprotective effects of APC were shown to be mediated 
through EPCR and PAR-1 [54]. In mice injected with NMDA to induce apoptosis, APC 
reduced the affected area in a dose dependent manner, which was reversed by blocking 
antibodies to PAR-1 and PAR-3 [64]. The most important information from these in vivo 
studies that I can utilize for my thesis is the potential receptors APC could be interacting with 
on the cell surface. APC can improve recovery from a stroke, which included the increase in 
post-ischemic cerebral blood flow. This increase could occur through APC anti-coagulant 
role and/or through its ability to increase cell migration in angiogenesis. 
APC has also been shown to have a role in promoting cell migration of various cell 
types. APC was shown to increase invasion of two different cancer cell lines through 
Matrigel by complexing with PAI-1 to allow for uPA to activate other ECM proteases [67]. 
uPA binds to urokinase plasminogen activator receptor (uPAR) on the cell surface and 
activates plasminogen to plasmin. uPA has been shown to not only activate MMP-2 but also 
regulate MMP-9 expression [68-70]. Plasmin activates MMP-9 [71] and MMP-2 [72]. 
However, this mechanism is controversial, since the physiological relevance of APC 
inhibition by PAI-1 is still not well understood. Through zymography, APC was shown to 
directly activate MMP-2 from the intermediate to fully active form [73-76], independent of 
membrane-type 1-matrix metalloprotease (MT1-MMP) [74, 75]. It has also been shown that 
APC [74, 75] [76] and APC generated on the cell surface in the presence of IIa bound to TM 
can activate MMP-2 [73]. The question still remains whether or not APC can activate MMPs 
bound to the cell surface in solution. Keratinocytes used in an in vitro wound healing assay 
showed that APC increased migration by increasing the expression and activation of MMP-2 
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and increased proliferation by increasing expression of interleukin-6 and -8 (IL-6 and -8), 
two inducers of keratinocyte proliferation [77]. APC also decreased NFκB, which at high 
levels will inhibit keratinocyte migration and initiate cell death during Ca2+-induced 
differentiation [77]. In another study using keratinocytes, it was shown that APC induced 
further expression of EPCR, PAR-1, and MMP-2 along with activation of ERK and p38 [78]. 
Blocking the binding of APC to EPCR and PAR-1 prevented the APC-induced proliferation, 
increased expression of MMP-2, and activation of ERK and p38 [78]. In fibroblasts and 
endothelial cells, APC was shown to increase MMP-2, VEGF, and MCP-1, all of which are 
pro-angiogenic factors [52]. In a concentration dependent manner, APC increased HUVEC 
proliferation through activation of ERK1/2 and MEK1/2. Signaling was shown to be 
dependent on binding to EPCR, with PAR-1 activation only necessary for initial activation of 
the MAPK pathway [79]. This has been the only study to state that one receptor is more 
important than another. Previous work has stated APC does not signal through EPCR [61]. 
Therefore, further work is needed to understand how APC interacts with the receptors. 
Endothelial nitric oxide synthase (eNOS) phosphorylation through PI3K was also induced by 
APC [79].  Through eNOS activation, APC is able to increase angiogenesis in mouse cornea 
angiogenesis assay [79]. Using an in vivo rat skin healing model, APC increased 
angiogenesis through MMP-2 activity and reduced inflammation through a reduction in 
neutrophil infiltration [52]. Each study identifies various pathways that are activated by APC 
to effect cell migration. I can focus in on EPCR, PAR-1, and EGFR as potential receptors, 
the MAPK and PI3K pathways, and MMPs and the Plasminogen Activation System as 
potential extracellular proteases.  
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G. Regulation of APC and the Protein C Pathway by Serpins 
Serine protease inhibitors (serpins) regulate the activation of PC as well as its activity 
to control the activity of APC. Protein C inhibitor [PCI; also known as plasminogen activator 
inhibitor-1(PAI-3)] will inhibit APC in the presence of heparin [80-85] and will prevents 
protein C activation by binding to IIa bound to TM [80, 82, 85, 86]. To control cleavage of 
the fibrin clot, PCI also inhibits both uPA and tPA [80] [82, 87, 88]. PCI can also inhibit 
proteases within the coagulation cascade, such as IIa, factors Xa and XIa, and kallikrein [80, 
82] making it a regulator of IIa production. The question remains if PCI can also inhibit APC 
and its effects on cell migration, particularly if APC is bound to EPCR and interacting with 
PAR-1 and EGFR.  
APC can also be inhibited by PAI-1. PAI-1 is a vitronectin (VN)-binding serpin 
involved in the fibrinolytic regulation of the coagulation pathway. PAI-1 is produced by 
endothelial cells and other epithelial tissues. It has a very short half-life in circulation, 
approximately 1 hour. Binding to VN increases the half-life of PAI-1 to 4-6 hours [89-91] 
and catalyzes its inhibitory reactions with proteases such as APC [92]. Upon depostition of 
fibrin, tPA will cleave and activate plasminogen to plasmin. Plasmin will degrade the fibrin 
clot, controlling the size of the clot in the blood vessel and remove the clot once the vessel 
wall is repaired. To control the degradation of the clot by plasmin to allow for repair and 
prevent hemorrhage, PAI-1 will inhibit tPA [93] to control the activation of plasminogen. 
PAI-1 will also inhibit IIa [94, 95], APC [92], and uPA [96, 97]. Whether or not PAI-1 and 
APC interact has been controversial. Previously, it had been shown that APC and PAI-1 form 
a complex, but that APC could cleave PAI-1, and inactivate the serpin [98] [99-104] [105]. 
Kobayashi, et al. showed that APC would form a complex with and be inhibited by PAI-1 in 
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a tumor cell setting, allowing for uPA activity and an increase tumor cell invasion [67]. 
Recent work has shown that, in fact, PAI-1 inhibits APC and the rate of inhibition increased 
in the presence of vitronectin approximately 300-fold [92].  If APC is bound to the cell 
through EPCR, it is unknown whether or not PAI-1 can inhibit APC and regulate its non-
hemostatis function. 
The non-fibrinolytic functions of PAI-1 have been extensively studied in vascular 
disease and cancer. PAI-1 has been linked to obesity and diabetes [106]. Visceral adipose 
tissue produces high levels of PAI-1. Synthesis is upregulated by insulin, glucocorticoids, 
angiotensin II, fatty acids, TNF-α, and TGF-β [107]. Clinical data has shown that high levels 
of PAI-1 are associated with a bad prognosis following a myocardial infarction [108, 109]. 
Research looking into the effects of PAI-1 in the development of atherosclerosis is 
controversial. Some work has shown PAI-1 to be protective by limiting plaque formation and 
matrix remodeling in the vessel wall [110, 111], while others have shown that PAI-1 
inhibition of the fibrinolytic system allows formation of fibrin thrombi [112, 113]. PAI-1 has 
also been shown to inhibit smooth muscle cell migration [114, 115]. In hypertension, PAI-1 
has been associated with increase in collagen deposition when NOS is inhibited [116]. 
Inflammatory cytokines, IL-6 and IL-1β, induce PAI-1 expression, seen in hypertensive 
patients [117]. Finally, PAI-1 has also been associated with kidney disease due to increased 
fibrin deposition [118, 119]. However, the opposite effect has been seen in PAI-1 deficiency 
mice, where a lack of PAI-1 was associated with severe glomerular injury [120].  
 The same contradictory results have been seen with PAI-1 and cancer. PAI-1 and 
uPA expression in breast cancer tissue is elevated and associated with a poor prognosis and 
an increased risk of relapse [121, 122]. In vitro work has shown PAI-1 disrupting the binding 
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of uPAR-VN-integrins and uPA-uPAR-integrins, detaching the cell and facilitating invasion 
[123, 124] [125, 126]. In vivo, mouse models for cancer have shown that PAI-1 either has no 
effect on tumor growth or metastasis [127] [128], or its expression reduces growth and 
metastasis by inhibiting uPA and extracellular matrix degradation and angiogenesis [129-
132]. Further, other mice models have shown that PAI-1 is associated with increased 
proliferation and vascularity in tumors implanted in knock out mice [133]. It is hypothesized 
that the surrounding environment stimulates PAI-1 production, which in turn will increase 
cell motility, decrease cell adhesion, and promote chemotherapeutic resistance. 
Finally, APC can be regulated by α1-antitrypsin (α1-AT; also known as α1-protease 
inhibitor), a serpin that primarily inhibits neutrophil elastase [134]. α1-AT inhibits APC in a 
heparin-independent manner, with a very slow second-order rate constant of 10 M-1s-1 [135]. 
However, this serpin is hypothesized to not be a relavent inhibitor of the non-hemostatic 
functions of APC because of the slow inhibition rate. In the reactive center loop of α1-AT, 
the P1 residue that interacts with the serine protease is a methionine at position 358. A 
known variant of this residue from Met to Arg creates a mutant inhibitor with the ability to 
interact and inhibit numerous coagulation serine proteases involved in coagulation. 
Individuals with this mutation, called α1-AT Pittsburgh, have a fatal bleeding disorder [136]. 
As a result, α1-AT becomes a potent inhibitor of IIa, independent of heparin [136], kallikrein, 
factor XIIa fragment [137], factor XIa, and APC, again, also independent of heparin [138, 
139]. Because of the greater association rate of α1-AT Pittsburgh variant for IIa than APC, 
the half like of IIa in the plasma of α1-AT Pittsburgh patients is 0.1s [138]. Therefore, 
patients suffer form hemorrhaging rather than from thrombosis. It has been shown that the 
plasma concentration of PC is decreased in these patients as well [140] because of an 
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increase in association with the variant serpin over its association with its physiological 
inhibitor, PCI. The variant form of this serpin would probably be an excellent inhibitor of 
APC and its non-hemostatic functions. The question that still remains is whether or not it can 
inhibit APC when bound to the cell surface. 
  
H. Conclusion 
 Cell migration has a key role in multiple processes, including cancer metastasis and 
angiogenesis. Many factors are involved to not only promote the movement of cells, but to 
control this movement. Understanding how these factors work in concert to allow for normal 
cell migration will help us understand how additional factors can promote pathological cell 
migration. The goal of this dissertation, entitled the “Role of the Protein C System in Breast 
Cancer Cell Invasion and Endothelial Cell Angiogenesis”, is to identify how the Protein C 
Pathway, specifically APC, known traditionally for its anticoagulant role, is able to promote 
cell migration in both pathological and normal processes. Previous work has proposed 
several mechanisms that are involved in APC-induced cell migration. The work proposed in 
this dissertation looks to clarify and add to these proposed mechanisms. Additionally, this 
work will show how in one setting of normal cell migration, such as angiogenesis, APC can 
promote this processes and increase wound healing in stroke and cardiovascular diseases to 
the benefit of the patient, while in another setting of pathological cell migration, such as 
cancer metastasis, APC can advance the disease and be detrimental to the patient, all 
mediated through a similar mechanism.  
 Chapter 2 of this dissertation is a review of hemostasis, thrombosis, and fibrinolysis, 
focusing on the role of serpins and the state-of-the-art research being done to advance the 
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field. Chapter 3 is a research article describing the effects of APC on breast cancer cell 
migration, mediated through EPCR and PAR-1. Chapter 4 is a submitted publication 
characterizing the intracellular signaling events and extracellular processes activated by APC 
to induce breast cancer cell migration. Chapter 5 focuses on the vascular aspect of this 
dissertation. It describes the effects of APC on endothelial cell migration, tube formation, and 
aortic ring sprouting, mediated through EGFR, PI3K, and MMPs. Chapter 6 is a hypothesis 
paper that focuses on the relationship of PAI-1, the Metabolic Syndrome, and breast cancer. 
It reviews ongoing work and presents data that supports the connection of breast cancer to 
the Metabolic Syndrome through the common link, PAI-1. Finally, Chapter 7 summarizes the 
findings presented in this dissertation and provides an overview of the future direction of this 
work. The research in this dissertation contributes to our overall knowledge of APC and the 
Protein C Pathway in a non-traditional setting apart from hemostasis, and it provides 
mechanistic insight into the processes used by APC to promote cell migration.  
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Serpins in Thrombosis, Hemostasis and Fibrinolysis 
with Jill C. Rau‡, Lea M. Beaulieu‡, James A. Huntington and Frank C. Church 
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Summary 
Hemostasis and fibrinolysis, the biological processes that maintain proper blood flow, are the 
consequence of a complex series of cascading enzymatic reactions. Serine proteases involved 
in these processes are regulated by feedback loops, local cofactor molecules, and serine 
protease inhibitors (serpins). The delicate balance between proteolytic and inhibitory 
reactions in hemostasis and fibrinolysis, described by the Coagulation, Protein C and 
Fibrinolytic Pathways, can be disrupted resulting in the pathological conditions of thrombosis 
or abnormal bleeding. Medicine capitalizes on the importance of serpins, using therapeutics 
to manipulate the serpin-protease reactions for the treatment and prevention of thrombosis 
and hemorrhage. Therefore, investigation of serpins, their cofactors, and their structure-
function relationships is imperative for the development of state-of-the-art pharmaceuticals 
for the selective fine-tuning of hemostasis and fibrinolysis. This review describes key serpins 
important in the regulation of these pathways: antithrombin, heparin cofactor II, protein Z-
dependent protease inhibitor, α1-protease inhibitor, protein C inhibitor, α2-antiplasmin and 
plasminogen activator inhibitor-1. We focus on the biological function, the important 
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structural elements, their known non-hemostatic roles, the pathologies related to deficiencies 
or dysfunction, and the therapeutic roles of specific serpins. 
 
Introduction 
 Blood flow is maintained by the proper balance of hemostasis and fibrinolysis, an 
interdependent network of physiologic processes and succession of proteolytic reactions.  
Hemostasis, the physiologic cessation of bleeding, involves the interaction of 
vasoconstriction, platelet aggregation and coagulation. The end result of coagulation is the 
deposition of cross-linked fibrin polymers to form blood clots.  Both the Protein C and the 
Fibrinolytic Pathways are activated by the Coagulation Pathway and serve to restrict 
excessive clot formation or thrombosis.  The enzymatic reactions that propel these pathways 
are dominated by serine proteases and are subject to control by serpins and their local 
cofactors.  Dysfunction, deficiencies or over-expression of serpins can cause either abnormal 
bleeding or thrombosis. Investigations into the structure and related activities of serpins, their 
target proteases and cofactors has provided valuable information regarding both serpin-
related disease states and potential mechanisms by which medicine can manipulate serpin-
protease interactions for the treatment and prevention of thrombosis and bleeding. 
 
Hemostasis 
Coagulation Pathway  
 The factors of the Coagulation Pathway generally circulate in an inactive state until 
they are activated through proteolysis by an upstream factor. While the end goal of 
coagulation is fibrin polymerization, the most crucial feature of the Coagulation Pathway is 
25 
the generation of thrombin (Figure 2-1).  Thrombin is responsible for cleaving fibrinogen to 
fibrin, activating fXIII to fXIIIa (which cross-links fibrin), activating platelets, and positively 
feeding back into the cycle by activating upstream factors [141].  
Thrombin generation is initiated when damage to a vessel wall exposes the blood to tissue 
factor (TF) in the subendothelium [142].  TF is also expressed by activated platelets and 
leukocytes [143]. Therefore, coagulation can also be initiated by inflammation. TF forms a 
complex with fVIIa and activates fX.  Together, fVa and fXa form the prothrombinase 
complex which then cleaves a small amount of prothrombin (fII) to thrombin (fIIa).  This 
small amount of thrombin activates platelets, fV, fVIII and fXI, feeding back into the cycle to 
increase thrombin formation.  Factor IXa, previously activated by either TF-VIIa or by fXIa 
on the platelet surface, and fVIIIa in the presence of calcium, complex on the platelet surface 
to form the platelet tenase complex.  Platelet tenase activates more fX, which with fVa, 
generates a “thrombin burst” (Figure 2-1). It is this burst of thrombin rather than the initial 
thrombin activation that is crucial for the formation of a stable hemostatic plug [142]. 
 In addition to its role in hemostasis, thrombin regulates many pro-inflammatory 
processes including leukocyte adhesion molecule expression on the endothelium, platelet 
activation, leukocyte chemotaxis and endothelial cell production of pro-thrombotic factors 
[144].  Thrombin is also a potent growth factor, initiating endothelial, fibroblast and smooth 
muscle cell proliferation and up-regulating other cytokines and growth factors [145].  These 
activities have been attributed to proteolytic cleavage of insulin-like growth factor binding 
proteins [146] and  protease activated receptors -1, -3, and -4 (PAR-1, -3, -4) [56] on cell 
surfaces, and account for thrombin’s central role in atherosclerotic lesion formation [147].
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Figure 2-1. Serpin Regulation of Coagulation, Protein C and Fibrinolytic Pathways.  
Serpins and inhibitory functions are shown in red, thrombin activity is shown in cyan. 
Prothrombinase and tenase complexes are shown in grey boxes. Coagulation is initiated by 
the exposure of tissue factor to fVIIa shown in grey oval. The symbol  indicates 
degradation. Necessary cofactors, Ca++, phospholipids, proteins S and Z, vitronectin and 
GAGs are not shown to maintain the simplicity of the schematic. 
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 Coagulation is regulated predominantly by antithrombin (AT) [148], tissue factor 
pathway inhibitor (TFPI) [149], the Protein C Pathway [150] and to a lesser extent heparin 
cofactor II (HCII) [151] and protein Z-dependent protease inhibitor (ZPI) [152].  Protein C 
inhibitor (PCI) and plasminogen activator inhibitor (PAI-1) may also contribute by inhibiting 
thrombin [153] van [94].  TFPI is not a member of the serpin family and so will not be 
discussed in this paper. 
 
Protein C Pathway  
 The Protein C Pathway works in hemostasis to control thrombin formation in the area 
surrounding the clot [46].  The zymogen protein C (PC) is localized to the endothelium by 
endothelial cell protein C receptor (EPCR) [154]. Thrombin, generated via the Coagulation 
Pathway, is localized to the endothelium by binding to the integral membrane protein, 
thrombomodulin (TM). TM occupies exosite I on thrombin which is needed for fibrinogen 
binding and cleavage, thus reducing thrombin’s procoagulant activities [155].  However, TM 
bound thrombin is able to cleave PC to activated protein C (APC), a serine protease, on the 
endothelial cell surface [156]. In the presence of protein S, APC inactivates fVa and fVIIIa 
[157] (Figure 2-1).  This limits further thrombin generation on the clot periphery where the 
endothelium is not damaged [158]. 
 The Protein C Pathway is also associated with non-hemostatic functions. APC has 
been shown to be an anti-inflammatory protein [50, 59] and modulates gene expression [60].  
It also enhances vascular permeability by signaling through both PAR-1 and sphingosine 1-
phosphate receptor-1 [159]. Using focal ischemic stroke animal models, APC treatment 
restored blood flow, reduced infarct volume and inflammation [160]. These neuroprotective 
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effects of APC were shown to be mediated through EPCR, PAR-1 [54], and PAR-3 [64].  In 
the PROWESS Study, patients diagnosed with severe sepsis were treated with recombinant 
human APC, resulting in a mortality reduction of 19.4% [48]. 
 The proteolytic activity of APC is regulated predominantly by protein C inhibitor 
(PCI) [148]. Additionally, plasminogen activator inhibitor-1 (PAI-1) [92] and α1-protease 
inhibitor (α1PI) [161] have been shown to inhibit APC, although their role in the hemostasis 
is not well understood.   
 
Fibrinolysis 
Fibrinolytic Pathway  
 Fibrinolysis is the physiologic breakdown of fibrin to limit and resolve blood clots 
[162].  Fibrin is degraded primarily by the serine protease, plasmin, which circulates as a 
zymogen, plasminogen. In an auto-regulatory manner, fibrin serves as both the cofactor for 
the activation of plasminogen and the substrate for plasmin (Figure 2-1).  In the presence of 
fibrin, tissue plasminogen activator (tPA) cleaves plasminogen to plasmin which proteolyzes 
the fibrin. Because it is a necessary cofactor for the reaction, the degradation of fibrin limits 
further activation of plasminogen [163-165]. The serine protease, tPA, is synthesized and 
released by endothelial cells [162].  In addition to binding fibrin, tPA binds Annexin II 
(AnII) and other receptors on endothelial cell and platelet surfaces [166]. Thus, plasmin 
generation and fibrinolysis are restricted to the site of thrombus formation. 
 In addition to its role in fibrinolysis, plasmin has other physiologic functions as 
evidenced by its ability to degrade components of the extracellular matrix [167] and activate 
matrix metalloproteases 2 and 9 [168, 169].   Plasminogen can also be converted to plasmin 
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by the serine protease, urokinase plasminogen activator (uPA) [167].  Urokinase-catalyzed 
events are localized on the cell surface through the uPA receptor (uPAR).  Complex 
formation and subsequent reactions are thought to be more important during pericellular 
proteolysis, cell adhesion and migration than it is for vascular fibrinolysis [162]. These 
additional functions contribute to the role of the Fibrinolytic Pathway in cancer [167, 170, 
171]. 
 Fibrinolysis is controlled predominantly by α2-antiplasmin (α2AP) [172], PAI-1 [163, 
173] and thrombin activatable fibrinolysis inhibitor (TAFI) [80, 174].  PCI can inhibit tPA 
and uPA [80, 175], but its role in fibrinolysis is unclear. TAFI is not a member of the serpin 
family and so will not be discussed in this paper.  
 
Serpin Overview 
Serpins 
Serpins are a superfamily of proteins classified into 16 clades (A-P). The systematic name of 
each serpin is, SERPINXy where X is the clade and y is the number within the clade [176]. 
Serpins have been identified in the genomes of organisms representing all of the branches of 
life (Bacteria, Archaea, Eukarya and Viruses), and the genome of humans contains ~36 
serpins [177].  While serpins are named for their ability to inhibit serine proteases (of the 
chymotrypsin family) (Table 2-1), some are capable of cross-class inhibition of proteases 
from the subtilisin, papain and caspase families. In addition, some serpins utterly lack 
protease inhibitory activity and serve other roles, such as hormone transporters, molecular 
chaperones or catalysts for DNA condensation.  Serpins are typically composed of ~400 
amino acids, but can have large N-, C-terminal or internal insertion loops [176].  Serpins can 
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also be post-translationally modified by glycosylation, sulfation, phosphorylation and 
oxidation to alter their function. In spite of a low overall primary sequence identity for the 
family, serpins share a highly conserved three-dimensional fold comprised of a bundle of 9  
α-helices (A-I) and a β-sandwich composed of three β-sheets (A-C) (Figure 2-2A). It is 
useful to view a serpin in the ‘classic orientation’ to illustrate the important structural 
features (Figure 2-2A, left panel). In this view the main β-sheet A is facing and the reactive 
site loop (RSL) is on top. The RSL is typically composed of 20 amino acids running from 
P17 at the N-terminus (at the C-terminal end of strand 5A) to P3′ at the C-terminal end (using 
the nomenclature of Schechter and Berger, where residues are numbered from the scissile P1-
P1′ bond). In the normal native state of a serpin, β-sheet A is composed of five strands and 
the RSL (bridging the C-terminus of strand 5A to the N-terminus of strand 1C) is exposed. 
This state is, however, not the most stable. An astounding increase in thermodynamic 
stability (best estimate -32 kcal/mol) [192] can be achieved through the incorporation of the 
RSL into β-sheet A, triggered either through extension of strand 1C (to form the so-called 
‘latent’ state), or through proteolytic nicking anywhere near the scissile bond (the cleaved 
state).  The metastability of the native serpin is critical for its unusual mechanism of protease 
inhibition [193]). 
The Serpin Mechanism of Protease Inhibition 
 The serpin mechanism of protease inhibition has been worked out over the last 20 
years through a series of biochemical, fluorescence and structural studies. A minimalist 
kinetic scheme is composed of two steps: the formation of the encounter complex (also 
known as the Michaelis complex) where the sequence of the RSL is recognized by the 
protease as a substrate; and, the formation of a final covalent complex where the protease is 
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trapped in an inactive state (Figure 2-2B).  The rates of formation and dissociation of the 
reversible Michaelis complex, along with colocalization in tissues, determines the specificity 
of the serpin-protease interaction [90, 194]. While the obligate RSL-active site contacts 
contribute significantly to the formation of the Michaelis complexes, exosite interactions may 
also be involved. As with actual substrates of serine proteases, this step is followed by the 
nucleophilic attack of the peptide bond between the P1-P1′ residues by the catalytic Ser195 
of the protease. This ultimately results in the formation of a covalent ester bond between the 
P1 residue and Ser195 of the protease (acyl-enzyme intermediate), and then separation of the 
P′ residues from the active site of the protease. At this stage the serpin rapidly adopts its 
lowest energy conformation through the incorporation of the N-terminal portion of the RSL 
into β-sheet A. The tethered protease is thus flung from the top to the bottom of the serpin 
(~70Å), and the resulting pulling force exerted on the catalytic loop results in a 
conformational distortion of the protease [195]. The acyl-enzyme intermediate is thus 
trapped, with deacylation prevented largely due to the destruction of the oxyanion hole. Two 
structures of final complexes have been solved by X-ray crystallography [196, 197], with one 
showing an additional distortion of ~37% of the protease structure [197]. This mechanism is 
particularly well suited to tightly regulated processes such as hemostasis and fibrinolysis 
because inhibition is irreversible, and the conformational changes in the serpin and the 
protease alter cofactor interactions. An example of the physiologic relevance of the 
conformational change in the protease component of the complex is the complete destruction 
of thrombin’s exosite I in complex with serpins [198]. Thus, when PCI inhibits thrombin 
bound to thrombomodulin the interaction with thrombomodulin is broken, allowing the 
serpin-protease complex to diffuse away so that another thrombin molecule can bind [86]. 
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Table 2-1.  Second Order Rate Constants of Protease Inhibition by Serpins  
in the Presence and Absence of Cofactors.a 
SERPIN SYSTEMATIC NAME 
TARGET 
PROTEASE COFACTOR 
SECOND ORDER 
RATE k2 (M-1 s-1) 
CITATION 
-- 7.5 x 103, 1 x 104 [178], [179] 
UFH 2 x 107, 4.7 x 107 [178],[180] 
LMWH 5.3 x 106 [180] Thrombin 
pentasaccharide 2 x 104 [179] 
-- 2.5 x 103, 6 x 103 [181] 
UFH 5 x 106, 6.6 x 106 [179], [180] 
LMWH 1.3 x 106 [180] fXa 
pentasaccharide 7.5 x 105 [179] 
-- 1.3 x 102, 5 x 102 [179], [182] 
UFH 8 x 106, 1.75 x 106 [179], [182] 
LMWH 3.7 x 105 [182] 
AT SERPINC1 
fIXa 
pentasaccharide 3 x 104 [179] 
--  6 x 102 [183] 
UFH  5 x 106 [183] 
LMWH ~ 5 x 106 [184] 
Dermatan sulfate 1 x 107 [183] 
HCII SERPIND1 Thrombin 
hexasaccharide    2 x 104 [185] 
fXa  -- , Ca++, PL 2.3 x 103 [186] 
 protein  Z, Ca++, PL 6.1 x 105 [186] 
-- 2 x 105 [86]; [187] ZPI  SERPINA10 fIXa UFH 4 x 105 [86]; [187] 
-- 1.7 x 104 [86] 
UFH ~2 x 105 [86] Thrombin 
thrombomodulin 2.4 x 106 [86] 
-- 3 x 102 [188] APC UFH 5 x 104 [188] 
 UFH, Ca++ 2.9 x 105 [83] 
tPA (2-chain) -- 8 x 102 [80] 
PCI SERPINA5 
 UFH 3 x 104 [80] 
Thrombin -- 4.8 x 101 [189] α1PI SERPINA1 APC -- 4 x 101 [84] 
Thrombin  4.8 x 105 [190] α1PIPittsburgh  APC  7 x 104 [190] 
α2AP SERPINF2 Plasmin  2 x 107 [172]; [191] 
Thrombin -- 7.9 x 102 [94] 
 UFH 1.6 x 105 [95] 
 vitronectin 1.9 x 105 [95] 
APC -- 5.7 × 102 [92] 
 vitronectin 1.8  × 105 [92] 
PAI-1 SERPINE1 
tPA (1- , 2-chain) -- 4 x 107, 1.5 x 108 [97] 
aThe rates constants indicated here are from selected references and may vary slightly under 
different experimental conditions. UHF = Unfractionated heparin, LMWH = low molecular 
weight heparin, PL = phospholipids. 
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Figure 2-2. Serpin Structure and Mechanism of Protease Inhibition.  A. The shared serpin 
fold is illustrated by the structure of the prototypical native serpin α1PI. The ‘classic’ 
orientation shown on the left places the RSL (yellow) on top and the main β-sheet A (red) to 
the front. Sheets B and C are blue and orange, respectively, and helices A, D and H are 
colored green, cyan and magenta. The accessibility of the RSL is illustrated by rotating the 
molecule by 110° to the left along the long axis. It shows how the P1-P1′ (rods) scissile bond 
is exposed for proteolytic attack. Also clearer in this orientation are helices D and H which 
are the heparin binding helices. B. The serpin mechanism of protease inhibition is minimally 
expressed as a two step process. In the first step native serpin (ribbon with the P1 and P1′ 
residues as magenta balls, below) interacts reversibly with a protease (surface representation, 
colored according to temperature factors from blue to red) to form the Michaelis complex 
(middle). After formation of the acyl-enzyme intermediate the protease is flung to the 
opposite pole of the serpin and its catalytic architecture is destroyed, and consequently there 
is a loss of ordered structure (notice the smaller size and increase in temperature factors). 
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Cofactor Interactions 
 Because serpin specificity is determined largely by the rate of formation of the 
Michaelis complex, cofactors which bind to serpins (and sometimes the protease) can 
radically alter specificity [90]. Table 2-1 presents serpin second order rates of protease 
inhibition in the presence and absence of relevant cofactors. The best understood cofactor for 
serpins is the glycosaminoglycan (GAG), heparin. It binds to and activates most of the 
serpins involved in hemostasis and thrombosis [199]. Acceleration of protease inhibition is 
generally conferred through a template effect where the protease and the serpin bind to the 
same heparin chain. The hypothesis is that this co-occupation will limit the diffusional 
freedom from three to one dimension to increase the likelihood (rate) of encounter. In 
addition, heparin also provides a bridge between the serpin and the protease to help stabilize 
the Michaelis complex. However, heparin and other GAGs are also capable in some cases of 
altering the conformation of the serpin to permit more rapid complexation with proteases. 
The best characterized examples are AT and HCII, whose activation by heparin is the basis 
of its therapeutic anticoagulant effect. In the next sections we describe each of the serpins 
involved in hemostasis and fibrinolysis, their targets, the role of cofactors and available 
structural data. 
 
Serpins in Hemostasis and Fibrinolysis 
Antithrombin – SERPINC1 
 Antithrombin (AT) is a 58 kDa, 432 amino acid glycoprotein [200], synthesized in 
the liver, circulating at approximately 150 µg/mL with a half-life of ~3 days [201]. It is the 
most important physiologic inhibitor of the coagulation pathway [202].  As its name implies, 
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antithrombin inhibits thrombin.  Additionally, AT is capable of inhibiting all of the other 
proteolytic coagulation factors (e.g. factors IXa, Xa, and XIa). The predominance of its 
anticoagulant activity, however is focused on the regulation of fXa, fIXa and thrombin. 
Measurement of thrombin-AT (TAT) complex is used as a marker of hemostatic activation 
and helps diagnose thrombotic events [203]. Thrombin bound to fibrin, clot-bound thrombin, 
is protected from inhibition by AT [204]. This may explain the occurrence of rethrombosis 
after fibrinolytic therapy as clot-bound thrombin is released from the dissolving hemostatic 
plug [205]. 
 The anticoagulant activity of AT is dependent on its cofactor, heparin. Consisting of 
variably sulfated repeating dissacharide units, heparin can have a molecular weight ranging 
from 3 to 40 kDa [206-208].  A unique pentasaccharide sequence in heparin is responsible 
for the high affinity binding to AT [209]. In vivo forms of heparin relevant to AT include 
heparan sulfate found on the endothelium, and heparin released from endothelium-associated 
mast cell granules. The interaction of AT with heparan sulfate on the endothelium and 
subendothelium localizes AT activity to the vessel wall and maintains its normal, 
nonthrombogenic nature [201]. AT is expressed as both an α-form and a β-form. α-AT 
represents 90% of AT and is glycosylated at all four positions.  While comprising only 10% 
of AT, β-AT, which is not glycosylated at one position (N135), has a higher affinity for 
heparin and is thought to exert an overall larger anticoagulant effect [210]. 
Heparin utilizes two distinct mechanisms for accelerating protease inhibition by AT. AT 
undergoes a well characterized conformational change upon heparin binding, which expels 
the N-terminus of the RSL from β-sheet A (Figure 2-3A).  This ‘liberation’ of the RSL is 
sufficient to confer the majoritiy of the acceleration of fIXa and fXa inhibition, but 
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thrombin inhibition is not appreciably affected. Recently, the structures of the AT-heparin-
protease Michaelis complexes have been solved [196, 211, 212] revealing the interactions 
behind the allosteric and template mechanisms (Figure 2-3B). 
 In addition to its anticoagulant activity, AT has been shown to have anti-
inflammatory and anti-angiogenic functions.   These properties are independent of AT’s 
inhibitory activity. AT regulates inflammation by signalling through heparan sulfate on 
endothelial and leukocyte cell surfaces [213].  Latent and cleaved AT exerts anti-angiogenic 
effects [214] by binding cell surface heparan sulfate.  This blocks fibroblast growth factor-2 
and vascular endothelial cell growth factor from forming pro-angiogenic ternary signalling 
complexes with their protein receptors and the heparan sulfate co-receptors [215]. 
Antithrombin in Disease-- Inherited and acquired AT deficiency predisposes 
individuals to different degrees of thrombotic disease. The severity of thromophilia can be 
exacerbated by other risk factors for thrombosis. Inherited AT is classified as type I or type 
II. Type I deficiencies, which generally confer a higher thrombotic risk, are caused by 
geneticmutations that impair the synthesis and secretion of AT.  Type II deficiencies are 
caused by genetic mutations that functionally imparied AT. Variations in the degree of  
thrombophilia in inherited AT deficiencies can be attributed to homozygosity versus 
heterozygosity and where the mutation lies in the AT structure [216].  An up-to-date database  
of AT mutations can be found online at http:// www1.imperial.ac.uk/medicine/about/ 
divisions/is/haemo/coag/antithrombin [217].  Some research suggests that certain mutations 
predispose AT to convert to its latent form, which preferentially dimerizes with native β-AT. 
Dimerization reduces the presence of highly active AT monomers, thus increasing 
thrombogenicity [218].  Concern has been raised that therapeutic preparations of AT-
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Figure 2-3. Native and Complexed Serpin Structures.  A. The native structures of important 
hemostatic and fibrinolytic serpins are shown as ribbon diagrams, colored essentially as in 
Fig. 2. The monomeric structure of AT is shown in the left panel, and is similar to that of 
HCII with the partial insertion of the N-terminal portion of the RSL. A modeled position for 
the N-terminal tail of HCII is shown in magenta although its true position is not known. For 
AT, HCII and PAI-1 the heparin binding helix (helix D) is shown in cyan, but for PCI 
heparin binds to helix H (blue). The increased size and flexibility of the RSL of PCI is also 
evident from this depiction.  B. Some important serpin complexes are shown. Using S195A 
proteases it was possible to obtain the structures of the AT Michaelis complexes with 
thrombin (magenta) and fXa (magenta) with their activating synthetic heparins (SR123781 
and fondaparinux, rods). Similarly, the HCII-thrombin (blue) complex was also solved. The 
somatomedin domain of VN (magenta) binds to s1A and helix E to prevent the latent 
transition through expansion of sheet A. 
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concentrates (contain >10% latent AT) might have thrombotic effects. However, a recent 
study demonstrated that the addition of latent AT alone does not decrease the activity of AT 
in plasma [219]. Other mutated forms of AT do not show impaired activity or decreased AT 
levels in the standard hospital laboratory assays despite associated thrombophilia. In 
particular, the antithrombin Cambridge II (A384S) variant was found to be undetected by 
some protocols, but estimated to be the most frequent cause of antithrombin deficiency in 
Caucasian populations [220]. These results suggest a need for alternative methods for 
detection of AT deficiencies [221].   
 Antithrombin related treatements for coagulation disorders-- Therapeutic 
unfractionated heparin (UFH), derived from porcine mucosa, is one of the most commonly 
used anticoagulant agents administered for treatment and prophylaxis of thrombotic events.  
Additionally, UFH is used to coat blood collection tubes and surgical devices to prevent 
clotting on their surfaces.  UFH’s primary mechanism of action is to accelerate AT’s 
inhibition of thrombin, fXa and fIXa.  UFH also accelerates thrombin inhibition by other 
circulating serpins. It has a very short half-life and optimal dosing of heparin is notoriously 
difficult to achieve, therefore requiring frequent monitoring [222].  Still in trials, an orally 
available form of heparin, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate bound heparin 
or SNAC-heparin, has dose-dependent antithrombotic effects, and  has an efficacy 
comparable to low-molecular weight heparin in reducing venous thrombosis in patients 
undergoing hip replacement surgery [223]. Contraintuitively, heparin can cause a dangerous 
thrombotic condition called heparin induced thrombocytopenia (HIT).  In this autoimmune 
reaction antibodies develop against platelets [224].  Currently in development stages, 
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synthetic oligosaccharide heparin mimetics show thrombin and fXa inhibition comparable to 
UFH without inducing HIT and with far fewer side effects [225]. 
 Low molecular weight heparin (LMWH) is a fractionated preparation of heparin 
between 1 and 10 kDa with an enriched population of high affinity pentassacharide 
sequences.  Because of the smaller average size, LMWH acts predominantly by inducing 
conformational change in AT, the mechanism which activates fXa. It has a longer half-life 
than UFH and does not need coagulation monitoring. LMWH also has significantly reduced 
risk of HIT. Multiple LMWH variants are available or in clinical trials [226]. 
 Fondiparinux and idraparinux are synthetic pentassacharide sequences derived from 
heparin, which activate AT to specifically inhibit fXa.  Because of this the single target, the 
side effect of over-anticoagulation, bleeding, is reduced. Both have longer half-lives than 
LMWH. Additionally, neither preparation causes HIT [226, 227].  
 Thrombotic events due to antithrombin deficiency are treated with AT purified from 
human plasma.  A covalent AT-heparin complex is currently under preliminary 
investigations for possible use as a novel anticoagulant because unlike AT or heparin alone, 
it is able to inhibit clot-bound thrombin [228]. 
 
Heparin Cofactor II – SERPIND1 
 Heparin cofactor II (HCII) is a 66.5 kDa, 480 amino acid glycoprotein, synthesized in 
the liver, circulating at ~80 µg/mL with a half-life of 2-3 days. HCII inhibits thrombin in the 
presence of many polyanionic molecules including the GAGs heparin and dermatan sulfate 
[151].  A unique hexasaccharide sequence within dermatan sulfate has been determined to be 
responsible for its high affinity binding to HCII [229].  Dermatan sulfate does not accelerate 
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any other serpin activity.  HCII has a unique N-terminal extension of ~80 residues that 
contains two acidic regions, critical for its GAG-associated anti-thrombin activity [230]. 
HCII inhibits thrombin and clot-bound thrombin, but not other coagulation proteases [151]. 
Evidence suggests that HCII contributes 20-30% to thrombin inhibition in coagulation.  
Neither humans nor mice deficient in HCII exhibit thrombophilia under normal conditions 
[231]. However, HCII homozygous deficient mice form occlusive thrombi faster than wild-
type mice after photochemical vascular endothelial cell injury to the carotid artery [232]. 
Recent data suggests that the primary physiologic function of HCII is to inhibit thrombin’s 
non-hemostatic roles such as in the development of atherosclerosis. Elevated levels of HCII 
are shown to protect against atherosclerosis and restenosis [233-235]. 
 The structure of native HCII was solved in 2002 and revealed a surprising 
resemblance to native antithrombin [230], with the N-terminus of the RSL inserted into β-
sheet A (Fig. 2-3). As HCII also shares a similar heparin binding site along helix D [148, 
236], it was proposed that HCII underwent a similar conformational change upon heparin 
binding [230]. Recently, it was shown that the smallest heparin length capable of tight 
binding to HCII was 14 monosaccharide unit chains, and that the majority of the acceleration 
effect was due to this allosteric change in HCII conformation [184]. Disappointingly, 
however, the native structure could not resolve the position of the N-terminal extension. 
Several mutagenesis studies concluded that the acidic tail is binding to the basic heparin 
binding site in native HCII [236], but it is still unclear how the tail interacts with the body of 
HCII in the native state. From the structure of HCII bound to S195A thrombin [230] it was 
clear how the tail confers specificity to thrombin. The tail binds to exosite I of thrombin in a 
manner similar to the hirudin, primarily through hydrophobic contacts. The tail was found 
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sandwiched between thrombin and the body of HCII, essentially providing a shared exosite 
(Fig. 2-3B). A complex allosteric mechanism has been proposed based on these structures, 
supporting biochemical studies and analogy to AT [194, 199].  
 HCII related treatements for coagulation disorders-- As alternatives to heparin-based 
treatments, dermatan sulfate derivatives and other polyanionic molecules that act to 
accelerate HCII’s antithrombotic activity are being investigated. They are of particular 
interest for use in HIT, AT deficiency and for the inhibition of clot-bound thrombin. Two 
types of fractionated dermatan sulfate enriched for the hexasaccharide sequence (Intimatan™ 
and Desmin™) have been tested in humans [237, 238]. Intimatan is beginning Phase I trials. 
Other HCII agonists in laboratory investigations include over-sulfated dermatan sulfate 
[239], fucosylated chondroitin sulfate [240] and fucoidan [241]. 
 
Protein Z-dependent Protease Inhibitor– SERPINA10 
 Protein Z-dependent protease inhibitor (ZPI) is a 72 kDa, 444 amino acid 
glycoprotein, synthesized in the liver, circulating at ~1.5 µg/mL. In the presence of protein Z, 
phospholipids and calcium, ZPI rapidly inhibits fXa.  In the absence of cofactors, ZPI also 
inhibits factor XIa, which can be accelerated two-fold by heparin. It is thought that the major 
physiologic function of ZPI is to attenuate the coagulation response prior to the formation of 
the prothrombinase complex [86, 187]. In humans, mutations in ZPI are associated with 
increased risk of venous thrombosis [242-244]. Additionally, reductions in protein Z plasma 
concentrations result in an aggravated thromboembolic risk in humans and mice with  fVLeiden  
[245]. 
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Protein C Inhibitor – SERPINA5 
 PCI is 57 kDa, 387 amino acid glycoprotein [246], synthesized in the liver, 
circulating at ~5 µg/mL.  It is also found in other bodily fluids including urine, saliva, 
amniotic fluid, milk, tears and seminal fluid [88, 247]. PCI is a heparin-binding serpin that 
inhibits many proteases including APC [82], IIa, IIa bound to TM [86] tPA and uPA [88]. 
PCI may have contrary anticoagulant and procoagulant functions depending on the target 
protease and the presence of specific cofactors. In the presence of heparin, PCI is 
anticoagulant, inhibiting the proteolytic cleavage of fibrinogen by thrombin.  However, in the 
presence of TM, PCI is procoagulant, inhibiting the activation of PC by thrombin [148].   
 The structures of RSL-cleaved PCI [246] and of native PCI (PDB # 2HI9 and # 
2OL2) (Fig. 3A) have now been solved, revealing a typical serpin structure with some 
notable differences. The RSL of PCI is unusually long and flexible, accounting for its broad 
protease specificity, and its heparin-binding site is found along the highly basic helix H. The 
effect of heparin on PCI activity can either be to accelerate protease inhibition (e.g. APC) 
[248] or to abrogate it (tissue kallikrein) [249]. The position of the heparin-binding site close 
to the protease docking site may help explain this property. 
 Protein C Inhibitor in Disease-- PCI is not synthesized by the liver in mice, and thus 
PCI is unlikely to play a role in hemostasis or fibrinolysis in the mouse [250]. Transgenic 
mice that over-express human PCI (hPCI) provide evidence of PCI’s ability to inhibit 
thrombin, APC and tPA. These mice do not exhibit symptoms of pulmonary hypertension 
induced by monocrotaline. TAT complexes are reduced compared to their wild-type 
counterparts suggesting that PCI competes with AT to inhibit thrombin.  Additionally, a 
decrease in free tPA and subsequent reduction in fibrinolysis is seen.  Finally, when APC 
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was administered for endotoxemia, hPCI-expressing transgenic mice demonstrated a 
reduction in the anticoagulant and anti-inflammatory effects of the treatment [251].   Male 
homozygous PCI-knockout mice were infertile due to abnormal spermatogenesis caused by 
loss of the Sertoli cell barrier [252] due unregulated proteolytic activity.   
 In humans, APC-PCI complex is indicative of atherosclerosis and aortic aneurysms 
[253], an early indicator of myocardial infarction [254] and predicts poor patient outcome 
after aortic surgery [255]. Additionally APC-PCI complex is increased (4-fold) in patients 
with fVLeiden who have suffered a previous venous thrombosis [256].  PCI alone has been 
shown to be elevated in survivors of acute coronary events [257].  
 
α1-Protease Inhibitor – SERPINA1 
 α1-protease inhibitor (α1PI) – historically known as α1-antitrypsin – is a 51 kDa, 394 
amino acid glycoprotein, synthesized in the liver, circulating at ~1.3 mg/mL with a half-life 
of 4.5 days (structure shown in Fig. 2).  Its physiologic target is neutrophil elastase [134], 
however, it has also been shown to inhibit APC in a heparin-independent manner [161].  In 
pediatric ischemic stroke patients, α1PI levels were significantly increased independent of 
other pro-thrombotic factors.  Authors suggest this pathology is due to APC inhibition [258]. 
 α1PI is not thought to contribute significantly to coagulation.  However, a variant of 
the protein (α1PIPittsburgh) with a reactive site mutation (M358R) can cause a fatal bleeding 
disorder [136].  The Met ? Arg polymorphism creates a potent inhibitor of  several 
coagulation serine proteases, especially thrombin and APC, that is not dependent on heparin 
or other cofactors [259].  Therapies utilizing recombinant α1PIPittsburgh were considered but 
abandoned due to side effects of promiscuous protease inhibition [138, 140].  
44 
 
α2-antiplasmin – SERPINF2 
 α2-antiplasmin (α2AP) is a 63 kDa, 452 amino acid glycoprotein, synthesized in the 
liver, circulating at ~70 µg/ml with a half-life of 2.6 days [172, 260, 261].  α2AP is the 
primary physiological inhibitor of plasmin, but has also been reported to inhibit other 
enzymes such as trypsin, elastase, and APC.  Homozygous deficiency of α2AP results in 
uncontrolled fibrinolysis and subsequent severe hemorrhagic tendencies [260, 262]. While 
α2AP has all of the key structural features of the serpin family, it uniquely has both N- and 
C-terminal extensions of 42 and 55 residues, respectively [172, 263].  In thrombus formation, 
the N-terminal region of α2AP is cross-linked to fibrin by fXIIIa, and the C-terminal Lys 
binds to the Lys-binding site of plasmin. The rate of fibrinolysis is proportional to cross-
linked α2AP. 
 
Plasminogen Activator-1 – SERPINE1 
 PAI-1 is a 50 kDa, 379 amino acid glycoprotein, synthesized in endothelial cells, 
platelets and other mesenchymal cells surrounding the vasculature [264-266].  This serpin is 
relatively unstable with a half-life of 1-2 hours in circulation [267].  However, PAI-1 is 
found bound to the extracellular matrix protein, vitronectin (VN) [268, 269].  The PAI-1-VN 
complex has an enhanced half-life of 4-6 hours [267].  PAI-1 regulates both tPA and uPA 
and is considered the main physiological inhibitor of plasminogen activation [162, 163, 173, 
270].  As platelets are activated following vessel injury, they release PAI-1 to protect the 
developing thrombus from premature fibrinolysis.  Later in the coagulation process, tPA and 
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plasminogen/plasmin are bound to fibrin within the thrombus, which protects tPA from 
inhibition by PAI-1, resulting in plasmin generation and fibrinolysis [162, 163, 173, 270].   
 Several structures of PAI-1 have been solved, but, due to its rapid conversion to the 
latent form, all structures of native PAI-1 are of a stabilized quadruple mutant [271-273]. 
Although the structure shows a native state similar to α1PI, not AT and HCII, some 
mutagenesis studies suggest an equilibrium for wild-type PAI-1 where the native state is in 
equilibrium between α1PI-like and AT-like states [99, 274]. The structure of the stabilized 
mutant bound to the somatomedin domain of VN revealed the mechanism of stabilization of 
the native state through a blocking of the expansion of β-sheet A [269] (Fig. 3B). 
 PAI-1 can also inhibit APC [92] and thrombin [94, 95] in the presence of VN and/or 
heparin. It is not known to what extent these activities contribute to coagulation. Previously, 
it has been shown that APC cleaves PAI-1, inactivating the serpin [99, 105]. Recently, it has 
been shown that PAI-1 inhibits APC and the rate of inhibition increases in the presence of 
vitronectin ~300-fold [92].  
 Plasminogen Activator-1 in Disease-- Studies show that PAI-1 levels are sensitive to 
many different pathophysiological factors and increased synthesis of PAI-1 contributes to 
numerous cardiovascular disease states.  In metabolic syndrome, both glucose and insulin 
increase PAI-1 synthesis in vascular endothelial and smooth muscle cells [275].  Controlling 
hyperglycemia in type 2 diabetes results in a decrease in PAI-1 levels.  One of the clinical 
benefits of “statins” may be due to their decrease of PAI-1 expression and simultaneous 
increase of tPA expression, altering the balance of the Fibrinolytic Pathway [276, 277].  
Circadian clock proteins, including CLOCK, BMAL, and CRY, regulate PAI-1 gene 
expression which may explain the increased risk of adverse cardiovascular events in the 
46 
morning [278]. Inhibition of nitric oxide synthase induces PAI-1 expression, which 
contributes to the development of perivascular fibrosis [116].   Increased PAI-1 levels are 
associated with coronary artery disease and myocardial infarction.  However, studies 
examining the association of cardiovascular disease with a polymorphism within the PAI-1 
promoter region (4G/5G) which increases the expression PAI-1 are controversial [279]. 
Stents with rapamycin and paclitaxel are used in interventional cardiology due to the 
antiproliferative effects of these drugs [280, 281].  These stents have been shown to be 
associated with an increased risk of thrombosis and it is speculated that this may be due to an 
up-regulation of PAI-1 by rapamycin and paclitaxel [282]. There is also strong evidence for a 
role of PAI-1 in cancer metastasis independent of its protease inhibitory activity [171, 283, 
284]. 
 Effectors of Plasminogen Activator Inhibitor-1 Activity and Synthesis-- Physiological 
levels of PAI-1 provide crucial regulation of fibrinolysis, yet excess levels contribute to 
disease.  Numerous factors have been found that up-regulate PAI-1 expression and secretion, 
including inflammatory cytokines, angiotensin II, aldosterone, transforming growth factor-β, 
and very-low density lipoproteins [173, 285, 286].  Monoclonal antibodies have been 
prepared against PAI-1, which express inhibitory activity by (i) preventing the formation of 
the encounter complex between PAI-1 and tPA/uPA, (ii) increasing PAI’s susceptibility to 
cleavage by target proteases, and (iii) promoting the tendency of PAI-1 to become latent and 
inactive [287].  Sequence-specific catalytic DNA enzyme, short-interfering RNA structures, 
and antisense technology have all been used to down-regulate PAI-1 levels [288].  
Negatively charged organochemical compounds have been found to bind to a hydrophobic 
site on PAI-1 and induce polymerization and inactivation.  Finally, several small molecules 
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(XR5118, ZK4044, and PAI-039) have been developed to inhibit PAI-1 activity by either 
reduction of accessibility to the RSL, by promoting a latent-like state or by favoring a 
substrate-like conformation [289-291] [292-297].   
 
Closing Statement 
In this State of the Art manuscript, we have described our current knowledge of serpins that 
regulate hemostasis and fibrinolysis.  Utilizing the “suicide substrate” mechanism unique to 
serpins AT, HCII, ZPI, α1PI, PCI, α2AP and PAI-1 provide rapid and specific inhibition of 
the activated serine proteases in the Coagulation, Protein C and Fibrinolytic Pathways. These 
pathways are not single independent systems, but they represent a dynamic balance between 
procoagulant, anticoagulant, profibrinolytic and antifibrinolytic states with serpins playing 
multiple and sometimes conflicting roles. While we have learned a considerable amount 
about their physiologic control, their structure, related activities and regulation by local 
cofactors, much is left to be understood. Of note, there is deciphering the primary 
physiologic roles of HCII and PCI, resolving the crystal structures of ZPI and α2AP, and 
learning more about the non-hemostatic functions of AT and PAI-1.  Continued research with 
the less-studied serpins such as ZPI and α2AP will undoubtedly provide useful information 
about control of hemostasis and fibrinolysis and of serpins in general.  The serpins described 
in this paper have a multitude of functions, which under some circumstances contribute to 
disease, but which often can be maniupulated for the benefit of medicine.  Therefore, it is of 
paramount importance that we continue the investigations of serpins in thrombosis, 
hemostasis and fibrinolysis.  
 
 Chapter 3 
Activated Protein C Promotes Breast Cancer Cell Migration Through  
Interactions with EPCR and PAR-1 
with Lea M. Beaulieu and Frank C. Church, in (2007) Exp. Cell Res. 313(4): 677-687 
 
Summary 
 Activated protein C (APC) is a serine protease that regulates thrombin (IIa) 
production through inactivation of blood coagulation factors Va and VIIIa. APC also has 
non-hemostatic functions related to inflammation, proliferation, and apoptosis through 
various mechanisms. Using two breast cancer cell lines, MDA-MB-231 and MDA-MB-435, 
we investigated the role of APC in cell chemotaxis and invasion. Treatment of cells with 
increasing APC concentrations (1-50 mg/mL) increased invasion and chemotaxis in a 
concentration dependent manner. Only the active form of APC increased invasion and 
chemotaxis of the MDA-MB-231 cells when compared to 3 inactive APC derivatives. Using 
a modified “checkerboard” analysis, APC was shown to only affect migration when plated 
with the cells; therefore, APC is not a chemoattractant. Blocking antibodies to endothelial 
protein C receptor (EPCR) and protease activated receptor-1 (PAR-1) attenuated the effects 
of APC on chemotaxis in the MDA-MB-231 cells. Finally, treatment of the MDA-MB-231 
cells with the proliferation inhibitor, Na Butyrate, showed that APC did not increase 
migration by increasing cell number. Therefore, APC increases invasion and chemotaxis of 
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cells by binding to the cell surface and activating specific signaling pathways through EPCR 
and PAR-1. 
Introduction 
Activated protein C (APC) is a liver-derived serine protease [298], circulating in the 
blood as a zymogen [299, 300]. When the blood vessel wall is injured, the coagulation 
pathway is initiated to produce thrombin (IIa). IIa will cleave fibrinogen to fibrin, which 
polymerizes to form a clot. Circulating zymogen protein C (PC) localizes to the endothelial 
cell surface at the site of injury by binding to Endothelial Protein C Receptor (EPCR) [154]. 
EPCR facilitates the interaction of PC with the receptor complex of IIa:thrombomodulin 
(TM) on the endothelial cell surface, properly aligning PC with IIa [156].  IIa cleaves PC to 
generate activated protein C (APC) [301, 302]. Once it releases from EPCR, APC will 
inactivate coagulation factors Va and VIIIa [301, 303], in the presence of a cofactor, Protein 
S (PS) [304, 305]. A reduction of factors Va and VIIIa around the area of the clot prevents 
any further generation of IIa and effectively helps regulate hemostasis [44, 46]. Therefore, a 
key role of the protein C system is to control fibrin clot formation from expanding into the 
vessel without jeopardizing hemostasis and vessel repair.  
 Recent work has focused on other functions of the protein C system beyond 
hemostasis. Animal models using blocking antibodies to EPCR showed an important 
regulatory role of the protein C system with inflammation and coagulation related to E. coli 
infection [53]. In the Recombinant Human Activated Protein C Worldwide Evaluation in 
Severe Sepsis Study (PROWESS), patients diagnosed with sepsis and acute organ 
dysfunction were treated with recombinant human APC, which resulted in a mortality 
reduction of 19.4% [47, 48, 50]  [51, 58]. It was initially believed that APC increased patient 
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survival through its anticoagulant properties, reducing microvasculature thrombi formation 
and promoting blood flow. However, through in vitro and in vivo models, APC has been 
shown to not only regulate coagulation in the microvasculature but also affect inflammation, 
apoptosis, proliferation, and angiogenesis. APC inhibits apoptosis through upregulation of 
anti-apoptotic Bcl-2 [54, 60, 64], and down-regulation of p53, Bax [54, 64], and caspases 3 
[54, 64, 65], 8, and 9 [64, 65] all through interactions with EPCR and protease activated 
receptors (PAR).  Using a murine focal ischemic stroke model, human and mouse APC 
treatment restored blood flow, reduced infarct volume and edema, eliminated neutrophil 
infiltration, and reduced fibrin deposition [54, 64] [65, 66, 306], all mediated through EPCR 
[54], PAR-1 [54, 64], and PAR-3 [64]. 
 APC has also been shown to have a role in both cell migration and proliferation. 
APC/PC reduces the migration of immune cells towards chemoattractants through its binding 
to EPCR [58] and to epidermal growth factor receptor (EGFR) [59]. In a concentration 
dependent manner, APC increases human umbilical vein endothelial cells (HUVEC) 
proliferation through activation of the MAPK, PI3K, and eNOS pathways primarily via 
binding to EPCR rather than to PAR-1 [79]. In a mouse cornea angiogenesis assay, APC was 
shown to increase angiogenesis via the eNOS pathway [79]. APC increases proliferation and 
migration in keratinocytes by increasing the expression and activation of matrix 
metalloprotease-2 (MMP-2) [77]. Further, using a rat wound healing model, APC treatment 
reduced neutrophil infiltration and increased angiogenesis through MMP activation [52]. The 
initial studies looking at APC and cancer cell migration used ovarian cancer and 
choriocarcinoma cells in a transwell invasion assay [67]. These studies showed that APC 
formed a stable complex with PAI-1, which allowed for uPA to activate extracellular matrix 
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proteases and increase invasion [67]. From these results, it is hypothesized that APC has a 
regulatory role in migration that is mediated through various pathways both intracellularly 
and extracellularly. 
The first goal of this study was to characterize the effects of APC on cell invasion and 
chemotaxis using two breast cancer cell lines, MDA-MB-231 and MDA-MB-435, with 
transwell assays. The second goal was to study the interaction of APC with EPCR and PAR-
1, receptors involved in mediating other non-hemostatic effects of APC on expression of 
apoptotic genes and cell proliferation [57, 63] [54]. The following results show APC 
increases chemotaxis and invasion when incubated with the cancer cells, which requires 
active protease and is dependent on an interaction with both EPCR and PAR-1. 
 
Materials and Methods 
Cell Culture 
MDA-MB-231 and MDA-MB-435, two breast cancer cell lines, were grown in 
Minimum Essential Media (Gibco) with 10% FBS (Gemini), 1% sodium pyruvate (Gibco), 
and 1% antiobiotic/antimycotic (Gibco). Both of these cell lines were obtained from the UNC 
Lineberger Comprehensive Cancer Center Tissue Culture Core Facility. Human Umbilical 
Vein Endothelial Cells (HUVEC) were grown in Endothelial Basal Media (EBM) with 2% 
FBS, 0.4% bovine brain extract with heparin, 0.1% hydrocortisone, 0.1% human epidermal 
growth factor, and 0.1% Gentamicin/Amphotericin B-1000 (Cambrex). HUVEC were 
obtained from Cambrex. All cell lines were maintained at 37oC and 5% CO2. 
 
Transwell Invasion and Chemotaxis Assay 
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Invasion and chemotaxis [307, 308] were assayed using a transwell system in which 
cells are plated onto a porous membrane insert (pore diameter of 8 µm; BD Biosciences) and 
migrate through the pores to the underside towards a chemotactic agent placed in the well 
below. The inserts were either uncoated, indicative of chemotaxis, or coated with 1.67 µg/mL 
of Matrigel (BD Biosciences) per insert, indicative of invasion. 50,000 cells were plated per 
insert in serum free media (SFM) with 0.1% BSA, 1% sodium pyruvate, and 1% 
antiobiotic/antimycotic. The chemotactic agent for the breast cancer cells in the well below 
was media containing 10% FBS, 1% sodium pyruvate, and 1% antibiotic/antimycotic.  
Cells were plated with increasing concentrations of recombinant human APC (also 
known as Xigris®; 1-50 µg/mL; Eli Lilly and Co.), human 5-dimethylaminonaphthalene-1-
sulfonyl-glutamylglycylarginyl chloromethyl ketone (DEGR)-APC (10 µg/mL; 
Haematologic Technology), human PC (10 µg/mL; Haematologic Technology), S195A 
recombinant human APC (10 µg/mL; provided by Dr. Alireza R. Rezaie, St. Louis 
University, St Louis, MO), 5nM human α-IIa (Haematologic Technology), and 50 nM 
hirudin (Centerchem). Cells were pretreated at room temperature for 15 minutes with mouse 
serum IgG (4 or 30 µg/mL; Sigma), JNK 1494 anti-EPCR antibody (4 µg/mL; provided by 
Dr. Charles T. Esmon, OMRF, Oklahoma, OK), wede15 (20 µg/mL; Immunotech) and atap2 
(10 µg/mL; Zymed) (wede15 and atap2 are anti-PAR-1 antibodies) prior to treatment with 
APC or α-IIa. Cells were also pretreated for 1 h at room temperature with 10 mM Na 
Butyrate (Sigma) prior to treatment with APC. The MDA-MB-231 breast cancer cells were 
incubated at 37oC, 5% CO2 for 12 h for the chemotaxis assay and 24 h for the invasion assay. 
The MDA-MB-435 breast cancer cells were incubated for 24 h for the chemotaxis assay and 
48 h for the invasion assay.  
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The MDA-MB-231 cells were also used in modified “checkerboard” invasion and 
chemotaxis assays in order to determine if APC could also serve as a chemotactic agent. APC 
(10 µg/mL) in either SFM with 0.1% BSA or in media containing 10% FBS was plated with 
the cells onto Matrigel coated or uncoated inserts. These conditions were alternated with 
APC (10 µg/mL) in either SFM with 0.1% BSA or media containing 10% FBS placed in the 
well as the chemotactic agent. “Checkerboard” invasion and chemotaxis assays were 
incubated for 24 h. 
After incubation, cells that did not migrate through to the underside of the membrane 
were removed with a cotton-tipped applicator. The cells that migrated through to the 
underside of the membrane were fixed in 100% methanol, washed in 1X PBS, and stained 
with a nuclear fluorescence dye, Hoechst (1:20000 in 1X PBS; Molecular Probes). 
Membranes were then cut out from the inserts and mounted on glass sides in a 50% glycerol 
solution. Using a fluorescent microscope, the total number of cells were counted in 4-400X 
fields, averaged, and compared to no treatment [307, 308]. Each individual experiment was 
done in duplicate and data shown represents at least 3 experiments.  
 
APC Activity Assay 
 APC activity was assessed by measuring the cleavage of an APC specific 
chromogenic substrate. Excess conditioned media from setting up the transwell invasion and 
chemotaxis assays was centrifuged for 5 minutes at 500 x g to remove cells.  Fifty µL of the 
conditioned media was added to the APC substrate, Pefachrome Pca (final concentration of 
0.3 mM; Centerchem) in a 96-well plate coated with 0.2% BSA. Change in absorbance was 
read at 405 nm for 2 minutes. At the end of each transwell assay, 50 µL conditioned media 
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from the insert was added to substrate and the change in absorbance was measured. Each 
condition was done in triplicate and averaged. 
 
Generation of APC on a Cell Monolayer 
Assays were based on experiments done previously [156, 309-311], with 
modifications. Briefly, either HUVEC or MDA-MB-231 cells were grown to confluency in a 
96-well plate. Cells were washed with 1X PBS and serum starved overnight. Cells were 
washed two times with Hanks’ Balanced Salt Solution (HBSS) without phenol red. Either 
JNK 1494 anti-EPCR antibody (2-20 µg/mL) or mouse serum IgG (20 µg/mL) was added 
and incubated at room temperature for 15 minutes. Zymogen PC (100 nM) was added to the 
wells and incubated for an additional 15 minutes at room temperature. Finally, 2 nM α-IIa 
was added to each well, giving a final volume of 170 µL.  The reaction was incubated for 5 
minutes to 24 h. At each timepoint, 20 µL from each well was added to 5 nM hirudin 
(Haematologic Technologies), a specific IIa inhibitor, in a separate 96-well plate. 
Pefachrome Pca (0.15 mM) was added to each well and read at 405 nm for 30 minutes. Each 
condition was done in triplicate. 
 
Western Blots 
 Cells were grown to form a confluent monolayer and washed with 1X PBS. For 24 h, 
cells were treated with serum free media and collected. Cell lysate or conditioned media 
protein concentrations were determined with a dye-binding assay (Biorad), using BSA as a 
standard. 25 µg of total protein for the cell lysates or 10 µg of total protein for the 
conditioned media were loaded per sample, run reduced on a 12% polyacrylamide gel, and 
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transferred to PVDF (Millipore). Membranes were probed with a mouse monoclonal anti-
EPCR antibody (1:1000; JNK 1494), mouse monoclonal anti-PAR-1 (1:1000; Immunotech), 
rabbit polyclonal anti-Erk2 (1:1000; Santa Cruz Biotechnology), and a rabbit polyclonal anti-
PAI-1 antibody (1:1000; Molecular Innovations).  
 
Immunofluorescence 
 Cells were grown on Lab-Tek II chamber slides (Nunc) until they were at least 80% 
confluent. The cells were fixed in 2% paraformaldehyde in 1X PBS for 30 minutes at room 
temperature, then washed 2 times in 1X PBS. Cells were next treated with 0.2 M glycine and 
incubated for 20 minutes at room temperature and then washed an additional 2 times in 1X 
PBS. Cells were blocked in 10% goat serum in 1X PBS, 1% BSA for 30 minutes at room 
temperature. This was followed by incubation with either 50 µg/mL anti-EPCR (JNK 1494) 
or 40 µg/mL PAR-1 (Zymed) in 1X PBS, 1% BSA for 1 hour at room temperature. Negative 
controls were treated with buffer containing no primary antibody. Cells were then washed 5 
times with 1X PBS, 1% BSA and treated with 1:20 secondary anti-mouse IgG F(ab’)2 
fragment-R-phycoerythrin sheep antibody (Sigma) in 1X PBS, 1% BSA for 1 hour at room 
temperature. Cells were finally washed 5 times with 1X PBS and stored covered at 4oC in 1X 
PBS until photos were taken. Photographs were taken with an Olympus DP70 Microscope 
Digital Camera and DP70-BSW Software using an Olympus BX51WI fluorescent 
microscope with a TRITC filter. Photographs were taken at a 200X magnification with the 
same exposure time and sensitivity levels for each cell line and each antibody. 
 
Statistical Analysis 
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 For each transwell experiment, conditions were done in duplicate and averaged. 
Experiments were repeated as indicated in the figure legends. Averages of each condition 
were compared to No Treatment, APC, or α-IIa. All experiments were averaged and the 
percentages of No Treatment were reported. Averages of the comparisons of various APC or 
α-IIa treatments to APC or α-IIa alone treatments were also done (not reported). Statistical 
analysis was performed using a one sample T-test with a normal distribution, a theoretical 
mean of 100, and significance of p < 0.05 comparing back to No Treatment, APC, or α-IIa 
treatment.  
 
Results 
APC Increases Breast and Endothelial Cell Invasion and Chemotaxis 
Incubation of the MDA-MB-231 cells with increasing concentrations of APC (1-50 
µg/mL) increased both invasion and chemotaxis 150-300% compared to no treatment (Figure 
3-1A) in the transwell assays. Unexpectedly, the same effect was seen with the MDA-MB-
435 cell line when treated with increasing concentrations of APC (Figure 3-1B). APC 
increased the MDA-MB-435 cell invasion and chemotaxis 125-375% compared to no 
treatment. It was previously reported that APC increased ovarian cancer and choriocarcinoma 
cell invasion through Matrigel only when PAI-1 was present in the culture media [67]. This 
suggested that APC complexed to PAI-1, allowing uPA to increase activation of extracellular 
proteases. APC alone was believed to have no effect in the absence of PAI-1 [67]. From this 
study, we hypothesized APC would only increase invasion and chemotaxis in the MDA-MB-
231 cells because they express PAI-1 (inset in Figure 3-1A), and have no effect on the MDA- 
MB-435 cells since they do not express PAI-1 (inset in Figure 3-1A). 
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Figure 3-1. APC Increases Invasion and Chemotaxis of Breast Cancer Cells. Increasing 
concentrations of APC (0-50 µg/mL) are incubated with MDA-MB-231 cells (A) for 12 h 
transwell chemotaxis assay (white bars) and 24 h transwell invasion assay (black bars). Inset 
is a representative western blot showing the presence of PAI-1 in the conditioned media of 
HUVEC and MDA-MB-231 cells but PAI-1 is absent in the MDA-MB-435 cells. Increasing 
concentrations of APC were also incubated with MDA-MB-435 cells (B) for 24 h transwell 
chemotaxis assay (white bars) and 48 h transwell invasion assay (black bars). Cells migrate 
towards media containing 10% FBS as the chemotactic agent. The graphs represent the 
average of 8 separate experiments; * p<0.05, ** p<0.01, *** p<0.001 compared to No 
Treatment. (C) Hirudin (50 nM) is added with or without APC (10 µg/mL) to the MDA-MB-
231 cells in a 12 h transwell chemotaxis assay. As control, 5 nM α-IIa is added with or 
without hirudin (50 nM) in a 12 h transwell chemotaxis assay to verify effectiveness of 
hirudin. Cells migrated towards media containing 10% FBS as the chemotactic agent. The 
graphs represent the average of 5 experiments; * p<0.05, ** p<0.01, *** p<0.001 compared 
to No Treatment, aaa p<0.001 compared to Hirudin Treatment, bb p<0.01 compared to α-IIa 
Treatment. 
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Because APC treatment of MB-435 cells since they do not express PAI-1 (inset in Figure 3-
1A). Because APC treatment of both cell lines yielded the same result, it was concluded that 
APC was activating other mechanisms to increase cell invasion and chemotaxis in the 
transwell assay that are not dependent on the presence of endogenous PAI-1. Similar results 
were generated using HUVEC in the transwell assays, but with lower concentrations of APC, 
0.1-10 µg/mL (data not included).  These results indicate that the effects of APC on 
migration in the transwell assay are not isolated to cancer cells and, further, there is a 
common pathway among these three cell lines that is activated by APC.  The remainder of 
the studies presented here will focus on the effects of APC on the MDA-MB-231 cells as a 
model system for the effects of APC on cellular invasion and chemotaxis.   
 We also verified that thrombin, which could potentially be present in the APC 
preparation, was not responsible for promoting the increase in migration seen with APC 
treatment. Cells were treated with hirudin, a specific thrombin inhibitor, and APC in the 12 h 
transwell chemotaxis assay. As seen in Figure 3-1C, hirudin alone has no effect on cell 
migration when plated with the cells. APC significantly increases chemotaxis of the MDA-
MB-231 cells by 175% in either the presence or absence of hirudin. As a control, cells were 
also treated with α-IIa in the presence or absence of hirudin.  α-IIa alone increases 
chemotaxis of the MDA-MB-231 cells by 144%. This effect is lost with α-IIa and hirudin. 
Therefore, the effect of APC on cellular migration is due to APC alone and not the presence 
of trace amounts of α-IIa.  
 
Active Protease is Necessary to Increase Invasion and Chemotaxis of the MDA-MB-231 
Cells.  
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It is important to determine if active protease is necessary to increase cell migration in 
the transwell assays. The MDA-MB-231 cells were treated with APC, inactive forms of 
APC, or PC in a 12 h transwell chemotaxis assay and a 24 h transwell invasion assay. Active 
APC (10 µg/mL) was the only protease that significantly increased cell invasion by 190% 
(Figure 3-2A). The addition of inactive forms of APC- DEGR-APC, active site mutant APC 
(S195A) and zymogen PC - all at the same concentration had no effect on cell invasion. The 
same results were seen in the transwell chemotaxis assay with the MDA-MB-231 cells 
(Figure 3-2B). APC activity was verified by measuring the rate of cleavage of an APC 
specific chromogenic substrate. Conditioned media was sampled at the beginning and end of 
the experiment to verify the activity of the active and the inactive forms of APC, as seen in 
Figure 3-2C and 3-2D pre- and post-experiment.  These results indicate the active form of 
APC is necessary to increase invasion and chemotaxis in the MDA-MB-231 cells using the 
transwell system. 
 
APC Increases Chemotaxis of the MDA-MB-231 Cells, but It Is Not a Chemotactic Agent. 
 α-IIa, another serine protease, has been shown to be both a chemotactic agent for the 
MDA-MB-231 cells [8] and an enhancer of the cell’s response to chemotactic agents [8]. 
Using a modified “checkerboard” analysis, we next determined if APC could affect cell 
migration in the same manner as α-IIa. APC (10 µg/mL) was plated in the insert with the 
cells either in 10% FBS containing media or in SFM with 0.1% BSA. These conditions were 
varied with the conditions in the well below, where APC (10 µg/mL) was added with either 
10% FBS containing media or SFM with 0.1% BSA. All assays were run for 24 h in order to 
give APC sufficient time as a putative chemotactic agent. In the transwell chemotaxis assay, 
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Figure 3-2.  Active Protease is Necessary to Increase Invasion and Chemotaxis in the 
MDA-MB-231 Cells. 10 µg/mL APC, DEGR-APC, zymogen PC, and S195A APC were 
used in a 24 h transwell invasion assay (A) and 12 h transwell chemotaxis assay (B). Cells 
migrated towards media containing 10% FBS as the chemotactic agent. APC activity assays 
were done to verify the presence or absence of activity of each protease at the beginning 
(black bars) and at the end (white bars) of the transwell invasion (C) and chemotaxis (D) 
assays. The graphs represent the average of 4 separate experiments with the exception of 
S195A APC, which was done only 1-2 times due to the limited amount of protein available; 
*p<0.05 compared to No Treatment. 
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APC is not a chemotactic agent since there was no difference in the number of cells that 
migrated towards SFM, 0.1% BSA or 10% FBS containing media with or without APC 
(Table 3-1).  When the cells were plated in 10% FBS containing media with APC, there was 
no difference in the number of cells that migrated either to SFM, 0.1% BSA with or without 
APC or 10% FBS containing media with or without APC. When cells were plated in SFM, 
0.1% BSA with APC and migrated towards SFM, 0.1% BSA with or without APC, there 
was, again, no difference in the number of cells that migrated between the two conditions. In 
fact, there were very few cells that did migrate. The only difference seen with the modified 
checkerboard transwell chemotaxis assay was the increase in the number of cells that 
migrated when 10% FBS containing media was the chemotactic agent and APC was plated 
with the cells in SFM, 0.1% BSA. Similar results were seen in a modified checkerboard 
transwell invasion assay (data not shown). These results suggest that APC increases cell 
migration when plated with the MDA-MB-231 cells, enhancing the response of the cells to 
the chemotactic agent.   
 
APC Binding to EPCR is Necessary to Increase Chemotaxis of the MDA-MB-231 Cells. 
To study the role of EPCR in the pro-migratory effects of APC, we showed the 
presence of EPCR using both western blots of cell lysates (Figure 3-3A) and 
immunofluorescence staining of cell monolayers (Figure 3-3B) of HUVEC, as the positive 
control, and both breast cancer cell lines. A blocking antibody (JNK 1494) to the PC/APC 
binding site on EPCR [309-311] [156]was used in a 12 h transwell chemotaxis assay with the  
MDA-MB-231 cells. Initially, it was necessary to determine the optimal concentration of 
EPCR blocking antibody to use with the MDA-MB-231 cells. HUVEC, as a control, and 
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Table 3-1: Modified Checkerboard Analysis of APC on Chemotaxis of the MDA-MB-231 Cellsa 
  APC Concentration (mg/mL) Above Membrane 
APC Concentration 
(µg/mL) Below Membrane 0 + SFM 10 + SFM 0 + 10% FBS 10 + 10% FBS 
0 + SFM 5.0 ± 6.5 2.4 ± 2.3 113.4 ± 28.4 64.3 ± 33.9 
10 + SFM 1.6 ± 1.7 1.9 ± 3.1 82.0 ± 29.1 104.2 ± 27.0 
0 + 10% FBS 498.8 ± 112.9 590.7 ± 148.5 156.1 ± 46.2 188.1 ± 68.7 
10 + 10% FBS 471.3 ± 120.9 341.7 ± 84.2 148.1 ± 42.6 144.1 ± 44.1 
aTwo different concentrations of APC (0 and 10 mg/mL) were added above or below the 
uncoated insert membrane in wither SFM-0.1% BSA or media containing 10% FBS. After a 24 h 
incubation, the number of cells that underwent chemotaxis were determined as described in the 
"Material and Methods". Data represents the mean number of cells that migrated ± standard 
deviation of 4 separate experiments, each done in duplicate. 
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Figure 3-3. PAI-1, EPCR, and PAR-1 Expression in HUVEC, MDA-MB-231, and MDA-
MB-435 Cell Lines.  Representative western blots (A) showing the presence of EPCR and 
PAR-1 in cell lysates of HUVEC, MDA-MB-231, and MDA-MB-435 cells. Total Erk2 is 
used as a loading control. Immunofluorescence staining (B), as described in the Material and 
Methods, was done on the HUVEC, MDA-MB-231, and MDA-MB-435 cell lines to show 
the expression pattern of EPCR and PAR-1 on the cell surface. 
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MDA-MB-231 cells were treated with increasing concentrations of the EPCR blocking 
antibody to block the generation of APC on the cell surface [156, 309-311]. Figure 3-4A and 
4B shows the generation of APC on both HUVEC and MDA-MB-231 cell surfaces increases 
over time in the absence and presence of control mouse IgG. The generation of APC is 
reduced in the presence of the anti-EPCR antibody, even at a concentration of 2 µg/mL. 
Reduction of APC generation was seen out to 24 h at concentrations as low as 4 µg/mL.  
 In the transwell chemotaxis assay, MDA-MB-231 cells were pre-incubated with 4 
µg/mL control mouse IgG or anti-EPCR antibody for 15 minutes at room temperature prior 
to APC treatment. In Figure 3-5, there was a 150 and 130% increase in chemotaxis when the 
cells were incubated with 10 µg/mL APC or APC and control IgG, respectively, compared to 
no treatment. Neither control IgG alone nor anti-EPCR antibody alone had an effect on 
chemotaxis. However, anti-EPCR antibody (4 µg/mL) attenuated the effects of APC, 
reducing chemotaxis back to baseline. These results indicate that an interaction between APC 
and EPCR is necessary to increase chemotaxis in the MDA-MB-231 cells. 
 
APC Interaction with PAR-1 is also Necessary to Increase Chemotaxis of the MDA-MB-231 
Cells. 
PAR-1 has been shown to be involved in mediating the non-hemostatic effects of 
APC [54, 63, 64, 79].  With western blots of cell lysates (Figure 3-3A) and 
immunofluorescence staining of cell monolayers (Figure 3-3B) of HUVEC, as a positive 
control, and both cancer cell lines, we verified the presence and expression of PAR-1 on the 
cell surface. To study the role of PAR-1 in the pro-migratory effects of APC with the MDA-
65 
  
Figure 3-4. Generation of APC on Either HUVEC (A) or MDA-MB-231 (B) Cell 
Monolayer is Blocked With Anti-EPCR Antibody. In a 96-well plate, serum starved 
confluent monolayers were treated with either buffer, 20 µg/mL mouse serum IgG, or (0-20 
µg/mL) anti-EPCR (JNK 1494) antibody for 15 minutes. Cells were then treated with 
zymogen PC (100 nM) for an additional 15 minutes. α-IIa (2 nM) was added and samples 
were taken from each well at various timepoints from 5 minutes – 24 h. Samples were added 
to hirudin (5 nM) and APC substrate (0.15 mM). The change in absorbance was read at 405 
nm. The graphs represent the average of 3 separate experiments for HUVEC (A) and 4 
separate experiments for MDA-MB-231 (B) done in triplicate.  α-IIa only;  α-IIa 
and PC;  20 µg/mL mouse serum IgG, α-IIa, PC;  2 µg/mL anti-EPCR IgG, α-IIa, 
PC;  4 µg/mL anti-EPCR IgG, α-IIa, PC;  10 µg/mL anti-EPCR IgG, α-IIa, PC; 
 20 µg/mL anti-EPCR IgG, α-IIa, PC. 
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Figure 3-5. APC Binds to EPCR to Increase Chemotaxis in the MDA-MB-231 Cells. Cells 
were pretreated with either anti-EPCR IgG (JNK1494; 4 µg/mL) or mouse serum IgG (4 
µg/mL) for 15 minutes prior to the addition of APC (10 µg/mL) in a transwell chemotaxis 
assay incubated for 12h. Cells migrated towards media containing 10% FBS as the 
chemotactic agent. The graphs represent an average of 6 separate experiments; **p<0.01 
compared to No Treatment; a p<0.01 compared to APC treatment or APC and mouse serum 
IgG treatment. 
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MB-231 cells, two PAR-1 blocking antibodies were used in a 12 h transwell chemotaxis 
assay. The cells were pre-incubated with either PAR-1 blocking antibodies (wede15 and 
atap2) or control mouse IgG for 15 minutes at room temperature prior to APC treatment. In 
Figure 3-6, 10 µg/mL APC (± control IgG) increased chemotaxis approximately 150%. In the 
presence of PAR-1 blocking antibodies, the effects of APC was attenuated. To verify that the 
PAR-1 blocking antibodies were properly blocking the binding of the protease to the 
receptor, cells were also treated with 5 nM α-IIa, a known ligand of the PAR-1 receptor that 
will affect migration of the MDA-MB-231 through its activation [8, 312, 313]. α-IIa alone or 
α-IIa with control IgG increased chemotaxis approximately 150%, and this increase was 
attenuated in the presence of the PAR-1 blocking antibodies. These results suggest that 
binding of APC to EPCR and PAR-1 are necessary to increase chemotaxis in the MDA-MB-
231 cells. 
 
APC Does Not Increases Chemotaxis of the MDA-MB-231 Cells By Increasing Cell Number. 
 Na Butyrate was used as an inhibitor of proliferation to determine if APC increases 
the number of cells that migrate in the transwell assays by increasing proliferation. Treatment 
of the MDA-MB-231 cells with 10 mM Na Butyrate in 12 h reduces cell proliferation but 
does not induce apoptosis (data not shown). In a 12 h chemotaxis assay (Figure 3-7), Na 
Butyrate reduces chemotaxis compared to no treatment as expected due to differentiation and 
inhibition of undefined pathways in breast cancer cells. When APC is added with Na 
Butyrate, APC increases cell chemotaxis over Na Butyrate treatment alone (approximately 
150% increase over Na Butyrate treatment alone), which is the approximately the same ratio 
as APC treatment alone compared to no treatment (approximately 130% increase over No 
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Figure 3-6.  Interaction with PAR-1 is Necessary for APC to Increase Chemotaxis in the 
MDA-MB-231 Cells. Cells were pretreated with either PAR-1 blocking IgG (10 µg/mL atap2 
and 20 µg/mL wede15) or 30 µg/mL mouse serum IgG for 15 minutes prior to addition of 
APC (10 µg/mL) or α-IIa (5 nM) in a transwell chemotaxis assay incubated for 12 h. Cells 
migrated towards media containing 10% FBS as the chemotactic agent. The graphs represent 
the average of 8 separate experiments for studies done with APC and 7 separate experiments 
done with α-IIa; *p<0.05, **p<0.01, ***p<0.001 compared to No Treatment; a p<0.05 
compared to APC treatment or APC and mouse serum IgG treatment; bbb p<0.05 compared 
to α-IIa treatment or α-IIa and mouse serum IgG treatment. 
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Figure 3-7. APC Does Not Increase Migration in the MDA-MB-231 Cells by Increasing 
Cell Number. Cells were pretreated for 1 h with 10 mM Na Butyrate prior to addition of 
APC in the transwell chemotaxis assay incubated for 12 h. Cells migrated towards media 
containing 10% FBS as the chemotactic agent. The graph represents an average of 3 separate 
experiments; *p<0.05 compared to No Treatment; a p<0.05 compared to Na Butyrate 
treatment. 
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Treatment). Therefore, these results show APC increases chemotaxis by affecting other 
pathways involved in migration and not by increasing proliferation of the cells.  
 
Discussion 
Historically, studies on the protein C system have focused on the role of APC as an 
anticoagulant. However, there have been recent studies, such as the PROWESS trial [48], on 
the anti-inflammatory and anti-apoptotic role of APC. Many recent reports have looked into 
these non-hemostatic roles of APC in vivo and in vitro.  In this study, we showed that APC 
affects breast cancer cell migration in the transwell invasion and chemotaxis assay. APC, in a 
concentration dependent manner, increases invasion and chemotaxis in both the MDA-MB-
231 and MDA-MB-435 breast cancer cell lines. Previously, it had been published that APC 
increased cancer cell invasion through Matrigel coated membranes only in the presence of 
PAI-1 [67]. It was hypothesized that APC complexed with PAI-1 [67]. This stable complex 
removed active PAI-1 from the cell environment and allowed uPA to activate plasminogen to 
plasmin. Plasmin can go on to activate MMP-9 [71] and MMP-2 [72]. uPA can also activate 
MMP-2 and regulate MMP-9 expression [68-70]. Since the MDA-MB-435 cell line does not 
express PAI-1 but still was affected by APC treatment in the transwell assay, we concluded 
that another mechanism is activated by APC to increase cell migration.  
As previously reported, IIa is approximately 104 fold more potent that APC at 
activating PAR-1 [314]. Cells were treated with hirudin in the absence and presence of APC 
to assess if trace amounts of IIa were influencing the APC-induced transwell migration 
assays. We showed that APC alone was able to increase chemotaxis of the MDA-MB-231 
cells and this was not due to IIa. The amount of APC needed to promote cellular migration is 
71 
greater than physiological protein C blood plasma levels (~ 4µg/mL). In the PROWESS trial, 
sepsis patients that were treated with APC have a steady state level of 45 ng/mL [314]. 
However, our overall goal was to characterize the mechanism of APC to promote cell 
migration and we used similar APC concentrations as in previous in vitro studies (0.5-50 
µg/mL) [54, 67, 79]. Interestingly, levels of APC used in HUVEC experiments are closer to 
physiological concentrations of APC (0.1-10 µg/mL) (data not shown).  
As part of the anti-inflammatory action of APC, it had been previously reported that 
either APC or zymogen PC, through EPCR and EGFR, inhibits lymphocyte migration [58, 
59]. Using zymogen PC, chemically inactivated DEGR-APC, and an active site mutant of 
APC (S195A) with the MDA-MB-231 cancer cells, one finding of our study showed that the 
active protease was needed to increase cell migration. Therefore, unlike the inhibitory role of 
APC with lymphocytes, the pro-migratory role of APC in the MDA-MB-231 cells requires 
the active site of the protease, most likely to bind and activate receptors, such as PAR-1 [54, 
57, 63, 64, 79], and to activate extracellular matrix proteases, such as MMP-2 and MMP-9 
[74, 77]. It is possible that when bound to EPCR, APC may undergo modifications to its 
macromolecular substrate recognition. Thus, APC bound to EPCR could promote migration 
and invasion through both activation of signaling pathways and activation of extracellular 
proteases.  
Another finding in our study was that APC itself is not a chemotactic factor for the 
MDA-MB-231 cells, but it promoted chemotaxis and invasion through direct interactions 
with the cells. By contrast, an analogous serine protease, IIa, can either promote migration 
when treated with the cell or when used as a chemotactic factor. Using the transwell invasion 
and chemotaxis assay with the MDA-MB-231 cells and altering the treatment of APC from 
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the insert to the well, we found that APC must interact with the cells directly to allow for the 
increase in migration. Our results parallel what is known about uPA as a mediator of cell 
migration. This serine protease is not considered a chemotactic factor [315, 316].  When 
bound to uPAR, uPA is able to promote both cell migration and invasion. Therefore, APC 
does not act as a chemotactic agent, but functions similarly to uPA and not IIa. 
 Past studies have indicated that APC is either activating proteases that degrade the 
extracellular matrix [52, 77] and/or activating receptor(s) that initiate signaling pathways to 
increase invasion and chemotaxis. Other studies have shown that the ability of APC to 
interact with EPCR and PAR-1 is a critical aspect of the mechanism responsible for altering 
inflammation, proliferation, and apoptosis [54, 59, 64-66, 77, 79, 306]. We found that the 
relationship of APC, EPCR, and PAR-1 is similar to that shown in anti-apoptotic [54, 63] and 
anti-inflammatory [54] studies, where binding and activating of both receptors by APC is 
important to initiate the effects of APC on cell migration. Using blocking antibodies to both 
of these receptors, we showed that APC must bind to EPCR and PAR-1 in order to increase 
chemotaxis in the MDA-MB-231 cells. Blocking one or the other receptor completely 
attenuated the effects of APC on the MDA-MB-231 cells. We hypothesize that APC binds to 
EPCR, which localizes the protease and aids in the interaction of APC with PAR-1. Upon 
activation of PAR-1, the heterodimer of EPCR and PAR-1 initiates signaling pathways that 
increase MDA-MB-231 chemotaxis. It is important to note that this heterodimer pair is what 
allows for the unique effect of APC on the cell and distinguishes it from the effects of IIa on 
the cell. IIa signaling through PAR-1 is the opposite of APC in many aspects, such as IIa 
promotes both apoptosis and inflammation.  
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There are other studies that describe slight variances for the requirements of APC, 
EPCR, and PAR-1 to modify cell responses, suggesting either some diversity in the response 
or some cellular adaptation to APC as a modulator of cell function. In one setting it was 
shown that APC binding to EPCR is necessary for increases in HUVEC proliferation while 
PAR-1 activation by APC is only important for initial signaling events and not in maintaining 
the effect [79]. In a different setting, APC binding to EPCR and EGFR was critical for 
lymphocyte migration, not any PARs [58, 59]. It is still possible that other receptors, 
including EGFR [59], have a role in the effects of APC on MDA-MB-231 cell migration. 
Additional studies on the interactions of APC and the cell surface are needed to further our 
understanding of how APC affects various cellular processes, including migration. 
 Na Butyrate has been used as an inhibitor of proliferation in the MDA-MB-231 cells 
[317, 318]. Na Butyrate inhibits histone deacetylase, increases p21 expression, and decreases 
cyclin D gene expression [317] resulting in an arrest of the cell in G2 [318]. Na Butyrate also 
induces cell differentiation [317], as shown with an increase in lipid accumulation, and a 
reduction in migration across multiple extracellular matrices [319]. We found that unlike the 
effects of APC on HUVEC proliferation, in breast cancer cells, binding to EPCR and 
activation of PAR-1 by APC increases migration but not proliferation. APC is able to 
increase MDA-MB-231 cell migration over Na Butyrate treatment alone by the same ratio as 
APC treatment compared to control. Further, the pathways activated by Na Butyrate [319, 
320] are not the same pathways utilized by APC to increase migration in these cells. Other 
pathways, such as MAPK and PI3K pathways [79], that have been implicated in the 
mechanism by which APC increase HUVEC proliferation may have a role in increasing 
migration in the MDA-MB-231 cells. Within the context of the MDA-MB-231 cells as a 
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model system of cell migration, our results imply that in the presence of APC a pro-
migratory process is initiated that is not dependent on cell proliferation. 
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Summary 
Activated protein C is an anticoagulant serine protease that regulates hemostasis. 
Activated protein C also has several non-hemostatic functions related to inflammation, 
proliferation, apoptosis, and migration. Using the MDA-MB-231 breast cancer cell line as a 
model system, we investigated the mechanism by which activated protein C promotes 
chemotaxis and invasion. An active site inhibitor of urokinase and blocking antibodies to 
both urokinase and plasminogen activator inhibitor-1 did not alter the ability of activated 
protein C to increase MDA-MB-231 cell invasion. However, inhibitors to matrix 
metalloproteases-2 and -9 significantly reduced the ability of activated protein C to promote 
MDA-MB-231 invasion. Activated protein C-promoted cellular invasion is also attenuated in 
the presence of blocking antibodies to endothelial cell protein C receptor, protease activated 
receptor-1, and epidermal growth factor receptor. Cells treated with pharmacological 
inhibitors showed that activated protein C increased migration through the mitogen-activated 
protein kinase and the phosphatidylinositol 3 kinase pathways, but not the c-Jun NH2-
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terminal kinase pathway. Our results suggest that activated protein C promotes cell motility 
(i) by binding to endothelial cell protein C receptor, (ii) by activating both protease activated 
receptor-1 and epidermal growth factor receptor to interdependently activate the 
phosphatidylinosital 3 kinase and mitogen-activated kinase pathways intracellularly, and (iii) 
by interacting with matrix metalloproteases-2 and -9 to increase matrix degradation 
extracellularly. 
 
Introduction 
Activated protein C (APC) is a liver-derived serine protease [298], which circulates in 
the blood as a zymogen [299, 300], with known functions in vivo as an anticoagulant. 
Zymogen protein C (PC) is localized to the endothelium by endothelial cell protein C 
receptor (EPCR) [154]. Upon activation by thrombin (IIa) bound to thrombomodulin (TM) 
[156, 302] on the endothelial cell surface, APC proteolytically inactivates factors Va and 
VIIIa [301, 303] in the presence of protein S (PS) [304, 305]. The importance of this pathway 
is seen in both mouse models and human disease. PC-/- mice do not survive 24 h after 
delivery due to formation of thrombi in the brain and liver, resulting in a consumption of 
coagulation factors and hemorrhage [321]. In humans, severe thrombophilia occurs due to 
deficiencies in PC or PS or due to a mutation in factor Va that prevents its inactivation by 
APC, known as Factor V Leiden [322]. 
In the Recombinant Human Activated Protein C Worldwide Evaluation in Severe 
Sepsis Study (PROWESS), patients diagnosed with sepsis and acute organ dysfunction were 
treated with recombinant human APC, resulting in a mortality reduction of 19.4% [48]. This 
study and others show APC has anti-inflammatory activity [47, 48, 50, 58, 59].  APC inhibits 
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apoptosis through upregulation of anti-apoptotic Bcl-2 [54, 60, 64], and down-regulation of 
p53, Bax [54, 64], and caspases 3[54, 64, 65], and 8 [64, 65] all dependent on interactions 
with EPCR and protease activated receptors (PARs).  In a murine focal ischemic stroke 
model, human and mouse APC treatment restores blood flow, reduces infarct volume and 
edema, eliminates neutrophil infiltration, and reduces fibrin deposition [54, 64-66, 306]. 
These in vivo neuroprotective effects of APC are shown to be mediated through EPCR [54], 
PAR-1 [54, 64], and PAR-3 [64].  
APC is shown to have a role in regulating migration of various cell types. Studies 
done by Kobayashi, et al. (1994) originally report APC increases invasion of ovarian cancer 
and choriocarcinoma cells only in the presence of the serine protease inhibitor (serpin), 
plasminogen activator inhibitor-1 (PAI-1). They suggested that APC forms a stable complex 
with PAI-1, thereby removing a potent inhibitor of uPA from the system [67]. Then free uPA 
can subsequently activate plasminogen to plasmin, an extracellular matrix (ECM) serine 
protease to promote invasion. uPA is also known to activate matrix metalloprotease (MMP)-
2 and to regulate MMP-9 expression [68] [69, 70], which are zinc-dependent proteases that 
degrade the ECM. Plasmin can also activate both MMP-9 [71] and MMP-2 [72]. Previously, 
APC has been shown to activate MMP-2 from an intermediate form to a fully active protease 
[73, 74] [75, 76]. In vitro cell culture assays with keratinocytes show that APC promotes cell 
migration by increasing both the expression and activation of MMP-2 [52, 77]. In HUVEC, 
APC increases proliferation in a concentration dependent manner through activation of the 
mitogen activated protein kinase (MAPK), phosphatidylinositol 3 kinase (PI3K), and 
endothelial nitric oxide synthase (eNOS) pathways primarily via binding to EPCR rather than 
to PAR-1 [79]. With MDA-MB-231 breast cancer cells, the active form of APC increases 
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migration in a concentration dependent manner by binding to EPCR and activating PAR-1, 
priming the cell to respond to a chemotactic factor [323]. As part of its anti-inflammatory 
actions, APC/PC reduces the migration of immune cells towards multiple chemoattractants 
through its binding to both EPCR [58] and to epidermal growth factor receptor (EGFR) [59].  
In vivo, APC promotes angiogenesis and wound healing in a rat skin healing model through a 
reduction in inflammation, an increase in VEGF expression, and MMP-2 activation [52]. In 
an in vivo mouse cornea angiogenesis assay, APC promotes angiogenesis via the eNOS 
pathway [79].  
Previous studies suggest that APC regulates cell motility through various 
mechanisms. The first potential mechanism involves the extracellular manipulation of the 
plasminogen activation system by APC, which includes uPA and PAI-1. The second possible 
mechanism implicates the activation of MMPs by APC to increase motility. The third 
potential mechanism relies on the activation of intracellular signaling pathways, such as the 
MAPK and PI3K pathways, through EPCR, PAR-1, and/or EGFR. The results described here 
provide evidence that APC promotes cell motility by binding to EPCR, activating PAR-1 and 
EGFR to promote intracellular signaling through MAPK and PI3K pathways, and by 
extracellular interactions with MMP-2 and -9 to promote ECM degradation. 
 
Experimental Procedures 
Cell Culture 
Assays were performed using the MDA-MB-231 breast cancer cell line obtained from 
the University of North Carolina – Chapel Hill Tissue Culture Facility. These cells were 
maintained in Minimum Essential Media (MEM; Gibco) with 10% fetal bovine serum (FBS; 
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Sigma), 1% sodium pyruvate (Gibco), and 1% antibiotic/antimycotic (Gibco). Cells were 
kept in an incubator at 37 oC, 5% CO2. 
 
Transwell Invasion and Chemotaxis Assays 
Migration was evaluated as previously described using the transwell invasion and 
chemotaxis assays [323]. Human recombinant APC (also known as Xigris®; Eli Lilly and 
Co.) was plated with the cells. Blocking antibodies used to study the potential receptors 
bound by APC were also plated with the cells and allowed to incubate at room temperature 
for 15 min prior to the addition of APC. These antibodies include mouse EPCR antibody 
(provided by Dr. Charles T. Esmon, OMRF, Oklahoma, OK), mouse PAR-1 antibodies 
(atap2 and wede15; Zymed and Immunotech, respectively), mouse EGFR antibody (Upstate), 
and mouse serum IgG (Sigma). Blocking antibodies used to study the role of the 
plasminogen activation system, including goat PAI-1 antibody (American Diagnostica), 
mouse uPA antibody (American Diagnostica), and serum mouse or goat IgG (Sigma), were 
plated with the cells and allowed to incubate at room temperature for 1 h prior to the addition 
of APC. Amiloride, an inhibitor of uPA, was also plated with the cells and preincubated for 
1h prior to the addition of APC. Pharmacological inhibitors that block specific signaling 
pathways were plated with the cells and also allowed to preincubate at room temperature for 
1 h prior to treatment with APC. These compounds include PD 98059 (Biomol), LY 294002 
(Biomol), SP 600125 (Biomol), and DMSO alone. Finally, inhibitors for MMPs, GM 6001 
(Biomol), SB-3CT (Biomol), and DMSO, were plated with the cells and preincubated for 15 
min prior to the addition of APC. To determine if selective inhibitors of MMPs were 
affecting APC activity levels, conditioned media from the transwell assays were tested for 
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APC activity using an APC-specific chromogenic substrate (final concentration of 0.15 mM; 
Centerchem) as previously described [323].  
In each experiment, conditions were done in duplicate and averaged. Experiments 
were averaged together and graphed as a comparison to No Treatment, set at 100%.  
 
Western Blots 
25 µg total protein from cell lysates created in complete RIPA buffer were run on 
12% SDS-PAGE gels and transferred onto PVDF (Millipore). Cell lysates were probed for P-
Erk1/2 (Santa Cruz Biotechnology), total ERK2 (Santa Cruz Biotechnology), P-Akt (Cell 
Signaling), total Akt (Cell Signaling), P-c JUN (Cell Signaling), total c JUN (Cell Signaling), 
tubulin (Sigma), tubulin (Sigma), and actin (Santa Cruz Biotechnology).  
 
Immunofluorescence 
Cells were grown to form a confluent monolayer in 2-chambered slides (Lab Tek II 
by Nunc). Cell monolayers were then washed in 1X DPBS and fixed for 30 minutes in 2% 
paraformaldehyde in 1X DPBS. After the paraformaldehyde was aspirated off, glycine (0.2 
M) was added to the cell monolayers for 20 minutes to block any potential interactions with 
free aldehyde groups from the paraformalhehyde. Cells were blocked in 10% goat serum in 
1X DPBS, 1% BSA for 30 minutes and treated for 1 hour with mouse EGFR antibody or 
serum mouse IgG (5 µg/mL) in 1X DPBS, 1% BSA. After multiple washes in 1X DPBS, 1% 
BSA, cells were treated with sheep anti-mouse IgG F(ab´)2 fragment-R-phycoerythrin 
antibody (1:20) in 1X DPBS, 1% BSA for 1 hour. Cells were then washed multiple times in 
1X DPBS and stored in 1X DPBS at 4oC. Photographs were taken with an Olympus DP70 
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Microscope Digital Camera with DP70-BSW Software using an Olympus BX51WI 
fluorescent microscope with a TRITC filter. Photographs were taken at a 200X magnification 
with the same exposure time. 
 
3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) Assays Using 
Epidermal Growth Factor 
Cell viability was measured using a MTT assay. 10,000 cells/well were plated in a 
96-well plate, incubated overnight at 37oC, 5% CO2. Cells were treated with SFM containing 
1% sodium pyruvate, 1% antibiotic/antimycotic with or without mouse EGFR antibody or 
mouse serum IgG for 15 min followed by the addition of recombinant human epidermal 
growth factor (EGF; 1nM final concentration; Invitrogen). After a 48 h incubation, cells were 
treated with SFM containing 1% sodium pyruvate, 1% antibiotic/antimycotic and 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (0.5 mg/mL; Sigma) for 
2 h. DMSO was added to each well to dissolve formazan crystals formed by living cells for 
15 min at 37oC, 5% CO2. The absorbance of each well was read at 560 nm. In each 
experiment, conditions were done in triplicate and compared to No Treatment.  
 
Statistical Analysis 
For each transwell experiment, conditions were done in duplicate and averaged. 
Averages of each condition were compared to No Treatment, APC alone, or blocking 
antibody/inhibitor alone. Experiments were repeated as indicated in the figure legends and 
averaged together. Results show the percentages compared to No Treatment. Statistical 
analysis was performed on each comparison – to No Treatment, APC, or blocking 
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antibody/inhibitor – using a one sample T-test with a normal distribution, a theoretical mean 
of 100, and significance of p < 0.05.  
 
Results 
APC increased invasion of the MDA-MB-231 cells, independent of the balance between uPA 
and PAI-1.  
To determine if APC is altering the endogenous expression ratio of PAI-1 to uPA to 
increase invasion in the breast cancer cell line, MDA-MB-231, reverse transcription-pcr was 
performed on samples treated with or without APC. Results showed that APC did not alter 
mRNA levels of either uPA or PAI-1 (data not shown). Transwell invasion assays were 
performed with amiloride and blocking antibodies to uPA and PAI-1 along with APC. In 
figure 1A, APC or APC and DMSO increased invasion of the MDA-MB-231 cells greater 
than 150%. The amiloride treatment alone reduced invasion to approximately 70% of No 
Treatment. This result was expected since uPA was inhibited, reducing the activation of 
plasminogen and MMPs. If uPA was a key component to the mechanism by which APC 
promotes invasion of the MDA-MB-231 cells, then the treatment of APC and amiloride 
should have the same result as amiloride treatment alone. However, APC still increased 
invasion of the MDA-MB-231 cells even when uPA was inhibited, indicating that APC 
promotes cell invasion through another mechanism other than through uPA. APC activity 
assays verified that APC was not inhibited by amiloride (data not shown). To further confirm 
that uPA was not involved in the mechanism, a blocking antibody to the active site of uPA 
was then used in the transwell invasion assay (Figure 4-1B). As was found with amiloride, 
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even in the presence of the uPA blocking antibody, APC was able to increase cell invasion 
approximately 150% compared to No Treatment.  
To determine if PAI-1 had a role in the increase in invasion by APC, a blocking 
antibody to PAI-1 was used along with APC in the transwell invasion assays (Figure 1C). In 
contrast to control goat serum IgG, the blocking antibody to PAI-1 increased invasion 
approximately the same amount compared to APC alone. With no PAI-1 to inhibit uPA, the 
serine protease can more freely activate proteases that degrade the ECM, such as plasmin and 
MMPs. Interestingly, the addition of APC with the blocking antibody to PAI-1 had an 
additive effect,  increasing invasion further (approximately 200%) over PAI-1 blocking 
antibody alone (Figure 4-1C). These results suggest that APC promotes motility of the MDA-
MB-231cells by a mechanism distinct from that involved in altering the ratio between PAI-1 
and uPA.  
 
APC increased invasion of the MDA-MB-231 cells via MMP-2 and MMP-9. 
A broad-spectrum hydroxamate inhibitor of MMPs, GM 6001 was used to determine 
if MMPs have a role in APC promoted cell invasion. As shown in Figure 4-2A, GM 6001 
treatment reduced invasion compared to No Treatment in a concentration dependent manner 
as expected due to a reduction in active proteases to degrade the ECM. GM 6001 and APC 
together yielded similar results. As the concentration of GM 6001 increased, the effects of 
APC were reduced further and further below No Treatment (Figure 4-2A). These results 
imply that the increase in invasion caused by APC involves MMPs. Because the GM 6001 
MMP inhibitor is a broad-spectrum inhibitor, we also used a specific MMP-2 and -9  
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Figure 4-1. APC Does Not Increase Invasion of the MDA-MB-231 Cells Through the 
Plasminogen Activator System. Cells were pretreated with 0.2 mM amiloride (A), 20 µg/mL 
anti-uPA (B), 20 µg/mL anti-PAI-1 (C), and corresponding control antibodies for 1 h prior to 
the addition of 10 µg/mL APC. Cells invaded and migrated towards 10% FBS containing 
media for 24 h. Graphs represent the average of 3 separate experiments; * p<0.05, ** p<0.01 
compared to No Treatment; a p<0.05, aaa p<0.001 compared to APC treatment; b p<0.05, bb 
p<0.01 compared to amiloride/anti-uPA/anti-PAI-1 treatment. 
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inhibitor, SB-3CT, to determine if these MMPs were involved in the increase in cell invasion 
caused by APC. Invasion was reduced in a concentration dependent manner upon SB-3CT 
treatment alone as expected (Figure 4-2B). With SB-3CT and APC treatment, we see 
continued concentration dependent reduction in invasion and abrogation of the increase seen 
with APC treatment alone (Figure 4-2B). APC activity assays verified that neither GM 6001 
nor SB-3CT had an effect on APC activity (data not shown). These results imply that APC 
promotes invasion of the MDA-MB-231 cells is dependent on MMP-2 and MMP-9 
degradation of the ECM. 
 
APC Increased Invasion of the MDA-MB-231 Cells by Binding to EPCR and PAR-1. 
 Previously, we showed that APC binds to both EPCR and PAR-1 to increase 
chemotaxis of the MDA-MB-231 cells [323]. Using blocking antibodies to both receptors, 
we next wanted to determine if both EPCR and PAR-1 are also required for APC promoted 
cell invasion. Blocking antibody to EPCR abrogated the effects of APC on invasion (Figure 
3A). The PAR-1 blocking antibodies also abrogated the effects of APC, reducing the level of 
invasion back to No Treatment (Figure 4-3B). Solution-phase APC could interact with latent 
and intermediately active MMPs, specifically MMP-2 and -9. However, although there may 
be an increase in active MMP-2 and -9, it is not enough to promote invasion. These results 
suggest that APC must both bind to the cell surface through EPCR and PAR-1 and increase 
MMP-2, -9 activities to promote invasion of the MDA-MB-231 cells.  
 
APC Increased Invasion and Chemotaxis of the MDA-MB-231 Cells Through EGFR. 
  
86 
  
 
Figure 4-2. APC Increases Invasion of the MDA-MB-231 Cells Through the MMP-2 and 
MMP-9 Degradation of the Extracellular Matrix. Cells were pretreated with increasing 
concentrations of GM 6001 (0-25 µM; A) or SB-3CT (0-10 µM; B) for 15 minutes prior to 
the addition of 10 µM APC. Cells invaded and migrated towards 10% FBS containing media 
for 24 h. Graphs represent the averages of 8 separate experiments; * p<0.05, ** p<0.01 
compared to No Treatment; a p<0.05, aa p<0.01, aaa p<0.001 compared to APC treatment. 
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It had been previously shown that APC downregulated migration of lymphocytes by binding 
to EPCR and EGFR. Thus, we became interested in exploring the role of EGFR during APC-
promoted MDA-MB-231 cell motility.  First, we verified that our MDA-MB-231 cells 
expressed EGFR (Figure 4-4A). Second, EGF induced cell proliferation was reduced in the 
presence of an EGFR blocking antibody (20 µg/mL) (Figure 4-4B). Finally, to see if EGFR 
had a role in the increase of cell migration by APC, MDA-MB-231 cells were pretreated with 
the EGFR blocking antibody (20 µg/mL) prior to the addition of APC (10 µg/mL) in the 
transwell assays. Treatment with EGFR blocking antibody alone had no effect on cell 
migration (Figure 4-4C).  By contrast, the EGFR blocking antibody substantially reduced 
APC-promoted invasion and chemotaxis of the MDA-MB-231 cells (Figure 4-4C). These 
results indicate that EGFR is activated by APC on the MDA-MB-231 cells, along with EPCR 
binding and PAR-1 activation, to increase invasion and chemotaxis. 
 
APC Increased Chemotaxis of the MDA-MB-231 Cells by Activating PI3K and MAPK 
Pathways. 
 To determine if the PI3K and MAPK pathways are activated by APC in order to 
increase MDA-MB-231 cell motility, western blots were run on lysates of cells collected at 
multiple timepoints up to 12 h. As seen in Figure 4-5A, there was an increase in 
phosphorylation of ERK, which was used as an indicator of the activation of the MAPK 
pathway. At 2 h, there was no difference in P-ERK levels between 0 and 10 µg/mL APC. By 
the 6 h timepoint, APC treatment consistently increased the level of P-ERK over no APC 
treatment. Blots were also probed for P-Akt as an indication of the activation of the PI3K 
pathway, and they showed a similar consistent increase in the levels of P-Akt upon treatment  
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Figure 4-3. APC Increases Invasion of the MDA-MB-231 Cells by Binding to EPCR and 
PAR-1. (A) Cells were pretreated with 4 µg/mL EPCR antibody (JNK 1494) or control 
mouse serum IgG for 15 minutes prior to the treatment of 10 µg/mL APC. (B) In a separate 
experiment, cells were pretreated with 10 µg/mL atap 2 and 20 µg/mL wede15 (PAR-1 
blocking antibodies) for 15 minutes prior to the addition of 10 µg/mL APC. Cells invaded 
and migrated toward 10% FBS containing media for 24 h. The graphs represent the average 
of 8 separate experiments for both (A) and (B); * p<0.05, ** p<0.01 compared to No 
Treatment; a p< 0.05, aa p<0.01 compared to APC treatment; b p<0.05 compared to mIgG 
treatment. 
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with APC at 6 h (Figure 4-5A). Based on these results, western blots were run on cell lysates 
from MDA-MB-231 cells that were treated for 6 h with 10 µg/mL APC, PC, or chemically 
inactived APC-DEGR. As seen in Figure 4-5B, active protease, APC, was able to 
consistently increase the level of both P-ERK and P-Akt at 6 h compared to no treatment, 
while PC and APC-DEGR have similar if not lower levels of P-ERK and P-Akt as no 
treatment. This result suggests that APC interactions at the cell surface require active 
protease to activate of the PI3K and MAPK pathways. Western blots were also performed on 
cell lysates from MDA-MB-231 cells treated with APC (10 µg/mL) and either control mouse 
serum IgG (mIgG; 4 µg/mL) or EPCR blocking antibody (4 µg/mL) for 6 h (Figure 4-5B). 
The EPCR blocking antibody prevented any increase in P-Akt levels in the presence of APC 
compared to the EPCR blocking antibody treatment alone. The same is true for P-ERK 
(Figure 4-5B). This result suggests that APC binds to EPCR and activates both the PI3K and 
MAPK pathways in order to increase motility of the MDA-MB-231 breast cancer cells.  
Three signaling pathways (PI3K, MAPK, and JNK) were then studied in the transwell 
assays to determine if they had an impact on APC promoted cell migration. LY 294002 was 
used to inhibit PI3K activity and reduce phosphorylation of Akt.  LY 294002 reduced P-Akt 
levels (Figure 4-6A) with an accompanying loss of migration (Figure 4-6B), as expected 
since this is an important signaling pathway for cell migration (under these treatment 
conditions cell survival was not reduced). If this pathway was not activated by APC, we 
would expect that combined APC and LY 294002 treatment would be increased 150% over 
LY 294002 alone. However, APC and LY 294002 treatment was the same as LY 294002 
treatment alone (Figure 4-6B). These results show that APC increases cell migration through 
a PI3K dependent pathway.  
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Figure 4-4. APC Increases Invasion and Chemotaxis of the MDA-MB-231 Cells by 
Activating EGFR. (A) Immunofluorescence done on the MDA-MB-231 cell monolayer for 
EGFR. (B) Cells were pretreated with increasing concentrations of EGFR antibody or control 
mouse serum IgG (0-20 µg/mL) prior to the addition of 1 nM EGF in SFM. Cells were 
allowed to grow for 48 h and then treated with MTT in SFM and analyzed as described in 
“Experimental Procedures” to determine cell viability. Graphs represent the average 
absorbance for each condition for 4 separate experiments. (C) Cells were pretreated with 20 
µg/mL anti-EGFR or control mouse serum IgG for 15 minutes prior to the addition of APC 
(10 µg/mL). Cells invaded for 24 h and chemotaxed for 12 h towards 10% FBS containing 
media. Graphs represent the average of 4 separate experiments for invasion and 3 separate 
experiments for chemotaxis assays; * p<0.05, ** p<0.01 compared to No Treatment; a 
p<0.05 compared to APC treatment; b p<0.05, bb p<0.01 compared to mIgG treatment.  
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Figure 4-5. APC Treatment of MDA-MB-231 Cells Results in the Increased 
Phosphorylation of ERK1/2 and Akt at 6 h. (A) Representative western blots showing 
timpoints from 2 h to 8 h of cells treated in SFM with or without APC (10 µg/mL). 25 µg 
total protein from cell lysates were probed for pERK1/2, total ERK2, p-Akt, total Akt, and 
actin. Westerns were run on 5 separate experiments. (B) Representative western blots of cells 
treated with 10 µg/mL of APC, PC, APC-DEGR, 4 µg/mL mouse serum IgG, and 4 µg/mL 
anti-EPCR blocking antibody for 6 h. 25 µg of total protein from cell lysates were probed for 
pERK1/2, total ERK2, pAkt, total Akt, and actin. Westerns were run on 5 separate 
experiments.  
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The PD 98059 compound was used to inhibit MEK1/2 phosphorylation of ERK1/2 
(Figure 4-6C). Because the MAPK pathway is an important signaling pathway for cell 
migration, treatment with the PD 98059 compound alone reduced chemotaxis (Figure 4-6D).  
APC and PD 98059 treatment was also reduced to the same level as PD 98059 treatment 
alone, suggesting that the MAPK pathway is activated by APC. 
 The JNK pathway is involved in cell survival and cell migration [23-25], and is 
activated by EGFR [26] and G protein-coupled receptors [27].The SP 600125 compound 
inhibited JNK phosphorylation of c JUN (Figure 4-6E). SP 600125 treatment alone had no 
effect on cell migration (Figure 4-6F). However, APC and SP 600125 treatment was 
increased 150% compared to No Treatment, suggesting that the JNK pathway is not required 
for APC promoted cell migration. 
 
DISCUSSION 
 APC has been previously shown to increase chemotaxis and invasion of breast cancer 
cells, particularly the MDA-MB-231 and MDA-MB-435 cell lines [323] toward a 
chemoattractant. In this study, we look into the mechanism by which APC increases cellular 
invasion and chemotaxis. Extracellularly, APC does not interact with the plasminogen 
activation system to promote invasion as previously reported [67]. Instead, APC promoted 
cellular invasion is dependent on MMP-2 and MMP-9 degradation of the ECM. However, 
extracellular degradation by MMP-2 and -9 is not sufficient for APC promoted cellular 
invasion. Using blocking antibodies in the transwell invasion assay, we show that APC 
interacts with EPCR and PAR-1, as was previously shown to be important in chemotaxis 
[323]. Not only is APC binding to EPCR and activating PAR-1, APC treatment also leads to  
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Figure 4-6. APC Increases Chemotaxis of the MDA-MB-231 Cells by Activating both the 
PI3K and MAPK Pathways, but not the JNK Pathway. Cells were treated with increasing 
concentrations of LY 294002 (0-50 µM; A), PD 98059 (0-50 µM; C), or SP 600125 (0-10 
µM; E) for 12 h to determine the optimal concentration of each inhibitor to be used in a 12 h 
transwell chemotaxis assay. Cell lysates were probed for phosphorylated and total AKT (A), 
ERK (C), and c Jun (E), tubulin, and actin. Western blots shown are representative of 3 
separate experiments. In 12 h transwell chemotaxis assay, cells were pretreated with 50 µM 
LY 294002 (B), 20 µM PD 98059 (D), or 5 µM SP 600125 (F) for 45 minutes prior to the 
addition of 10 µg/mL APC. Cells migrated towards 10% FBS containing media for 12 h. 
Graphs represent the averages of 9 separate experiments for (B), 8 separate experiments for 
(D), and 4 separate experiments for (F); * p<0.05, ** p<0.01, *** p<0.001 compared to No 
Treatment; aa p<0.01 compared to APC treatment; b p<0.05 compared to SP 600125 
treatment.  
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the transactivation of EGFR through PAR-1 to increase both invasion and chemotaxis. The 
interaction of these 3 receptors leads to the increased phosphorylation of ERK and Akt, but 
not c JUN, implicating that APC promotes cell migration via PI3K and MAPK, and not JNK, 
dependent pathways (Figure 4-7).  
Kobayashi, et al. (1994) found that APC increased invasion of cancer cells in vitro by 
forming a stable complex with the serpin, PAI-1 [67]. Removing the major inhibitor in the 
system allowed for increased protease activity and degradation of the ECM. uPA, a serine 
protease inhibited by PAI-1, would be free to activate plasminogen to plasmin, which would 
not only degrade the ECM but also activate MMPs that could degrade the ECM. These 
experiments added both PAI-1 and APC exogenously [67]. In experiments presented here, 
APC is added exogenously and we study how endogenous uPA and PAI-1 expressed by the 
MDA-MB-231 breast cancer cells interacts with APC. Some APC could be inhibited, 
forming a complex with PAI-1 to allow for uPA to activate both MMPs and plasminogen to 
degrade the ECM. However, this is not the major mechanism utilized by APC to increase 
invasion. Blocking uPA with either the chemical inhibitor amiloride or a blocking antibody 
to its active site did not alter the ability of APC to increase invasion of the breast cancer cells. 
Additionally, in the presence of a PAI-1 blocking antibody and APC, the effect was 
essentially additive. When either the general MMP inhibitor GM 6001 or specific MMP-2 
and -9 inhibitor SB-3CT compounds are used in conjuncture with APC, the increase in 
invasion of the breast cancer cells is lost. APC, therefore, increases invasion through MMP 
degradation of the ECM, not through uPA. There is prior evidence that APC directly 
activates MMPs, specifically MMP-2. Through zymography, APC was shown to activate 
MMP-2 from the intermediate to fully active form [73-76], independent of MT1-MMP  
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Figure 4-7. Schematic of the Proposed Intracellular and Extracellular Mechanism Utilized 
by APC to Increase Cellular Migration in the MDA-MB-231 Cells. 
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[74, 75]. Additionally, it has also been shown that solution phase APC [74-76] and APC 
generated on the cell surface in the presence of IIa bound to TM can activate MMP-2 
[73].Therefore, APC increases invasion through extracellular interactions either directly or 
indirectly to activate MMP-2 and -9 and this does not involve altering the balance between 
uPA and PAI-1.  
 As previously shown in the transwell chemotaxis assays, APC binds EPCR on the cell 
surface and is localized to a nearby PAR-1 receptor, which it cleaves to activate and promote 
cell motility [323]. The same is true in the transwell invasion assay. Using blocking 
antibodies to either EPCR or PAR-1, the effects of APC on invasion are inhibited. These 
results suggest that the degradation of the ECM by MMPs is not the only mechanism utilized 
by APC to increase invasion. Activation of PAR-1 by EPCR-bound APC, in addition to the 
MMP-mediated degradation of the ECM, is required to substantially promote invasion.  
 In addition to APC binding to EPCR and activating PAR-1, it is shown using a 
blocking antibody in both the transwell invasion and chemotaxis assays that APC also 
activates EGFR to increase cellular motility. Previously, APC was shown to inhibit 
lymphocyte migration through both EPCR and EGFR [59], characteristic of its anti-
inflammatory role. In our model, EGFR promotes cell migration. These results suggest that 
the effects of APC are cell type specific. Immune cell migration is inhibited by APC, while 
cancer cell migration is promoted. There are three likely mechanisms by which APC could 
lead to the activation of EGFR. One, APC could bind directly to EGFR, like recently shown 
for another serine protease, tissue plasminogen activator [324]. Second, APC could bind to 
EPCR and activate PAR-1, which then would promote the transphosphorylation of EGFR.  In 
this pathway, PAR-1 activation would lead to Gα or β/γ subunits activating c-Src, which 
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would phosphorylate Tyr 845 on the cytoplasmic tail of EGFR [36]. Via EPCR and PAR-1, 
APC has been shown to transactivate another receptor, sphingosine-1-phosphate1 receptor, 
which affects vascular permeability of endothelial cells [159]. And third, APC could also 
bind to the cell through EPCR, and activate PAR-1. PAR-1 would then activate the TNF-
alpha converting enzyme (TACE; ADAM-17), a membrane-bound disintegrin 
metalloprotease that processes membrane-associated cytokines such as heparin bound-EGF 
(HB-EGF) or other EGFR-family member ligands to transactivate EGFR [38] [39].  HB-EGF 
would bind to the ligand binding domain of EGFR, leading to the phosphorylation of the 
receptor [40-42].  Our results do not favor the direct activation of EGFR by APC, but suggest 
that APC-EPCR interactions through PAR-1 promotes either the transphosphorylation of 
EGFR (since the EGFR blocking antibody reduced motility in the presence of APC) or by 
ADAM-17-directed ligand transactivation (since the MMP inhibitor GM 6001 is known to 
inhibit ADAM-17). 
 Since PAR-1 and EGFR are both activated by APC to increase invasion and 
chemotaxis, there are many signaling pathways that could be involved, including the MAPK, 
PI3K, JNK, NFκB, or eNOS pathways. Previously, the MAPK, PI3K, and eNOS pathways 
have been implicated in APC induced proliferation of HUVEC and, additionally, the eNOS 
pathway was implicated in APC induced angiogenesis [79]. Based on these previous studies, 
we focused on the role of the MAPK, PI3K, and JNK pathways in the APC induced cellular 
motility. Using pharmacological inhibitors and western blots, we show that APC activates the 
PI3K and MAPK pathways, to increase motility of the MDA-MB-231 cells. The JNK 
pathway, which has been shown to be activated by EGFR [325], is not involved in the APC 
promoted cellular motility of the breast cancer cells. Therefore, we propose a model in which 
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APC is focused at the MDA-MB-231 cell surface through its binding to EPCR. PAR-1 is 
subsequently cleaved by APC-bound to EPCR [54]. Either through intracellular or 
extracellular transactivation, EGFR is activated. EGFR will activate Ras and the MAPK 
pathway [16, 17]. Ras can also activate PI3K, which will lead to the activation of Akt and the 
MAPK pathway [16, 20, 32]. Additionally, PAR-1 can also activate PI3K through c-Src , 
which would also result in the activation of Akt and the MAPK pathways [17, 32]. 
Ultimately, the resultant signal amplification culminates in the promotion of cellular 
migration (schematically shown in Figure 4-7). 
 In summary, our results show an interesting interdependent nature of the pathways 
that are activated by APC to increase motility of the MDA-MB-231 breast cancer cells. 
Blocking of any one of the three involved receptors (EPCR, PAR-1 or EGFR) or by 
inhibiting MMP-2 and MMP-9 results in a loss of the increase in motility promoted by APC. 
This leads us to speculate that the extracellular and intracellular events induced by APC are 
dependent on one another to facilitate increased motility (Figure 4-7).  Our results also imply 
that APC binding to EPCR not only localizes the protease to aid its interaction with PAR-1 
but also in its interactions with MMPs. Overall, the effect of APC is coordinated with both 
intracellular activation of signaling pathways, which promote motility, and with extracellular 
activation of MMPs, which primes the MDA-MB-231 cells to respond to chemoattractants at 
an increased rate. 
Chapter 5 
APC Increases Endothelial Cell Motility, Tube Formation, and Angiogenesis 
 
Summary 
 Activated protein C (APC) is an anticoagulant serine protease involved in the 
regulation of hemostasis, inflammation, apoptosis, and cell migration. The mechanism used 
by APC to alter endothelial cell functions was studied using the transwell chemotaxis and 
invasion assay, a tube formation assay, and an ex vivo aortic ring assay. In the transwell 
invasion and chemotaxis assay, APC increased both types of cell migration of human 
umbilical vein endothelial cells (HUVEC) that peaked at 0.1 and 0.5 µg/mL, respectively, 
which are near physiologic concentrations. APC also augmented the formation of tube-like 
structures with HUVEC, which did require active protease. Finally, APC promoted the 
formation of sprouts from aortic rings of wild-type C57BL/6 mice. This sprout formation 
required active APC and was not a result of any trace contamination by thrombin.  
Furthermore, the increase in sprout formation from murine aortic rings involved the 
activation of both epidermal growth factor receptor (EGFR) and phosphatidylinositol 3 
kinase (PI3K) signaling pathways, along with the requirement for the increased degradation 
of the extracellular matrix by the action of matrix metalloproteases (MMPs).  Collectively, 
these results suggest that APC promotes endothelial cell motility and angiogenesis through a 
similar mechanism shown previously for breast cancer cell migration and invasion, which 
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points to essentially the same interdependent extracellular and intracellular signaling process 
for both cell motility and angiogenesis. 
 
Introduction 
 Activated protein C (APC) is a serine protease [298] involved in the regulation of 
thrombin (IIa) generation. Zymogen protein C (PC), produced in the liver, is found in 
circulation [299, 300]. At the site of injury in the blood vessel, PC will be sequestered to the 
endothelium surface through the binding to endothelial cell protein C receptor (EPCR) [154]. 
PC bound to EPCR is localized to IIa bound to thrombomodulin (TM). IIa will cleave PC to 
activate it [156, 302]. APC, with the aid of protein S [304, 305], will inactivate factors Va 
and VIIIa [301, 303] on the periphery of the clot to control excessive IIa formation and 
prevent the occlusion of the blood vessel. It is also here on the endothelial cell surface, bound 
to EPCR, that APC can interact and modulate the cellular processes, including inflammation, 
apoptosis, proliferation, and migration.  
 Much research is currently focused on characterizing the non-hemostatic role of APC 
and the other components of the protein C pathway, including EPCR, PC, and IIa bound to 
TM. APC reduces the inflammatory response by reducing chemoattractant expression [47, 
48, 51], migration [58, 59] and adhesion of immune cells [47, 48] all shown to be mediated 
through EPCR [53, 54, 58, 59], protease activated receptor-1 (PAR-1) [54], and epithelial 
growth factor receptor (EGFR) [59]. APC has also been shown to promote survival by up-
regulating anti-apoptotic genes, such as Bcl-2 [54, 60, 64], and down-regulating pro-
apoptotic genes, such as p53 [64] and BAX [54, 64]. APC also prevents the activation of 
caspases 3 [63-65] and 8 [64, 65]. Again, these anti-apoptotic effects of APC are shown to 
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occur through EPCR [54, 63], PAR-1 [54, 63, 64] in neurons and endothelial cells, and PAR-
3 in mouse neurons [64].  
 APC has also been shown to modulate cellular migration and proliferation. In 
HUVEC, APC increases proliferation through EPCR and PAR-1 activation of the MAPK, 
PI3K, and eNOS pathways [79]. APC increases keratinocyte proliferation by interacting with 
EPCR and PAR-1 [78] and increasing the expression of mitogenic factors, interleukin-6 and 
interleukin-8 [77]. APC increases cellular migration of various cell types. In cancer cells, 
APC increases chemotaxis and invasion. Extracellularly, it has been shown that this increase 
occurs because APC is inhibited by plasminogen activator inhibitor-1 (PAI-1) [67], allowing 
another serine protease, urokinase plasminogen activator (uPA), to activate other 
extracellular matrix (ECM) proteases [68-71]. Using zymography, APC is shown to directly 
activate MMP-2 from the intermediate to fully active form [73-76], independent of MT1-
MMP [74, 75]. It has also been shown that APC [74-76] and APC generated on the cell 
surface in the presence of IIa bound to TM can activate MMP-2 [73]. Additionally, we have 
shown that APC increases cancer cell chemotaxis and invasion through EPCR [323, 326], 
PAR-1 [323, 326], and EGFR [326] activation of the MAPK and PI3K pathways [326], along 
with the increase activation of MMP-2 and -9 [326]. In keratinocytes, APC increases 
migration, again, through MMP-2 [77, 78] activity and inhibition of NFκB, a promoter of 
senescence in keratinocytes [77]. Through EPCR and PAR-1, APC is able to increase the 
expression of MMP-2 and the activation of ERK and p38 in keratinocytes [78]. In fibroblasts 
and endothelial cells, APC was shown to increase MMP-2, VEGF, and MCP-1, all of which 
are pro-angiogenic factors [52]. From these studies, we can focus on specific extracellular 
and intracellular events that APC could be utilizing to affect endothelial cell migration. 
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 In vivo, APC has been shown to increase angiogenesis in wound healing assays, 
concluded to be through MMP-2 [52]. APC has also been shown to increase the formation of 
blood vessels in a murine cornea angiogenesis assay through the eNOS pathway [79]. 
Finally, in the murine focal ischemic stroke model, APC has been shown to better the 
recovery through the reduction of inflammation [54, 66], apoptosis of endothelial cells and 
neurons[64, 65], and decreased fibrin deposition [54], while increasing cerebral blood flow 
post-onset of stroke and the recovery of neuromuscular function [54, 65, 66]. Additionally, 
APC reduced the expression of ICAM-1 on vessel walls in the area affected, thereby 
reducing the adhesion of neutrophils to the endothelium [66]. The benefits of APC in stroke 
were shown to be modulated through EPCR, PAR-1 [54, 64] and PAR-3 in mice [64]. 
 The work presented in this chapter aims to characterize the function of APC to 
promote endothelial cell migration.  I used multiple in vitro and ex vivo endothelial cell 
migration assays: transwell invasion and chemotaxis assay; tube formation assay; and an ex 
vivo aortic ring assay. I also characterized the role of other receptors, extracellular proteases, 
and signaling pathways involved in the modulation of APC promoted endothelial cell 
migration. The results show that APC increases HUVEC chemotaxis and invasion towards 
VEGF at closer to physiological levels of APC than was found for MDA-MB-231 cell 
motility. APC also promotes the formation of tube-like structures in HUVEC, dependent on 
active protease (inactive forms of APC were unable to promote tube formation). Finally, 
APC increased sprouting of murine aortic rings, independent of any trace amounts of IIa 
potentially present in the assay. Active APC is also required to increase the formation of 
sprouts. APC, through activation of EGFR and PI3K and degradation of the ECM by MMPs, 
is able to increase sprout formation in this ex vivo assay. These extracellular factors and 
103 
intracellular signaling network function interdependently to cause the increase in sprout 
formation by APC since elimination of any single factor by a pharmacological inhibitor 
prevents the APC-promoted increase in sprouting. 
 
Material and Methods 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC), obtained from Cambrex, were 
grown according to manufacturer’s specifications. Cells were grown in endothelial cell basal 
media with 2% fetal bovine serum, bovine brain extract (BBE) with heparin, GA-1000, 
hEGF, and hydrocortisone (Cambrex). Cells were kept in an incubator at 37oC, 5% CO2. 
 
Transwell Invasion and Chemotaxis Assay 
Based on previous work [307, 308, 323], matrigel (1.67 mg/mL; BD Biosciences) 
coated and uncoated inserts (BD Bioscience) with 8 µm diameter pores were hydrated and 
coated with serum-free minimal essential media (Gibco) containing 0.1% bovine serum 
albumin (Sigma), 1% sodium pyruvate (Gibco), and 1% antibiotic/antimycotic (Gibco) for 2h 
at 37oC. The chemotactic agent, 1 ng/mL VEGF (R&D Systems) in endothelial cell basal 
media with 2% FBS, BBE with heparin, GA-1000, hEGF, and hydrocortisone, was added to 
the well. 50,000 cells/membrane with increasing concentrations of APC (0-10 µg/mL; Xigris 
®; Eli Lilly and Co.) in endothelial basal media with 2% FBS, BBE with heparin, GA-1000, 
hEGF, and hydrocortisone was added to the insert, which was placed in the well. Each 
condition was done in duplicate and allowed to incubate for 24 h at 37oC, 5% CO2 . Cells that 
migrate through were fixed in 100% methanol then stained with a fluorescent nuclear dye, 
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Hoechst 3342 (1:20000 in 1X PBS; Molecular Probes). Membranes were cut from the insert 
and mounted in 50% glycerol. Using a Nikon Eclipse E600 with a UV1A filter, 4-400X 
fields were counted and totaled to represent the number of cells that migrated per membrane. 
Duplicates were averaged together and compared to No Treatment, set at 100%. 
 
Tube Formation Assay 
In a 24-well plate, wells were coated with Growth Factor-Reduced Matrigel (BD 
Biosciences) and incubated for 1 h at 37oC. 80,000 cells per well were plated with increasing 
concentrations of APC (0-10 µg/mL), PC (10 µg/mL), APC-DEGR (10 µg/mL), or VEGF 
(100 ng/mL) as the positive control and incubated at 37oC for 18 h. Photographs with Adobe 
Photoshop and a Kodak DC290 Digital Camera mounted on an inverted microscope were 
taken at 6, 12, and 18 h. The number of tube-like structures (defined at a structure no more 
than 3 cells wide with junction points on each end) were counted in 4-100X views. Each 
condition was done in triplicate, averaged, and compared to No Treatment set at 100%. 
 
Murine Ex Vivo Aortic Ring Assay 
Wildtype C57BL/6 mice were maintained by the Veterinary Staff of the University of 
North Carolina at Chapel Hill Department of Laboratory Animal Medicine and all mouse 
protocols were reviewed and approved by the University’s Institutional Animal Care and Use 
Committee (IACUC). All mouse protocols were reviewed and approved by IACUC. 
Based on previous work [327], male and female mice, at varying ages, were 
anesthetized with 1.25% tribromethanol (0.2 mL/10g) and monitored by toe reflex response 
and respiratory rate. Once properly anesthetized, an incision was made midline and the 
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organs were removed to expose the aorta from the heart to the renal artery branch point. The 
aorta was dissected from the heart to the point above the split to the renal arteries. The 
dissected aorta were placed in a 100 mm dish containing Dulbecco’s Modified Eagle Media 
(DMEM; Gibco) containing 1% antibiotic/antimycotic (Gibco) and cleaned of connective 
tissue and fat. Cleaned aortas were then sectioned into 1-2 mm pieces and placed into a new 
100 mm dish containing DMEM with 1% antibiotic/antimycotic and set in an incubator for 
approximately 1 h at 37oC, 5% CO2 until implantation.  
In a 48-well plate, 200 µL of Growth Factor-Reduced Matrigel was plated in each 
well and put in an incubator at 37oC, 5% CO2 for 10 minutes. One aortic section per well was 
placed on top of the gelatinized Matrigel, covered with an additional 200 µL of Growth 
Factor-Reduced Matrigel, and incubated for 10 minutes. 200 µL of endothelial basal media 
with 2% FBS, BBE with heparin, GA-1000, hEGF, and hydrocortisone was added to each 
well with either no additional treatment (negative control), 100 ng/mL VEGF (positive 
control), or increasing concentrations of APC (0-10 µg/mL).  To eliminate any effects of IIa 
on sprout formation, 50 nM of hirudin was added to the aortic sections with or without APC 
(10 µg/mL). To determine if the active form of APC was needed to increase sprout 
formation, aortic sections were also treated with PC (10 µg/mL) with or without hirudin (50 
nM) or APC-DEGR (10 µg/mL). In studies for EGFR, PI3K, and MMPs in APC-promoted 
sprout formation, pharmacological inhibitors, AG 1478 (10 µM) [328], LY 294002 (10 
µg/mL) [329], and GM 6001 (10 µg/mL) [330], were added to the aortic sections 30 minutes 
prior to the addition of APC (10 µg/mL). Every 24 h for 5 days, media from each well was 
removed and replaced with fresh conditioned media. On days 3-5, the number of sprouts 
extending form the periphery of the aortic sections was counted and digital photographs were 
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taken as described above. Each condition was done in either duplicate or triplicate, averaged, 
and compared to No Treatment set at 100%. 
 
Immunofluorescence 
After 5 days in culture, media covering the implanted aortic ring was aspirated off 
and each ring was washed with 1X PBS. Aortic sections were fixed in 4% paraformaldehyde 
in 1X PBS for 30 minutes on ice. After 2 washes in 1X PBS, the sections were permeabilized 
with 0.5% Triton X-100 in 1X PBS for 15 minutes on ice and washed as before. To block 
any reactive aldehyde groups, the sections were treated with 0.2 M glycine for 20 minutes on 
ice and washed as before. Each section was blocked overnight in 10% goat serum, 1X PBS, 
at 4oC. The following day each section was washed in 1X PBS and then treated with a rabbit 
polyclonal anti-von Willebrand factor (vWF) antibody (1:50 in 1X PBS, 1% BSA; Dako) or 
normal rabbit serum, overnight at 40C. The next day, each aortic section was washed 5 times 
with 1X PBS, 1% BSA, then allowed to sit in this wash solution overnight at 4oC. Each 
section was treated with goat F(ab´)2 anti-rabbit IgG conjugated to Lissamine Rhodamine-B 
(1:50 in 1X PBS, 1% BSA; BioSource International), covered, and stored overnight at 4oC. 
The following day, each aortic section was washed 5 times with 1X PBS and then stored in 
1X PBS and covered at 4oC, until photographs could be taken with the Olympus IMT2 
Inverted Flourescence Microscopy using a TRITC filter. 
 
Statistical Analysis 
For each experiment, conditions were performed in duplicate or triplicate and 
averaged. Averages of each condition were compared to No Treatment, which was set to 
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100%. Experiments were repeated as indicated in the figure legends. Statistical analysis was 
then performed using a one-sample T-test with a normal distribution, a theoretical mean of 
100, and a significance of p<0.05. 
 
Results 
APC Increased HUVEC Invasion and Chemotaxis in the Transwell Assays 
HUVEC were treated with increasing concentrations of APC in the transwell 
chemotaxis and invasion assay with VEGF as the chemotactic agent. As seen in Figure 5-1, 
APC increased invasion of HUVEC at 0.1 µg/mL and increased chemotaxis at 0.5 µg/mL. 
APC increased HUVEC migration compared to No Treatment at optimal concentrations that 
were below the physiological levels of PC found in plasma (~4 µg/mL). The highest 
concentration of APC (10 µg/mL) used to treat the HUVEC in this assay reduced migration 
compared No Treatment. These results suggest that in these experimental conditions, 
endothelial cells migration can be increased at physiologically relevant concentrations and 
inhibited at much higher levels.  
 
APC Increased Tube Formation of HUVEC Requires Active Protease 
 HUVEC plated onto growth factor-reduced Matrigel will form a network of tube-like 
structures (consisting of 1-3 cells wide) that intersect at junction points. Upon the addition of 
a stimulus, such as VEGF, HUVEC will form a more extensive network of tube-like 
structures that last longer in culture. As seen in the transwell assays, upon treatment with 
increasing concentrations of APC (0-10 µg/mL), the increase in the formation of tube-like 
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structures occurs at an optimal concentration (1 µg/mL) and at an optimal timepoint (12 h) 
similar to the effects of VEGF (data not shown).  
 To understand if the effects of APC are due to its proteolytic activity, HUVEC in the 
tube formation assay were also treated with 2 inactive forms of APC, the zymogen PC (1 
µg/mL) and the chemically inactive protease, APC-DEGR (1 µg/mL). At the 12 h timepoint,  
only the active protease is able to significantly increase the formation of tube-like structures 
compared to No Treatment (Figure 5-2A and B). These results suggest that APC must 
proteolytically cleave another protease or receptor to increase the formation of tube-like 
structures to a level similar to that of VEGF. The concentration of APC (1 µg/mL) needed to 
promote this formation is, again, closer to physiologically relevant levels of PC. 
 
APC Increased Sprout Formation of Murine Aortic Rings Requires Active Protease 
 In the ex vivo aortic ring assay, murine aortic sections will form sprouts, composing 
of endothelial cells that will lengthen over time. Upon treatment with a stimulus, such as 
VEGF, the formation of endothelial cell sprouts will increase in number, grow longer, and 
last in culture. As seen in Figure 5-3A, increasing concentrations of APC (0-10 µg/mL) 
increased the formation of sprouts compared to No Treatment, but only the highest 
concentration of APC (10 µg/mL) was able to significantly increase this formation. The 
highest concentration was also able to increase the number of sprouts that form significantly 
earlier that even VEGF treatment. Photographs depicted in Figure 5-3B are from day 4. They 
show the increase in the number of sprouts that form around the periphery of the aortic 
section compared to No Treatment. These sprouts were also longer than those for No 
Treatment. The ability to form sprouts at 10 µg/mL APC even exceeded the effect of the 
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Figure 5-1. APC Increases HUVEC Invasion and Chemotaxis. HUVEC were treated with 
increasing concentrations of APC (0-10 µg/mL) for 24 h, using 1 ng/mL VEGF as the 
chemotactic agent. Black bars depict the results for invasion and white bars depict the results 
for chemotaxis. Graphs represent the average of 3 separate experiments. * p<0.05 compared 
to No Treatment. 
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control proangiogenic factor VEGF. Immunofluorscence staining for vWF, an endothelial 
cell-specific marker, was done to verify that the cells responding to APC treatment were in 
fact endothelial cells. As seen in Figure 5-3C, both VEGF and APC were able to increase 
sprout formation of endothelial cells, and they both stained positive for vWF. 
Therefore, APC increased the formation of endothelial cell sprouts on murine aortic rings 
similar to the effects of VEGF. 
 To determine if the effects shown with APC are dependent on APC and not any IIa 
present in the sample, aortic sections were also treated with hirudin (50 nM), a potent and 
specific inhibitor of IIa that has been previously shown to inhibit IIa-promoted cell migration 
[323]. As seen in Figure 5-4, at day 4, APC increases sprout formation, in the presence or 
absence of hirudin. The effects of hirudin alone are not significant. Therefore, APC is 
increasing endothelial sprout formation, independent of any IIa present. 
 To further verify that in the ex vivo aortic ring assay, the active form of APC was 
required to increase the sprout formation, PC (10 µg/mL) and APC-DEGR (10 µg/mL) were 
used to treat the aortic sections. Because these aortic sections are in culture for 5 days, it is 
possible any IIa present in the media can bind to the endothelial cell surface and activate 
soluble PC added at high concentrations. Therefore, to inhibit the effects of IIa, hirudin (50 
nM) was also added with PC. As seen in Figure 5-4, at day 4, there was an increase in sprout 
formation with just the addition of PC to the aortic sections that was not statistically 
significant. When hirudin was added with PC, there was no effect on sprout formation. The 
same was true with the addition of APC-DEGR. Therefore, these results suggest that APC 
promotes endothelial cell sprout formation through its proteolytic activity, as seen with the 
transwell and tube formation assays. 
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Figure 5-2. APC Increases Tube Formation of HUVEC. HUVEC were plated onto Growth 
Factor-Reduced Matrigel and treated with APC (1 µg/mL), PC (1 µg/mL), APC-DEGR (1 
µg/mL), or VEGF (100 ng/mL; positive control) for 12 h.  (A) Representative photographs 
were taken at 12 h. Black bars in No Treatment photograph depicts what was considered a 
vessel-like structure. (B) Graphs represent the average of 3 separate experiments. * p<0.05 
compared to No Treatment. 
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Figure 5-3. APC Increases Sprout Formation of Murine Aortic Rings. (A) Murine aortic 
rings were treated with increasing concentrations of APC (0-10 µg/mL) or VEGF (100 
ng/mL) for 5 days. On days 3-5, the number of sprouts that projected from the periphery of 
the aorta was counted. Graphs represent the average of 4 separate experiments. * p<0.05, ** 
p<0.01 compared to No Treatment. (B) Representative photographs of aorta taken on day 4. 
(C) Representative immunofluorescent staining of aortic rings stained for vWF. 
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APC Increased Endothelial Sprout Formation through EGFR, PI3K, and MMPs 
 To further characterize the effects of APC on endothelial cell sprout formation, 
pharmacological inhibitors were used to block the binding or function of specific factors that 
have been shown to be important in APC-mediated events in other experimental settings. 
First, EGFR has shown to be important to mediate the effects of APC on inflammation, by 
reducing the migration of lymphocytes [59]. It has also been shown through EGFR, APC 
increases breast cancer cell chemotaxis and invasion [326]. Aortic rings were pretreated with 
a chemical inhibitor, AG 1478, that blocks ligand binding to EGFR. As seen in Figure 5-5A, 
at day 4, AG 1478 alone reduces the formation of sprouts because of the importance of this 
receptor in angiogenesis. If this receptor is not important to the mechanism utilized by APC 
to increase endothelial cell sprout formation, then APC treatment with the inhibitor will be 
increased over No Treatment. In the presence of the EGFR inhibitor, AG 1478, APC is 
unable to increase endothelial cell sprout formation. As shown in Figure 5-5B, AG 1478 
treatment reduces the number and the length of the endothelial cell sprouts that form.  
 Second, the PI3K pathway has been implicated in mediating the effects of APC on 
HUVEC proliferation [79] and breast cancer cell invasion [326] and chemotaxis [323]. Using 
the pharmacological inhibitor, LY 294002, that blocks PI3K phosphorylation of Akt, there 
was a complete loss of endothelial cell sprout formation, as seen in Figure 5-5A. If the PI3K 
pathway is not important to the mechanism utilized by APC to increase endothelial cell 
sprout formation, then there should be an increase in sprouts, both numerically and visually 
(Figure 5-5B). However, as seen in Figure 5A, LY 294002 was able to abrogate the effects of  
114 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-4. Active Protease is Required to Increase Sprout Formation of Murine Aortic 
Rings. Murine aortic rings were treated with 10 µg/mL APC with or without Hirudin (50 
nM), 10 µg/mL PC with or without Hirudin (50 nM), and 10 µg/mL APC-DEGR for 5 days. 
Graphs represent the average of 2-3 separate experiments from data collected on day 4. * 
p<0.05, **p<0.01 compared to No Treatment. 
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APC on sprout formation. Figure 5-5B shows an almost complete lack of endothelial sprouts 
around the periphery at day 4. If any sprouts are formed, they are only approximately one cell 
in length, unlike the sprouts formed with APC alone.  
Finally, MMPs have been implicated in modulating the effects of APC on migration. 
MMP-2, specifically, has been shown to have a role in APC-promoted wound healing [77, 
78]. MMP-2 and -9 also have been implicated in APC-promoted invasion of breast cancer 
cells [326]. Using a general MMP inhibitor, GM 6001, there was little effect on sprout 
formation compared to No Treatment (Figure 5-5A) at day 4. Photographs also taken on day 
4 (Figure 5-5B) show few sprouts with some length around the periphery of the aortic 
section. However, with APC present, GM 6001 blocks the effect of APC on endothelial cell 
sprout formation (Figure 5-5A). Photographs (Figure 5-5B) show that there is no difference 
between treatment with GM 6001 and GM 6001 with APC. There are sprouts that form 
around the periphery of the aortic section, however, these sprouts are neither as numerous, 
nor as long as the ones that form with APC treatment alone.  Taken together, these results 
imply that APC through EFGR activation of PI3K and degradation of the ECM by MMPs, 
increases endothelial cell sprout formation in the ex vivo aortic ring assay. 
 
Discussion 
 APC had been previously shown to increase proliferation of HUVEC through binding 
to EPCR and activating PAR-1 to activate the MAPK, PI3K, and eNOS pathways [79]. APC 
also increases tube formation of HUVEC, dependent on active protease [79] at a 
concentration of 300 nM [79]. Using the transwell assays, we present data that shows APC is 
able to increase HUVEC invasion and chemotaxis at an optimal concentration of 0.1 µg/mL 
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Figure 5-5. APC Increases Sprout Formation of Murine Aortic Rings Through EGFR, 
PI3K, and MMPs. (A) Murine aortic rings were pretreated on day 1 with 10 µM of AG 
1478, LY 294002, or GM 6001 for 30 minutes prior to the addition of APC (10 µg/mL). 
Treatments continued out for 5 days. Graphs represent the average of 2 separate experiments 
from data collected on day 4. (B) Representative photographs of aorta taken on day 4.  
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and 0.5 µg/mL, respectively. These concentrations, equal to 1.77 nM and 8.83 nM, 
respectively, are much less then what has been previously used and closer to the 
physiological level of PC in plasma (~4 µg/mL or ~70.8 nM). The amount of APC 
administered to patients in the PROWESS study resulted in a steady state level of 45 ng/mL 
(~0.8 nM) [314]. Also, APC increases the formation of tube-like structures in HUVEC, 
verifing what had been previously shown [79]. APC increases tube formation of HUVEC 
through its proteolytic activity, at a lower concentration (17.7 nM) than used in previous 
studies (300 nM) [79]. Therefore, the effects of APC described here are more relevant to 
physiologically concentrations of protein C/APC. 
  HUVEC responded to an optimal concentration of APC in these assays. Endothelial 
cells respond to an optimal concentration of a pro-migratory factor, such as VEGF, during 
angiogenesis. As blood vessels form, oxygen and nutrients are brought closer to the tissue 
releasing VEGF, which promotes a decrease in any further release of this pro-angiogenic 
factor. With less VEGF present, endothelial cell migration is halted and differentiation into a 
mature blood vessel will occur. Higher concentrations of VEGF will result in vessels that are 
leaky and have large lumens [331]. Unlike what has been shown in breast cancer cells, where 
APC is able to continuously increase migration as the concentration of APC increases [323], 
endothelial cells appear to respond to an optimal concentration of APC in both the transwell 
assays and the tube formation assay. The highest concentration of APC (10 µg/mL) actually 
reduces endothelial cell migration in the transwell assays. Thus, depending on the 
experimental setting, there is an optimal concentration of APC that will increase endothelial 
cell invasion, chemotaxis, and tube formation, with higher or lower concentrations having 
either no effect or a negative effect on HUVEC migration. 
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 Using the ex vivo aortic ring assay, APC is shown to increase the formation of vWF-
positive endothelial cell sprouts at a higher concentration than was shown with human cells 
in culture. I used only human APC in my work, as was also initially used in the murine 
ischemic stroke models [66]. The concentration of human APC that effectively reduced the 
volume of cerebral infarct and increased cerebral blood flow post-onset of stroke was 2 
mg/kg [66]. Similar studies done with murine APC showed that the same beneficial effects 
can be seen using 10 times less, 0.2 mg/kg [63, 306]. Therefore, the level of APC used to 
increase endothelial cell sprout formation in the assays presented here (10 µg/mL) would 
theoretically be comparable to 1 µg/mL of murine APC.  
 The proteolytic active form of APC is required to increase endothelial cell sprout 
formation, since both inactive forms of APC, zymogen PC (with hirudin) and APC-DEGR, 
were unable to promote sprouting. It should be noted that hirudin was added to eliminate any 
effects of IIa on the system, such as activation of PAR-1 or activation of PC to APC.  These 
results both showed that it was APC and not IIa that was promoting sprout formation, and 
this increase required active protease. It has been previously shown in endothelial cells and 
other model systems that APC must cleave PAR-1 to initiate signaling events in the cell to 
promote proliferation [79], inhibit apoptosis [54, 63-66], decrease the inflammatory response 
[54, 65, 66], and increase recovery after the onset of a stroke [54, 65, 66]. It has also been 
shown that APC cleaves pro-MMP-2 to its fully active form [73-76]. Therefore, it is 
concluded that the proteolytic effects of APC are also required for the formation of 
endothelial sprouts, potentially activating PAR-1 and initiating signaling pathways to 
promote chemotaxis and invasion, and/or activate MMPs to promote endothelial cell 
invasion.  
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 APC increases endothelial cell sprout formation through EGFR. AG 1478 has been 
used on murine tissue or cells to block binding to EGFR [328, 332]. Endothelial cells express 
members of the ErbB receptor family [333-335] that are responsive to AG 1478 [334, 335]. 
EGFR has previously been shown to modulate the anti-inflammatory effects of APC by 
inhibiting lymphocyte migration [59]. EGFR has also been shown by our laboratory to be 
involved in APC-promoted invasion and chemotaxis of breast cancer cells [326]. APC may 
be directly activating the receptor, similar to the effects of tissue-type plasminogen activator 
on EGFR [324]. APC may also be transphosphorylating EGFR [38, 39] through EPCR and 
PAR-1. APC has been previously shown to transactivate another receptor, sphingosine 1-
phosphate receptor-1, through EPCR and PAR-1 [159]. The results presented here show that 
APC is activating EGFR, and that EGFR activation is important not only for the increase in 
the number of sprouts that form on the periphery of the aorta, but also the lengthening of 
each sprout, as seen in the representative photographs taken on day 4.  
 APC also increases endothelial cell sprout formation through the activation of the 
PI3K pathway. The LY 294002 compound, which inhibits PI3K from phosphorylating its 
downstream effecter Akt, almost completely inhibits the formation of any sprouts on the 
periphery of each aortic section. The PI3K pathway has been shown to be important for 
angiogenesis [16]. Therefore, blocking this key pathway blocks APC-promoted sprout 
formation. Furthermore, APC has been shown to activate PI3K to increase HUVEC 
proliferation [54] and to increase breast cancer cell migration [326]. APC must also utilize 
this pathway to increase endothelial cell migration, as shown in the ex vivo aortic ring model. 
 Finally, APC also increases endothelial cell sprout formation through MMP 
degradation of the ECM. GM 6001 is a broad-spectrum inhibitor of MMPs, including MMP-
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2 and -9 that have been shown to be important for angiogenesis [336]. Using the ex vivo 
aortic ring sprouting assay, unlike that seen for AG 1478 and LY 294002 above, my results 
show that GM 6001 alone did not suppress sprout formation compared to No Treatment. 
However, when GM 6001 was added with APC, there was no increase in sprout formation, 
particularly no increase in the number of sprouts and no increase in length of the sprouts as 
seen with APC treatment alone. Therefore, as seen in previous cell motility studies, MMP 
degradation of the ECM is important for the APC-promoted increase in sprout formation. 
Previously it was shown that APC increased expression of MMP-2 [52, 78]. Through MMP-
2, APC enhances wound healing [52, 77]. APC has also been shown to directly activate 
MMP-2 [73-76]. Previously, our laboratory has shown that MMP-2 and -9 degradation was 
important for APC-increased breast cancer cell invasion [326]. It is speculated that APC is 
either increasing the expression of MMP-2 or directly activating MMP-2, particularly since 
the active form of APC is required to increase sprout formation.  
 In conclusion, the work presented here gives further insight into how APC is affecting 
endothelial cell motility and angiogenesis. APC, and not the zymogen PC, activates EGFR or 
a member of the ErbB family of receptors on the endothelial cell surface. The activation of 
this receptor leads to the activation of the PI3K pathway to increase endothelial cell 
migration. The effect of APC on endothelial cell migration also involves the degradation of 
MMPs to allow for the increased number and lengthening of the sprouts. All of these 
components are required to increase sprout formation, since blocking just one completely 
inhibits the effects of APC.  
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Summary 
Plasminogen activator inhibitor-1 (PAI-1) is a physiological inhibitor of urokinase 
(uPA), a serine protease known to promote cell migration and invasion.  Intuitively, 
increased levels of PAI-1 should be beneficial in down-regulating uPA activity, particularly 
in cancer.  By contrast, in vivo, increased levels of PAI-1 are associated with a poor 
prognosis in breast cancer.  This phenomenon is termed the “PAI-1 paradox.”  Many factors 
are responsible for the up-regulation of PAI-1 in the tumor microenvironment. We 
hypothesize that there is a breast cancer predisposition to a more aggressive stage when PAI-
1 is up-regulated as a consequence of Metabolic Syndrome (MetS).  MetS exerts a 
detrimental effect on the breast tumor microenvironment that supports cancer invasion.  
People with MetS have an increased risk of coronary heart disease, stroke, peripheral 
vascular disease, and hyperinsulinemia.  Recently, MetS has also been identified as a risk 
factor for breast cancer.  We hypothesize the existence of the “PAI-1 cycle”.  Sustained by 
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MetS, adipocytokines alter PAI-1 expression to promote angiogenesis, tumor-cell 
migration, and procoagulant microparticle formation from endothelial cells, which generates 
thrombin and further propagates PAI-1 synthesis.  All of these factors culminate in a 
chemotherapy-resistant breast tumor microenvironment.  The PAI-1 cycle may partly explain 
the PAI-1 paradox.  In this hypothesis paper, we will discuss further how MetS up-regulates 
PAI-1 and how an increased level of PAI-1 can be linked to a poor prognosis. 
 
Introduction:  Western Diet, Metabolic Syndrome (MetS) and Breast Cancer 
“When diet is wrong medicine is of no use.  When diet is correct medicine is of no need.” 
Ancient Ayurvedic Proverb 
Breast cancer is the second leading cause of cancer deaths among women in the 
United States.  It is predicted that there will be more than 178,000 new cases of invasive 
breast cancer and more than 40,000 estimated deaths from breast cancer in 2007 [349].  The 
lifetime probability of a woman developing breast cancer is 1 in 7 [350].  The duration of 
exposure to estrogen is a major risk factor for breast cancer [350].   Modifiable risk factors 
for breast cancer include obesity, excessive alcohol use, and physical inactivity [350].  
Invasion and metastasis are significant hindrances to the effective treatment of women with 
breast cancer [351, 352].  Despite advances in detection and therapy, many women will 
return with distant metastases and eventually succumb to their disease.  Understanding the 
mechanisms that promote or permit invasion is crucial to the development of effective 
therapies.   
Obesity and the resulting associated metabolic pathologies, now termed Metabolic 
Syndrome (MetS), affect more than 50% of adults in the United States.  MetS is a group of 
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metabolic risk factors, including central obesity, dyslipidemia, hyperinsulinemia, 
hypertension, and prothrombotic/proinflammatory states [353, 354].  MetS increases the risk 
of coronary heart disease, stroke, peripheral vascular disease, and hyperinsulinemia [355, 
356].  There is growing epidemiological data to suggest a correlation between high-fat 
consumption from a Western diet and breast cancer in humans [357-359].  Recently, it was 
shown that obesity and weight gain are associated with increased breast cancer recurrence 
and cancer mortality [360-362].  
In the breast, adipocytes are responsible for the synthesis of adipocytokines, potent 
cellular modulators up-regulated during MetS [355, 356, 363-367].  Besides adipocytes, there 
are vascular endothelial cells and stromal fibroblasts that can be regulated by adipocytokines 
[368].  In addition, a prominent feature of MetS is the up-regulation of the serine protease 
inhibitor (serpin), plasminogen activator inhibitor-1 (PAI-1; systematic name, SERPINE1) 
[282, 368-370].  PAI-1 is a physiological inhibitor of urokinase-type plasminogen activator 
(uPA), a serine protease involved in the promotion of cellular de-adhesion, 
migration/invasion, and activation of plasmin from plasminogen [168, 371-373].  uPA is up-
regulated in breast cancer as it progresses to a metastatic disease.  Increased levels of the 
protease are associated with a poor prognosis [374].   
Instinctively, one would predict that increased expression of PAI-1 might be 
beneficial in breast cancer, since it potently inhibits uPA proteolytic activity.  In vitro, PAI-1 
has been shown to inhibit the effects of uPA in cancer [168, 371-373].  However, several 
clinical studies have found that increased PAI-1 expression in breast cancer is associated with 
a grim prognosis [351].  In the following sections, we present a hypothesis to possibly 
explain the relationship of MetS to breast cancer, via a link with PAI-1.  We hypothesize that 
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MetS and adipocytokines alter the microenvironment surrounding the tumor cell by changing 
the expression of various factors, including PAI-1, that promote breast cancer cell migration 
and invasion (Figures 6-1 and 6-2).  
 
Plasminogen Activator System and Breast Cancer 
The plasminogen activator (PA) system plays an important role in promoting tumor 
cell invasion [168, 371-373].  uPA is a serine protease involved in many cellular processes 
including motility, activation of plasminogen to plasmin, and activating pro-matrix 
metalloproteases (MMP’s).  While bound to the urokinase receptor (uPAR), uPA activates 
the zymogen plasminogen to the serine protease plasmin at the cell surface.  Plasmin 
activates MMP’s and degrades the surrounding extracellular matrix (ECM) [168, 371-373].  
Serpins control proteolytic activity during normal and pathological processes [178, 179].  
There are four serpins that regulate the serine proteases of the PA system, PAI-1, 
plasminogen activator inhibitor-2, plasminogen activator inhibitor-3 (also known as protein 
C inhibitor), and α2-plasmin inhibitor.  An imbalance in the ratio of protease to the inhibitor 
allows for increased degradation of the ECM and increased invasion of tumor cells, which 
explains why many components of the PA system are associated with poor prognosis in 
several types of cancer [168, 371-373]. There is an inherent balance among uPA, uPAR, and 
PAI-1 to regulate focal ECM proteolysis and invasion [375].  However, the known 
biochemical function of PAI-1 contradicts its pathological function in cancer.  An increased 
level of PAI-1 would be expected to inhibit uPA generation of plasmin, protecting the ECM 
from proteolysis, and thus inhibiting invasion.  By contrast, high PAI-1 levels correlate with 
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a poor prognosis and reduced survival in many cancers including breast cancer [351].  
Analyses of pooled data from 18 separate studies showed unequivocally that high levels of  
PAI-1 and uPA in the tumor are associated with an increase in relapse and metastasis, and a 
decrease in survival, indicative of a poor prognosis in primary breast cancer [351].  
Furthermore, a prospective randomized investigation found that the levels of PAI-1 and uPA 
in primary breast cancer are predictive of disease recurrence [374].   
PAI-1 is expressed in many cell types including endothelial cells, fibroblasts, 
adipocytes, smooth muscle cells, numerous tissue epithelial cells, keratinocytes, granulosa 
cells, and platelets.  PAI-1 is the primary inhibitor of the PA system targeting both uPA and 
tissue-type PA (tPA).  PAI-1, in the presence of either VN or heparin, also inhibits the serine 
protease thrombin, although the importance of this inhibition reaction in cancer biology is not 
well understood.  PAI-1 is found in trace levels in peripheral blood because it is a potent uPA 
and tPA inhibitor and its latent and protease-complexed forms are rapidly cleared.  PAI-1 is 
conformationally unstable, rapidly decaying to an inactive form within 1 to 2 hours [376].  
Binding to VN will stabilize PAI-1 for 4 to 6 hours [377, 378].  PAI-1 will rapidly inhibit 
uPA, which is bound to urokinase receptor (uPAR) on the cell surface.  The PAI-
1:uPA:uPAR ternary complex interacts with the low density lipoprotein receptor-related 
protein (LRP), which internalizes the quaternary complex [379]. uPAR and LRP will recycle 
to the cell surface while PAI-1 and uPA are degraded [380].   
The “PAI-1 paradox” exists because increased levels of PAI-1, which presumably 
would down-regulate uPA activity, should be considered good for cancer.  However, in vivo, 
PAI-1 is associated with a poor prognosis in breast cancer.  An increase in PAI-1 levels in the 
  
 
Figure 6-1. Breast Cancer, MetS and the PAI-1 cycle. 
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Figure 6-2.  Metastatic Breast Cancer and the PAI-1 Cycle.  Adipocytokines as a 
consequence of MetS will increase PAI-1 expression in breast adipocytes and surrounding 
tumor microenvironment.  The increased levels of PAI-1 will support tumor angiogenesis, 
promote tumor cell adhesion/de-adhesion, and activate signaling pathways to promote tumor 
cell invasion.  PAI-1 will promote the generation of pro-coagulant microparticles from Fibrin 
will coat the tumor cells to help the tumor cells avoid immune surveillance.  PAI-1 will also 
prevent apoptosis, and provide a chemotherapy-resistant breast tumor microenvironment.  
Ultimately, the PAI-1 cycle will lead to sustained PAI-1 synthesis.  
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breast tumor environment will affect cell adhesion, migration and invasion, apoptosis and 
proliferation, cell signaling, and tumor angiogenesis via a mechanism that is partly 
independent of its inhibitory site [168, 371-373, 381].  We suggest the concept that increased 
levels of PAI-1 involve both “traditional” and “non-traditional” roles for PAI-1 in cancer 
biology. 
The Hypothesis: PAI-1 Cycle 
 PAI-1 cycle links MetS with breast cancer.  We propose that PAI-1 is up-regulated as a 
consequence of MetS.  This increase in PAI-1 exerts a detrimental effect on breast tumor cells, 
adipocytes, stromal fibroblasts, and vascular endothelial cells to promote tumor cell invasion.  
The “PAI-1 cycle” is sustained by MetS, resulting in the increased expression of PAI-1 in the 
tumor microenvironment (Figure 6-1).  This PAI-1 will advance numerous pathological 
processes of breast cancer (Figure 6-2).  However, we do not presume that all people with 
MetS will be predisposed to breast cancer.  Adipocytokines, whose production is promoted by 
MetS, will alter PAI-1 expression [355, 356, 366, 382-384]. The induction of insulin-
resistance in adipocytes by MetS will also sustain PAI-1 expression [385, 386].  Increased 
levels of PAI-1 will support tumor angiogenesis [387-389], promote tumor cell adhesion/de-
adhesion, and activate signaling pathways to promote tumor cell invasion [168, 371-373, 390, 
391].  PAI-1 will also promote the generation of pro-coagulant microparticles from 
endothelial cells. These microparticles can support the activation of prothrombin to thrombin 
[392-394].   Thrombin facilitates tumor cell migration by activating protease-activated 
receptors to further promote PAI-1 synthesis [395, 396].  Additionally, fibrin produced near 
the tumor by thrombin will coat the tumor cells, disguising the tumor from the immune system 
[397, 398].  PAI-1 will also counteract apoptosis [399, 400], which could increase breast 
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cancer cell survival when treated with a chemotherapeutic drug.  Ultimately, the PAI-1 cycle 
would provide a chemotherapy-resistant breast tumor microenvironment primed for 
invasion/metastasis [399-403] (Figures 6-1 and 6-2). We will further discuss the various 
pathophysiological aspects of the PAI-1 cycle and its role in cancer. 
 
Tumor Angiogenesis 
 PAI-1 has been shown to be both pro-angiogenic and anti-angiogenic.  PAI-1-/- mice, 
described by Devy, et al. [404] and McMahon, et al [405], have a reduction in angiogenesis, 
up to 60% [405], compared to wild-type mice.  Addition of wild-type (wt)-PAI-1 at 
physiological concentrations, up to ~1 nM, restores/increases angiogenesis up to 3-fold, as 
seen in two different angiogenic assays [404, 405], while wt-PAI-1 above 1 to 2 nM reduces 
angiogenesis in these same assays [404, 405]. 
 How PAI-1 affects angiogenesis is not fully understood.  Adenoviral gene transfer of 
wt and mutant forms of PAI-1 that either bind ineffectively to vitronectin (VN) or are unable 
to inhibit the PA system show angiogenesis is promoted through PAI-1 inhibition of uPA and 
tPA [404, 406].  uPA and tPA activate plasminogen to plasmin.  Excessive plasmin activity 
could lead to vessel destabilization [406].  Others have shown that the interaction of PAI-1 
with the surrounding ECM is a key parameter affecting the progression of angiogenesis.  In 
neuroblastoma tumors, PAI-1 co-expresses with integrins, specifically αvβ3, on endothelial 
cells [407].  PAI-1 binds to VN and prevents VN-integrin cell interactions, resulting in 
endothelial cell migration towards fibronectin [407]. 
 
Cell Adhesion and Proliferation 
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The PA system is involved in both promoting and preventing cell adhesion.  Cells can 
bind VN through integrins, such as αvβ3 and uPAR [408, 409].  uPAR on the cell surface 
binds directly to VN [409, 410] and this interaction will up-regulate integrin binding to the 
ECM. uPA bound to uPAR also promotes the interaction of uPAR to VN and strengthens cell 
adhesion to the ECM [127, 411].  Occupied uPAR will also associate with integrins to further 
strengthen the cell’s adhesion to VN [reviewed in [412, 413]].   
PAI-1 inhibits PA system mediated cell adhesion by disrupting the interactions of 
uPAR and integrins with the ECM [408, 409, 414].  PAI-1 competes with uPAR for VN 
binding [409].  PAI-1 will lose the ability to bind to VN when it complexes with uPAR-
bound uPA [409, 415].  PAI-1 inhibition of uPA prevents the serpin from interacting with the 
cell and ECM, promoting cell adhesion to VN, fibronectin, and laminin [316, 416].  By 
removing PAI-1 from VN, cell adhesion is promoted through integrin interaction with the 
ECM.  PAI-1 inhibition of uPA can also promote cell de-adhesion.   Internalization of the 
integrin:uPAR: uPA:PAI-1 complex by LRP removes key components needed to adhere the 
cell to the ECM [124].  
We have found that over-expressing wild-type PAI-1 (wt-PAI-1) in the MDA-MB-
435 cells, a breast cancer cell line, decreased the rate of proliferation when compared to 
either parental cells or the inactive mutant P14 PAI-1-expressing MDA-MB-435 cells (P14 is 
T333R PAI-1) [416-418]. Anchorage-dependent colony forming efficiency was used as a 
measure of cell proliferation.  The wt-PAI-1-expressing MDA-MB-435 cells had a decreased 
ability to form colonies compared to the parental, Neomycin vector control, and P14-PAI-1-
expressing MDA-MB-435 cells (Table 1).  Anchorage-independent proliferation, a hallmark 
of metastatic potential, had similar results.  Wild-type-PAI-1-expressing MDA-MB-435 cells 
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had a reduced ability to form colonies in soft agar when compared with the other MDA-MB-
435 cells (Table 6-1).  Although PAI-1 has been associated with a negative prognosis in 
breast cancer, these results show it to be a negative regulator of proliferation of breast cancer 
cells in vitro. 
A possible explanation for the decrease in proliferation by PAI-1 may be through an 
established function of the cell signaling protein, Akt.  Akt is involved in cell survival and 
proliferation [reviewed in [419]].  PAI-1-/- endothelial cells have an increased level of 
phosphorylated Akt and an increased rate of proliferation [420].  Wild type-PAI-1-expressing 
MDA-MB-435 cells have less phosphorylated Akt compared to inactive P14-PAI-1-
expressing MDA-MB-435 cells, parental MDA-MB-435 cells, and Neomycin vector control 
MDA-MB-435 cells (data not included).  Our laboratory and others have recently shown that 
PAI-1 levels are increased in cells that have had the phosphatidylinositol 3-kinase/Akt-Akt 
signaling axis inhibited [386, 421].  Why a negative indicator of breast cancer survival slows 
down cell proliferation is not fully understood.  It is possible that PAI-1 may serve in a 
protective role; thus, slowing tumor cell growth could permit more genetic alterations to 
occur advancing breast cancer to a metastatic stage. 
 
Cell Migration and Invasion 
All components of the PA system are involved in regulating cell migration and 
invasion.  These interactions of the PA system can be complex, cell type-specific, and often 
context-specific.  uPA stimulates migration of breast cancer cells, dependent on uPAR 
ligation and subsequent activation of cell signaling pathways by integrins [422, 423].  There 
is a reduction in tumor cell migration and metastasis when uPA is inhibited by PAI-1. When  
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Table 6-1.  Stable Expression of wt-PAI-1 Decreases MDA-MB-435 Cell Proliferation* 
MDA-MB-435 Cell type Anchorage-dependent 
proliferation (% CFE) 
Anchorage-independent 
proliferation (% CFE) 
Parental 100 + 5 100 + 6 
Neomycin vector control 112 + 19 90 + 8 
wt-PAI-1-expressing 53 + 23** 58 + 14* 
P14-PAI-1-expressing 121 + 9 113 + 10 
*PAI-1-expressing [wildtype (wt) and inactive T333R (P14)] and control MDA-MB-435 
cells were generated as described previously [416-418].  For anchorage-dependent 
proliferation, cells were plated at 50 cells per 60 mm2 dish in 3 ml growth media and grown 
for 14 days.  Colonies were fixed in 3:1 methanol:acetic acid and stained with Giemsa.  
Colonies of >50 cells were counted and expressed as a % of the number of colonies in the 
parental MDA-MB-435 population to yield colony-forming efficiency (CFE).  For 
anchorage-independent proliferation, soft agar assays were performed by plating 20,000 cells 
per 60 mm2 dish.  Cells were suspended in a thin layer of 0.33% noble agar, which was 
overlaid on a 0.5% agar layer containing 10% FBS in 2x MEM.  CFE’s were assessed after 3 
weeks by counting colonies with >50 cells. The data represent the average of 4 experiments 
performed in triplicate.  * p<0.05, ** p<0.01, compared with the parental MDA-MB-435 
cells. 
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uPA is over-expressed, altering the ratio of protease to inhibitor, cell migration in vitro is 
promoted [424].   
PAI-1 has been shown to promote cell migration.  Chazaud et al. [425] showed PAI-1 
attaches to cells through uPA:uPAR, which alters cell morphology and promotes breast 
cancer cell migration.  This increase in migration can only occur when all of the components 
of the PA system are present [425].  Wild-type PAI-1-expressing MDA-MB-435 cells are 
shown to have significantly increased chemotaxis to VN and fibronectin compared to control 
cells [316, 416].  Alternatively, PAI-1 can support cell migration by preventing cell adhesion 
to VN [127, 426].  In smooth muscle cells, PAI-1 increases migration by binding to LRP, 
which results in morphology changes, cytoskeleton reorganization, and alterations in 
signaling pathways [427].   
PAI-1 also inhibits tumor cell migration [132, 415, 417, 428, 429].  HT1080 cells 
expressing wt-PAI-1 have reduced cell migration in vitro and do not form many lung 
metastases in vivo [424]. The same is true in glioma cells expressing PAI-1 with a reduction 
in invasion in vitro compared to wildtype [426]. Over-expressing PAI-1 in breast and ovarian 
cancer cells reduces both cell migration and invasion, dependent on the active form of PAI-1 
[417].  PAI-1 will complex with uPA and through the formation of a ternary complex with 
uPAR, will also bind LRP. This quaternary complex is internalized resulting in a loss of 
components of the PA system and reduction in cell migration [429].  Treatment with either 
receptor-associated protein (RAP), a LRP binding protein that competitively inhibits ligand 
binding, or LRP blocking antibodies reverses these effects on migration. However, PAI-1-
mediated inhibition of migration can also be independent of its uPA-inhibitory role.  A 
mutant form of PAI-1 that is unable to inhibit uPA also prevented cell migration by 
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disrupting the interactions of VN and integrins [317, 415].  Smooth muscle cell migration can 
also be inhibited in the presence of PAI-1 through the disruption of VN binding to the cell 
[428].   
Apoptosis and the Gene Expression Profile of PAI-1-expressing Cells 
 Components of the PA system may regulate apoptosis.  PAI-1 has been shown to 
inhibit apoptosis when added exogenously to both normal and tumor cells, again, due to its 
inhibition of uPA [399].  This fact alone might explain the PAI-1 paradox.  Excess PAI-1 
protects cancer cells from apoptosis. As a result, PAI-1 could promote the formation of a 
more aggressive tumor.  A closer examination of PAI-1’s inhibition of apoptosis showed that 
PAI-1 inhibits caspase-3-mediated apoptosis in vascular smooth muscle cells [400].  
 Slower proliferating cells tend to have a decreased sensitivity to chemotherapeutic 
agents [430].  We believe that endogenously produced PAI-1 confers a “survival advantage” 
upon cancer cells.  It has been shown that the disruption of the cytoskeleton with 
chemotherapeutic drugs will alter the balance of protease-to-protease inhibitor in favor of 
PAI-1 [431].  PAI-1 expression is affected by the perturbation of the actin cytoskeleton by 
cytochalasin D [401, 402].  Although multiple chemotherapeutic drugs are used to treat 
breast cancer, paclitaxel (Taxol®) has shown efficacy in patients with drug resistance 
cancers, including breast cancer [432].  In our studies with the PAI-1-expressing MDA-MB-
435 cells, paclitaxel initially induces cell death in both wt-PAI-1-expressing and P14-PAI-1-
expressing MDA-MB-435 cells (data not shown).  However, when the cells were allowed to 
recover for 48 hours after treatment in complete medium, wt-PAI-1 expressing MDA-MB-
435 cells had an increase in survival compared to P14-PAI-1 expressing MDA-MB-435 cells, 
although when plated onto either vitronectin or fibronectin surfaces the increase in survival 
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between cell types was less different (data not included).  These results imply that PAI-1 
increases cell survival that depends on the integrity of the inhibitory site.  
 The up-regulation of PAI-1 in a cancer cell is clearly conducive to promoting tumor 
cell progression to a malignant state.  A cDNA microarray analysis was done on RNA 
extracted from the PAI-1-expressing MDA-MB-435 cells compared to the parental and 
vector control MDA-MB-435 cells.  Of those genes, a list was generated of genes that were 
up-regulated ≥ 2.5 or down-regulated ≤ 0.5 compared to the MDA-MB-435 Neo cells (Table 
6-2).  Of the 23 genes up-regulated in the wt PAI-1-expressing MDA-MB-435 cells, many 
are associated with adhesion, motility, and angiogenesis, thereby bringing nutrients to the 
tumor and providing a means for metastasis to occur.  PAI-1 expression reduces cell 
proliferation by both up-regulating genes associated with senescence (G protein-coupled 
receptor 1) and down-regulating genes associated with promoting proliferation.  These results 
agree with what has been published about the effects of PAI-1 on cancer. 
 PAI-1 expression in the MDA-MB-435 cells increases the expression of genes that 
are typically up-regulated in various cancers, including breast cancer (Table 6-2).  ELAV 
results in unstable mRNA in breast cancer [433] and eta polypeptide, a 14-3-3 protein 
involved in various signal transduction pathways, binds to gremlin 1, which is up-regulated 
in numerous cancers, including breast cancer [434].   
Two genes that were up-regulated in the wt-PAI-1-expressing MDA-MB-435 cells 
would make the cells more responsive to stimuli produced by the MetS (Table 6-2).  Protein 
phosphatase 2C, magnesium-dependent, catalytic subunit is a mitochondrial enzyme 
regulated by insulin [435].  Niemann-Pick disease, type C1 is a lysosomal membrane protein 
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involved in cholesterol trafficking [436], and most importantly in drug resistance by its drug 
efflux and sequestration [437].  
 The genes down-regulated in the wt-PAI-1-expressing MDA-MB-435 cells were less 
numerous (Table 6-2).  These genes are associated with proliferation, differentiation, and 
adhesion.  Apolipoprotein D regulates both proliferation [438] and cell migration [439].  
Follistatin is typically down-regulated in cancer, and is an inhibitor of anti-proliferative 
pathways [440].  G protein-coupled receptor 126, which is associated with adhesion [441], is 
also down-regulated by PAI-1 expression. 
 
Concluding Remarks 
“What is food to one man may be fierce poison to others.” Lucretius (99 B.C.-55 B.C.) 
 Obesity is a worldwide problem that contributes to the risk and prognosis of many 
cancers, including breast cancer.  With a high-caloric and high-fat Western diet, the resulting 
MetS will enhance the synthesis of PAI-1 and other components of the PA system in the 
tumor microenvironment.  Adipocytokines (insulin, insulin-like growth factor 1, tumor 
necrosis factor-alpha, interleukin-6, and leptin/adiponectin) and other by-products of MetS 
(such as glucose and cholesterol) will alter PAI-1 expression not only in breast tissue 
adipocytes and in endothelial cells but also in breast cancer cells to potentially favor invasion 
and metastasis.  The complex role and interaction between obesity and MetS linked to PAI-1 
expression will clearly be studied for many years to come, as many study the pathological 
consequences of increased levels of PAI-1. 
We hypothesize that increased expression of PAI-1 and other components of the 
plasminogen activator system (uPA and uPAR) confers a survival advantage upon breast  
  
Table 6-2. The Genetic Profile of wt-PAI-1-expressing MDA-MB-435 Cells 
Genes Upregulateda 
Wt-PAI-1-
expressing 
MDA-MB-
435:MDA-
MB-435 Neo  
MDA-MB-
435:MDA-
MB-435 Neo 
UG Cluster Gene 
Symbol 
Gene Function 
18.63 1.22 Hs.414795 SERPINE1 serine (or cysteine) proteinase inhibitor, clade 
E (nexin, plasminogen activator inhibitor type 
1), member 1 (PAI-1) 
Serine protease inhibitor; PAI-1 
5.67 0.96 Hs.12379 ELAVL1 ELAV RNA transporter/stabilizer; upregulation results in 
unstable mRNA in breast cancer  
4.45 0.71 Hs.149609 ITGA5 integrin, alpha 5 (fibronectin receptor, alpha 
polypeptide) 
Adhesion/cell surface mediated signaling; interacts 
with uPAR; IGF-1 decreases its adhesion strength 
in breast cancer 
4.08 1.23 Hs.414332 OAS2 2'-5'-oligoadenylate synthase 2, 69/71 kDa Antiviral activity of interferons 
3.77 0.86 Hs.194710 GCNT3 glucosaminyl (N-acetyl) transferase 3, mucin 
type 
Inflammation/immune system 
3.64 0.83 Hs.201641     BASP1 brain abundant, membrane attached signal 
protein 
Regulate actin cytoskeleton/neuronal outgrowth in 
mammory gland 
3.62 1.38 Hs.111779 SPARC secreted protein, acidic, cysteine-rich 
(osteonectin) 
Extracellular matrix, adhesion; increased expression 
in breast cancer; Also associated with increased cell 
motility 
3.52 1.16 Hs.519385     FOXD1 forkhead box D1 Involved in the increase in PAI-1 gene expression 
3.5 1.19 Hs.173894     CSF1 Colony stimulating factor 1 (macrophages) Regulate differentiation, activity, survival of 
osteoclasts and monocytes/macrophages; Role in 
monocyte/macrophage mediated tumor 
angiogenesis 
3.15 0.97 Hs.22265 PPM2C Protein phosphatase 2C, magnesium -
dependent, catalytic subunit 
Mitochondrial enzyme regulated by insulin 
2.96 0.87 Hs.262960 TRPC4 transient receptor potential cation channel, 
subfamily C, member 4 
Component of Ca2+ signaling pathway; Activated 
by EGFR stimulation 
2.96 0.86 Hs.528634     OAS3 2'-5'-oligoadenylate synthetase 3, 100kDa Antiviral activity of interferons 
2.94 0.96 Hs.525392     SYNE2 spectrin repeat containing, nuclear envelope 2 Nuclear envelope scaffolding 
2.91 0.95 Hs.517601     RAC2 Ras-related C3 botulimun toxin substrate 2  
(rho family, small GTP binding protein Rac2) 
Ras superfamily GTPase involved in cell growth, 
cytoskeletal reorganization, and protein kinase 
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activation 
2.83 1.27 Hs.78068     CPZ carboxypeptidase Z Member of metallocarboxypeptidase gene family; 
Associated with extracellular matrix and Wnt 
binding 
2.73 0.83 Hs.184907 GPR1 G protein-coupled receptor 1 Senescence associated gene 
2.72 0.86 Hs.464779     NPC1 Niemann-Pick disease, type C1 Lysosomal membrane protein involved in 
cholesterol trafficking Associated with drug 
clearance in the cell 
2.66 0.97 Hs.468410     EPAS1 endothelial PAS domain protein 1 Hypoxia induced protein involved in angiogenesis; 
Regulates PAI-1 and VEGF gene expression 
2.65 0.87 Hs.249125     TLX3 T-cell Leukemia, homeobox 3 Involved in autonomic nervous system 
development; Gene rearrangement (t(5;14)) 
upregulated in acute lymphoblastic leukemia 
2.63 0.95 Hs.144795     KCNMA1 potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
Component of a conductance, voltage, and Ca2+ 
sensitive channel 
2.61 1.36 Hs.13155     ITGB5 Integrin, beta 5 Adhesion to extracellular matrix; Cell migration 
2.58 0.79 Hs.474751     MYH9 Myosin, heavy polypeptide 9, non-muscle Cytoskeleton and cell migration 
2.57 1.24 Hs.226755 YWHAH tyrosine 3-monooxygenase/tryptophan  
5-monooxygenase activation protein, eta 
polypeptide 
14-3-3 protein involved in signal transduction; 
Found to be bound to gremlin 1, which is 
upregulated in numerous carcinomas including 
breast 
Genes Down-Regulateda 
Wt-PAI-1-
expressing 
MDA-MB-
435:MDA-
MB-435 Neo  
MDA-MB-
435:MDA-
MB-435 Neo 
UG Cluster Gene 
Symbol 
Gene Function 
0.29 0.85 Hs.522555     APOD apolipoprotein D Regulate both proliferation and cell migration in 
response to growth factors 
0.41 1.04 Hs.318894     GPR126 G protein-coupled receptor 126 G-protein coupled receptor involved in cell 
adhesion 
0.42 1.14 HS.9914 FST Follistatin Downregulated in cancer; Inhibits activin, a 
member of the TGF-beta superfamily involved in 
regulating proliferation  
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0.44 1.39 Hs.25597     ELOVL1 elongation of very long chain fatty acids 
(FEN/Elo2, SUR4/Elo3, yeast)-like 2 
Unknown 
0.47 0.78 Hs.368226     SOX6 SRY (sex determining region Y)-box 6 Transcription factor involved in various 
developmental processes; Upregulated in gliomas 
and not other cancers 
aThe MDA-MB-435 cell line was transfected using pcDNA3.1 vectors (Invitrogen) containing wt PAI-1 using Effectene (Qiagen) 
according to manufacturer's instructions ) [416-418].  Clones were selected for resistance to neomycin analogue, G418 (Invitrogen).  
In collaboration with the Microarray Core Facility at NHGRI, a cDNA microarray was used to compare the gene expression profiles 
among the parental MDA-MB-435, Neomycin vector control MDA-MB-435 (MDA-MB-435 Neo), and wt-PAI-1-expressing MDA-
MB-435 cells. A standard human chip was used that contains over 29,000 elements: 28,200 human sequence verified clones and 800 
controls. These genes represent over 24,400 unique Unigene clusters. One sample of RNA was labeled with Cy3 and the other with 
Cy5. The mixture of the two-labeled RNAs was competitively hybridized to a glass slide containing the cDNAs. For analysis, only 
genes in which the ratio between MDA-MB-435 and MDA-MB-435 Neo was between 0.7-1.4 were considered.  From this list of 
genes the above tables were generated that list the genes upregulated > 2.5 fold and those genes that are reduced by <0.5 compared to 
the MDA-MB-435 Neo cells. 
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cancer cells by decreasing sensitivity to chemotherapeutic agents, regulating adhesion, increasing 
tumor angiogenesis, and increasing cell migration (Figures 6-1 and 6-2).  As many researchers 
and clinicians have been and are still trying to fully understand the role of PAI-1 in cancer, the 
PAI-1 cycle hypothesis may further explain the paradox as to why a protease inhibitor of ECM 
degradation is detrimental for women with breast cancer (Figure 6-2).   
 
 Chapter 7 
Discussion and Future Direction 
 
 APC is not only an anticoagulant serine protease that regulates IIa generation, but it is 
also involved in modulating inflammation, apoptosis, proliferation, and cell migration. The 
goal of this Dissertation was to investigate the role of APC in breast cancer cell invasion and 
endothelial cell angiogenesis. I tested a hypothesis that APC would increase both breast 
cancer and endothelial cell migration through similar pathways. I used various migration 
assays along with blocking antibodies and pharmacological inhibitors to characterize the 
effects of APC and the mechanism by which APC modulates migration.  
  Like many other serine protease, serpins, and receptors involved in the coagulation 
pathway, APC has other non-hemostatic functions. Other serine proteases, such as IIa, tPA, 
and uPA also modulate other cellular processes in numerous cell types. IIa is involved in 
inflammation, proliferation, and cell migration of endothelial and breast cancer cells. uPA is 
used as a diagnostic marker in breast cancer. tPA is used clinically to reduce fibrin deposition 
in the brain related to strokes. Similarly, serpins have been found to have their own functions 
on various cell processes. PAI-1 has been shown to have a negative role in various 
pathological processes including cardiovascular disease, cancer, and diabetes. PAI-1 is also 
proposed to link Metabolic Syndrome to breast cancer. Factors, such as hormone and 
inflammatory cytokines that are upregulated as a result of the Metabolic Syndrome, also 
increase the expression of PAI-1. PAI-1 increases tumor angiogenesis, tumor cell migration, 
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and survival. Another serpin, PCI, is involved in retinoic acid transport and regulating 
proteases in the testes to ensure proper spermatogenesis. Finally, receptors involved in the 
coagulation pathway also have non-hemostatic functions associated to activating various 
signaling pathways. The expression pattern of these receptors occurs not just on the 
endothelium, but these receptors can be found on cancer, immune, and epithelial cells. More 
than just the coagulation pathway, but pathways including inflammation also modulate the 
expression of these proteases, serpins and receptors. Therefore, it is possible that APC can 
modulate much more that just coagulation and have influence in cell migration and 
angiogenesis. 
 Based on previous work, I focused my studies of APC on cell migration and look at 
specific receptors, ECM proteases, and signaling pathways that had been implication in other 
functions of APC. First, I studied the effects of APC on breast cancer cells. APC increased 
breast cancer cell migration in a concentration dependent manner. This increase in both 
invasion and chemotaxis was dependent on active protease and on interactions with EPCR, 
PAR-1, and EGFR. I hypothesized that APC was localized to the cell surface by EPCR. APC 
bound to EPCR then cleaved PAR-1 at the same site as another serine protease, IIa. The 
activation of PAR-1 would then lead to the transphosphorylation of EGFR either through 
extracellular release of an EGFR ligand by TACE or through intracellular signaling by c-Src.  
Through this trimer of receptors (EPCR, PAR-1, and EGFR), APC is able to activate the 
PI3K pathway, which will lead to the activation of the Raf-MEK1/2-ERK1/2 pathway. These 
pathways will lead to actin polymerization, formation of leading edge protrusions, and 
modulations in FAK and integrin interactions with the ECM and other cells. Through Raf-
MEK1/2-ERK1/2 pathway, there is an increase in MMP-2 expression. Interestingly, I found 
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that APC does not increase breast cancer cell invasion through uPA and PAI-1, as previously 
described. APC increases invasion through MMP-2 and -9 degradation of the ECM. I 
hypothesized that APC upregulates the expression of MMP-2 and/or -9. Bound on the cell at 
EPCR on MDA-MB-231 cells, APC activated the zymogen to the fully active form of these 
ECM proteases. Importantly, all of these components work interdependently. Blockage of 
any single pathway, receptor or cell component results in the complete abrogation of the 
effects of APC. Thus, when APC is in solution and able to interact with MMPs, it must still 
bind to the cell surface and activate signaling pathways to increase cell migration.  
 In another aspect of this research, I showed that APC increases endothelial cell 
migration, resulting in an increase in angiogenesis. Unlike the breast cancer cells, the 
endothelial cells only responded to a specific concentration of APC. Knowing that the 
endothelial cell migration and invasion could be enhanced by APC, I then used a tube 
formation assay and found that APC enhanced the network of tube-like structures and 
junction points, representative of a network of blood vessels. Again, APC increased the 
formation of these tube-like structures dependent on active protease. Finally, using an ex vivo 
aortic ring assay, I explored whether or not APC could promote endothelial cells to de-
differentiate, migrate, and proliferate at an increased rate, representative of the beginning 
stages of angiogenesis. APC increased the number of vWF-positive endothelial cell sprouts 
to form on the periphery of the aortic sections and also increased their length comparable to 
the effects of VEGF. As was seen above, this increase was also dependent on active APC, 
activation of both EGFR and PI3K-dependent signaling pathways, and degradation of the 
ECM by MMPs. Thus, I hypothesized that APC binds to the endothelium through EPCR, 
where it can cleave and activate PAR-1. The activation of PAR-1 leads to the activation of 
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EGFR. This network of receptors including EPCR, PAR-1, and EGFR, will then activate the 
PI3K pathway, resulting in the increase in cell migration. APC will also increase the 
expression and activation of MMPs, specifically MMP-2 and -9, to increase degradation of 
the ECM. All of these components were again shown to be interdependent on each other. If 
even just one were inhibited, the effects of APC were abrogated. 
 There remain several questions that have evolved from the work presented in this 
Dissertation. First, three receptors, EPCR, PAR-1, and EGFR, have been identified as having 
a role in mechanism utilized by APC to promote cell migration. There is only speculation of 
how APC binds to and activates these receptors. Further work using fluorescently tagged 
proteins and cell models that quantitatively identify the activation of specific signaling 
pathways would help us understand how APC is interacting with the cell surface. Second, 
using siRNA, pharmacological inhibitors, and quantitatively measuring the phosphorylation 
of specific proteins in the signaling pathways examined would allow us to more fully map 
out the entire signaling pathway(s) activated by APC. Third, using real time rt-PCR we could 
determine if APC is increasing the expression of MMPs, specifically MMP-2 and -9. Also, 
using activity assays specific for these ECM proteases and by using zymography, we could 
directly determine how APC is involved in activating MMP-2 and -9 to increase invasion. 
Fourth, I found that endogenous levels of PAI-1 and uPA of breast cancer cells were not 
involved in the mechanism utilized by APC to increase cell migration. However, the question 
still remains whether or not APC bound to the cell surface can be inhibited by serpins, 
specifically PCI and PAI-1. Using wild-type serpins and serpins mutated at residues 
important for protease interaction, we could determine if these serpins inhibit the non-
hemostatic functions of APC and the specific points of interactions. Finally, as explored in 
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more detail in Chapter 4, additional work that could be linked to Chapter 5 includes the 
involvement of murine EPCR and PAR-1, activation of MAPK, MMPs, role of murine 
tPA/uPA/PAI-1 and further verification that endothelial cells are migrating in response to 
APC.  This would allow for us to more completely determine how similar the pathways to 
increase breast cancer cell and endothelial cell migration using murine endothelial cells and 
the aortic ring model of sprouting.  
In conclusion, APC is able to increase cell migration, shown using breast cancer cells 
and endothelial cells, through both extracellular and intracellular processes. APC binds to the 
cell surface through EPCR, activates PAR-1 and EGFR, which lead to the activation of the 
PI3K and MAPK pathways. APC also increases invasion with the help of MMP-2 and -9 
degradation of the ECM. APC could be both beneficial by promoting angiogenesis. 
However, in another setting, APC could be detrimental by promoting the spread of cancer 
cells through the same pathways utilized to promote angiogenesis. 
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